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ABSTRACT 
Title: Manual lymphatic drainage in chronic venous disease 
Objective: To assess the efficacy of manual lymphatic drainage (MLD) in the 
treatment of patients with chronic venous disease (CVD). 
Design: Three cross-sectional studies and one single-blind randomized 
controlled trial, were performed. 
Methods: A total of 108 participants with CVD and 62 healthy participants 
were assessed in four studies. The first study assessed calf muscle pump function 
(CMPF) and architecture of gastrocnemius muscles by ultrasound in CVD and 
healthy participants; the second and third studies were performed with duplex 
ultrasound to assess venous hemodynamics during MLD; the fourth study, a 
randomized controlled study, assessed for efficacy of the MLD in CVD management. 
Results: Ultrasound measures demonstrate changes in CMPF efficacy along a 
series of contractions as well as between CVD and healthy participants, although the 
method suffers from bias. MLD maneuvers increase superficial and deep venous 
flow, mostly when applied along the anatomical course of the major lower limb 
veins, but without differences between different MLD maneuvers. MLD decreases 
the symptoms and clinical severity (related to venous edema) of CVD, and improve 
dimension of pain of health-related quality of life in this condition, after four weeks 
of treatment and the effect is maintained after 4 weeks of follow up.  
Conclusions: MLD applied with skin-stretching along the course of venous 
vessels increases venous return, and may be used as a conservative coadjutant option 
to treat patients with CVD. 
Key Words: Chronic venous disease; manual lymphatic drainage; venous 
flow; health-related quality of life; calf muscle pump function.
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RESUMO 
Título: Drenagem linfática manual na doença venosa crónica 
Objetivo: Avaliar a eficácia da drenagem linfática manual (DLM) no 
tratamento de utentes com doença venosa crónica (DVC). 
Desenho do estudo: Foram realizados três estudos transversais e um estudo 
prospetivo, controlado e com ocultação simples. 
Metodologia: Nos 4 estudos foram avaliados 108 participantes com DVC e 
62 participantes saudáveis. No primeiro estudo foi avaliada a bomba muscular 
venosa da perna (BMVP) e a arquitetura dos músculos gémeos por ultrassonografia, 
em participantes com DVC e saudáveis. No segundo e terceiro estudos foram 
avaliadas por ultrassonografia vascular as variações hemodinâmicas venosas durante 
a DLM. No quarto estudo, o estudo prospetivo, avaliou-se a eficácia da DLM no 
tratamento de doentes com DVC.  
Resultados: A avaliação por ultrassonografia identificou alterações na 
eficácia da BMVP durante uma série de 10 contrações nos participantes com DVC e 
nos participantes saudáveis, contudo, este método apresentou uma fiabilidade pobre. 
As manobras de DLM aumentaram o fluxo venoso, sobretudo quando aplicadas na 
localização anatómica das principais veias do membro inferior. A DLM aliviou 
sintomas e reduziu a dimensão da dor da qualidade de vida relacionada com a saúde 
e severidade clinica da DVC (sobretudo edema) no fim de 4 semanas de tratamento. 
Parte destes resultados mantiveram-se após 4 semanas de follow-up. 
Conclusão: Tracionar a pele durante a DLM, ao longo do percurso das veias, 
aumenta o retorno venoso e revela-se como uma potencial estratégia conservadora e 
coadjuvante no tratamento de doentes com DVC. 
Palavras-chave: Doença venosa crónica; drenagem linfática manual; fluxo 
venoso; qualidade de vida relacionada com a saúde; bomba muscular venosa da 
perna.
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1 INTRODUCTION 
In Portugal the prevalence of chronic venous disease (CVD) in males is 
17.8% and in females is 34.1%, i.e., around 2.5 million cases, with around 70.000 
new cases every year (Capitão et al., 1995).  
Chronic venous insufficiency represents the most severe cases of CVD, and is 
related to a physiopathology that associates venous hypertension, vein valve damage, 
venous obstruction, calf muscle pump impairment, inflammations of tissues (skin, 
subcutaneous tissue and muscle) and veins, alterations of morphology and function 
of veins, with abnormal venous reflux, venous edema, changes of the skin and 
subcutaneous tissues, with ulcer representing the more severe stage of this condition 
(Eklof et al., 2004; Meissner et al., 2007b; Panny et al., 2009; Qiao et al., 2005; 
Rowland, 2001; Simka, 2007; Yamaki et al., 2010). It is estimated that 100.000 
Portuguese citizens present an open (or active) venous ulcer (Oliveira et al., 2003), 
and 280.000 an open or healed venous ulcer, with 10% of healed ulcer at risk for 
recurrence (Bradbury, 2010; Pina et al., 2005).  
The first problem referred from patients are the symptoms that, together with 
varicose veins, is present form mild to severe cases of CVD, strongly contributing to 
a the negative self-esteem that also characterizes this disease (Boisseau, 2007; 
Bradbury et al., 1999; Campbell et al., 2007; Cesarone et al., 2010; Darvall et al., 
2012; Eklof et al., 2009; Koupidis et al., 2008). The diminished health-related quality 
of life (HRQL) of this condition in these patients, with functional impairments, 
reflected in their daily activities are well studied (Andreozzi et al., 2005; Darvall et 
al., 2012; Furtado et al., 2008; Koupidis et al., 2008). This negative impact is so 
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important that the previous view of this condition as an aesthetic problem has been 
abandoned for years. 
The socioeconomic burden of this condition is very high. The indirect costs 
are substantial and are associated with the symptoms, functional impairment, 
emotional disturbances and negative impact in HRQL (Lamping et al., 2003). The 
direct costs of CVD treatment are almost entirely related to its high prevalence, 
morbidity, and chronicity (Labropoulos et al., 2009; Lamping et al., 2003). In 
developed countries, around 1-3% of the heath costs are due to CVD (Eklof et al., 
2004). However, when patients with less severe stages of the disease are diagnosed 
and treated early, the physiopathology course of the disease can be prevented or even 
receded (Nullen, 2010).  
Manual lymphatic drainage (MLD) is a low pressure form of skin-stretching 
massage, described as a conservative treatment option for the treatment of patients 
with CVD (Steins & Jünger, 2000) as a coadjutant of other treatments, like stockings 
and surgery for example (Molski et al., 2013; Molski et al., 2009). It is assumed that 
this technique may have an effect on superficial venous flow, when a special 
maneuver the so-called call-up maneuver from the Leduc method (Leduc & Leduc, 
2000) is applied, although to a limited extent (Leduc et al., 2011). 
This technique has been proposed as an option in the treatment of venous 
lymphedema associated to CVD (Mortimer, 2000; Raju et al., 2012). It is suggested 
by the literature that this technique should be applied in the course of the great 
saphenous vein (GSV) to treat patients with CVD, but the capacity of MLD to 
improve venous flow has been poorly studied (Leduc et al., 2000; Molski et al., 
2009; Peyre & Robert, 2000). Despite controversial evidence regarding the ability to 
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reduce edema or lymphedema, MLD associated with other treatments, the so-called 
lymphatic decongestive therapy, may have an important role in improving health and 
the functional status in patients with edema associated to sport injury or related to 
breast cancer surgery, just to mention two common situations (Ebert et al., 2013; 
Huang et al., 2013; Vairo et al., 2009). However, the real efficacy of MLD to treat 
patients with CVD remains unknown.  
The importance of calf muscle pump function (CMPF) in CVD development 
is well established (Araki et al., 1994; Kan & Delis, 2001; Moloney et al., 2007; 
O'Brien et al., 2012; Panny et al., 2009; Recek, 2013; Shiman et al., 2009; Simka, 
2007; Yang et al., 1999). Whether MLD has any role in improving calf muscle pump 
function in CVD patients has not been explored before. Also, it seems very important 
that low cost and reliable methods for dynamic evaluation muscle pump function in 
CVD are developed, taking into account its critical importance.  
The major aim of the work reported in this thesis was to evaluate the efficacy 
of MLD in the treatment of patients with CVD. To this end, the efficacy of MLD 
maneuvers (call-up and reabsorption) in increasing venous flow in both superficial 
and deep venous system of the lower limbs was evaluated. Also, the reproducibility 
of ultrasound evaluation of the CMPF was assessed in order to ascertain its potential 
role in testing the efficacy of MLD. 
For this purpose, after this brief introduction where an overall view of the 
work is presented we proceed to the "Review of the Literature" section, where major 
concepts on which our investigation relied are explored, like the social and health 
impact of CVD, its diagnose and major physiopathology, the importance and the role 
of calf muscle pump in this disease and the possibility of assessments of this 
 4 
function, the principles of MLD and the evidence supporting the use of this therapy 
as a conservative treatment of CVD, and the role of the conservative treatments in 
the intervention in this disease. In the section "Scope of the Problem and 
Hypothesis", the principles and objectives of this thesis are presented and our four 
basic hypotheses are established. The fourth section, "Instruments and Methods", 
describes the design for each of the four studies comprising this thesis, as well as the 
detail related with the participants, instruments and methodologies, and statistical 
analysis. The section "Results" presents the results and outcomes of the four studies 
in a descriptive manner and guided by the major objectives highlighted in previous 
sections. In the "Discussion" section offers an interpretation of the results based on 
existing evidence and taking into account the hypotheses that were formulated and 
divided in three subsections: "Ultrasound assessments of calf muscle pump 
function", "Hemodynamic effects of manual lymphatic drainage" and "Therapeutic 
efficacy of manual lymphatic drainage for treatment of patients with chronic venous 
disease". The "Conclusion" section presents the synthesis of the results of the thesis 
and reflects about clinical implications of the results and limitation of this work.  
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2 REVIEW OF LITERATURE 
2.1 Health and social impact of CVD 
2.1.1 Epidemiology 
Chronic venous insufficiency represents the most severe stages of CVD and 
is characterized by the presence of edema, alterations of the skin and venous ulcer, 
either healed or active, and comprises the C3-6 of clinical etiological anatomical 
pathological (CEAP) classification (Eklof et al., 2009). Despite its frequency in the 
population, the prevalence of CVD is still underestimated. Epidemiological data 
estimate that this condition affects 1-17% of men and 1-40% of the women 
(Robertson et al., 2008), accounting to around 2.5 million people in the USA 
(Koupidis et al., 2008). The estimated prevalence of CVD varies according to its 
severity, being around 10%, 9%, 1.5% and 0.5% for CEAP clinical levels C3, C4, C5 
and C6, respectively (Gloviczki et al., 2011). In Portugal, approximately 20.7-36.8%, 
of men and 40.8-62.4% of women aged 24 years or over suffer from CVD (Capitão 
et al., 1995), and around 50% of the total number of skin ulcers is of venous origin 
(Pina et al., 2005). In Europe, the prevalence of varicose veins (C2, from clinical 
CEAP classification) vary in the range 7-40% in men and 25-32% in women 
(Robertson et al., 2008). Variation in estimations of CVD prevalence are likely 
explained by differences in gender, age, ethnic group, and variations in diagnostic 
criteria and methods (Robertson et al., 2008). 
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2.1.2 Functional and HRQL implications of CVD 
Patients with CVD display impaired functional capacity (de Moura et al., 
2012; Koupidis et al., 2008) and diminished HRQL (Andreozzi et al., 2005; Beebe-
Dimmer et al., 2005; Furtado et al., 2008; Vasquez & Munschauer, 2008). The 
severity of CVD, HRQL scores, the clinical signs, and venous ultrasound findings 
are usually correlated (Passman et al., 2011). 
The impact of CVD on HRQL is primarily seen in the physical items and in 
the emotional role, but in advance stages (presence of venous ulcers) the mental 
dimension might also become involved (Andreozzi et al., 2005). In its most severe 
stages, the impact of CVD in HRQL is similar to that of other chronic diseases, such 
as diabetes, cancer, chronic pulmonary disease, or other like heart failure (Andreozzi 
et al., 2005). 
Patients with venous ulcer present severe pain, which is in relationship with 
impaired tissue healing ability, diminished HRQL, and lowered self-esteem and 
social interactions (Koupidis et al., 2008). The psychological effects of CVD may not 
be strictly related to ulceration itself but rather with the symptoms (80.5-69.4%), 
altered appearance and esthetical concerns (66.7%), lack of sleep (66.6%), functional 
impairment (58.3%), and disappointment with treatment outcomes (50%) (Koupidis 
et al., 2008). Also, patients with uncomplicated varicose veins often have severe 
symptoms that adversely affect their HRQL, irrespectively of the severity of the 
disease, refuting the view that this disease is mostly an aesthetic problem (Darvall et 
al., 2012). In this disease, 49% of men and 62% of women have symptoms related to 
CVD (Gloviczki et al., 2011), like pain, itching, tingling, cramps, restless legs, 
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swelling, heaviness, and fatigue (Darvall et al., 2012; Eklof et al., 2009). A recent 
survey reveals that 14.9% of the general Greek population refer symptoms and/or 
present signs related to CVD (Dimakakos et al., 2013). 
Concerning the lower extremities, one-third of people with CVD report health 
or cosmetic problems that turn going out of home and to participate in social 
activities a burden, and they avoid wearing clothes exposing their legs or going on 
vacations to very warm places (Dimakakos et al., 2013). According to self-reports, 
functional status is diminished in these patients (de Moura et al., 2012; Passman et 
al., 2011) also because of some physical dysfunctions, like abnormalities in gait (van 
Uden et al., 2005), impaired balance, peripheral neuropathy (Newland et al., 2009; 
Shiman et al., 2009), weak calf muscles (plantar and dorsiflexors muscles) (Panny et 
al., 2009; Qiao et al., 2005; van Uden et al., 2005), or diminished ankle range of 
motion (Dix et al., 2003; Furtado et al., 2008; Panny et al., 2009). These dysfunctions 
are also associated with impaired muscle pump function in the lower extremity 
(Shiman et al., 2009), an important risk factor for venous ulceration (Kan et al., 
2001). 
2.1.3 Socio-economic impact of CVD 
Severe CVD has a significant economic impact, mostly due to raised 
morbidity. During the last decade neither CVD-associated and inflation-adjusted 
mean hospital charge, nor length of hospital stay decreased, possibly as a result of 
poor advancements in prevention and treatment of this disease (Tsai et al., 2005). In 
advanced stages, venous ulcers require wound care, compression, chemical and 
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mechanical debridement and, in frequent cases, antibiotic therapy (Tsai et al., 2005). 
Western European countries spend 1.5-2% of their annual health budget in the 
treatment of this disease (Sandor, 2004). The economic burden is not just associated 
with clinical visits and outpatient treatments, but also with travel time, loss of work 
hours for patients and family, and physiological impairment related to analgesic and 
antibiotic use (Tsai et al., 2005). Limb amputation is a radical outcome of this 
disease: three in four amputations of venous origin are undertaken in ambulatory 
regimen, and many of these cases are also related to comorbidities, for instance 
diabetes and arterial vascular disease (Tsai et al., 2005). Other important 
complications, such as hemorrhage, thrombosis and pulmonary embolism, also 
compound the unhealthy profile of these patients (Dimakakos et al., 2013). Deep 
venous thrombosis may cause chronic conditions like post-thrombotic syndrome and 
CVD, increasing the costs of the treatment (Tsai et al., 2005). Preventing deep 
venous thrombosis and complications is one of the most important aims for reducing 
socio-economic burden associated to CVD (Tsai et al., 2005). 
Despite its cost, the efficacy of conservative pharmacological treatment of 
CVD is usually poor, and should be combined with other strategies, such as the use 
of elastic garment compression (Gloviczki et al., 2011).  
Similar procedures are recommended following surgery and sclerotherapy, in 
which case post-operative compression therapy and health education are crucial for 
treatment success (Bobridge et al., 2010; Dimakakos et al., 2013). There are several 
risk factors associated with CVD that patients should be informed of by the health 
professionals, like the use of hormonal contraceptives by women, daily routines 
(sitting or standing), pregnancy, age, obesity and heredity factors (i.e., family 
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history) (Beebe-Dimmer et al., 2005; Carpentier et al., 2004; Dimakakos et al., 2013; 
Tsai et al., 2005). Also important, advice regarding behavioral changes, engaging in 
so-called venous exercises and the proper use of the health care services should be 
offered to CVD patients (Dimakakos et al., 2013). Obtaining the right advice from 
health care professionals is an important measure for preventing and managing CVD 
(Dimakakos et al., 2013). 
Because of the wide spectrum of factors that cause functional impairment in 
these patients and the high costs of treatment (Darvall et al., 2012; Eklof et al., 2009; 
Koupidis et al., 2008), the prevention of CVD by educational and prophylactic 
interventions has been shown to be clinically cost-effective, by avoiding disease 
progression to the last stages (Allegra, 2003; Tsai et al., 2005). 
2.2 Pathology of CVD 
CVD is caused by venous hypertension, valvular insufficiency and/or reflux 
(Ibegbuna et al., 2006; Lim & Davies, 2009; Meissner et al., 2007a). Venous 
hypertension might be accompanied by outflow obstruction (Meissner et al., 2007a) 
and affects the superficial, perforator and deep veins (Eklof et al., 2009; Ibegbuna et 
al., 2006). Insufficient lymphatic drainage or a dysfunction of calf muscle pump are 
very often associated with this disease (Sandor, 2010). Venous hypertension is 
related to structural (veins and valves), hemodynamic (obstruction, reflux, stasis), 
biomechanical (calf muscle pump strength and ankle range of motion) and 
biochemical factors (leucocyte-endothelial process inflammation) (Ibegbuna et al., 
2006; Meissner et al., 2007a). 
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2.2.1 Etiology and anatomical location of CVD 
The etiology of CVD can be described as primary, secondary (post-
thrombosis) or congenital (Eklof et al., 2004). Although reflux is the only 
hemodynamic alteration in CVD, in secondary venous disease most of the cases 
present a mix of reflux and obstruction (Ibegbuna et al., 2006). It seems that 80% of 
cases of CVD have a secondary etiology of post-thrombotic pathology, and 20% are 
of primary cause, as a result of valvular incompetence (Meissner et al., 2007a). 
In superficial veins the insufficiency is most often the result of a primary 
preexisting weakness in the vessel wall or valve, as a consequence of a direct injury, 
excessive venous distention caused by hormonal effects or high hydrostatic pressure, 
or secondary to venous obstruction (i.e., phlebitis) (Eberhardt & Raffetto, 2005; 
Gloviczki et al., 2011; Padberg, 2005; Sandor, 2010). Failure of valves (superficial 
veins) may increase superficial venous pressure, resulting in venous dilatation and 
varicose veins (Sandor, 2010). Although the primary mechanism of valvular 
incompetence in superficial veins is not fully known (Meissner et al., 2007a), it 
appears that first there are changes in mechanical properties of vein walls caused by 
increased collagen content and decreased amount of elastin and smooth muscle, 
leading to vessel enlargement and, secondarily, to valvular insufficiency (Meissner et 
al., 2007a). 
The perforating veins can also become insufficient by primary incompetence 
of vein valves or secondary to venous obstruction (Delis, 2004). In these cases, there 
is reflux from deep to superficial venous system: with valve incompetence the reflux 
to saphenous veins may allow the re-entry of venous blood to the deep venous 
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system (Delis, 2004). In the case of secondary incompetence, the high pressures are 
transmitted to superficial veins causing the enlargement of dermal capillarity bed, 
increasing filtration to the interstitial space (Delis, 2004; Meissner et al., 2007a). 
Deep veins insufficiency has been suggested to be most often the 
consequence of deep veins thrombosis, i.e., from secondary etiology (Sandor, 2010). 
However, primary deep venous incompetence is also common (8-22% of the cases 
(Labropoulos et al., 2009)) but is usually compensated by a strong CMPF 
(Labropoulos et al., 2009; Meissner et al., 2007a). It seems that outflow obstruction 
and reflux caused by valve damage may cause deep vein thrombosis and these two 
alterations together they increase the probability of the development of post-
thrombotic syndrome (Labropoulos et al., 2009; Lopez et al., 2004).  
Deep venous thrombosis may also occur because of an intrinsic venous 
process, such as a previous deep venous thrombosis episode with inadequate 
recanalization or venous stenosis, or because of extrinsic compression, as in May-
Thurner syndrome (Eberhardt et al., 2005). Also, it can be caused by venous 
agenesis, such as in the Klippel-Trenaunay syndrome, trauma, surgical mishap, and 
tumors (Meissner et al., 2007a). 
Congenital etiology of CVD, in which case the condition is already present at 
birth, also occurs, despite this it might only be recognized later in life, such as in the 
cases of the Klippel-Trenaunay (varicosities and venous malformations, capillary 
malformation, and limb hypertrophy) (Gloviczki et al., 2011) and Parkes-Weber 
(venous and lymphatic malformations, capillary malformations, and arteriovenous 
fistulas) syndromes (Eberhardt et al., 2005).  
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2.2.2 Physiopathology hypothesis for CVD 
The exact mechanisms behind the development of CVD are not clear yet 
(Bergan et al., 2008; Meissner et al., 2007a). The major hypothetical sequence of 
events is that venous hypertension in the initial stages of the disease triggers 
inflammation affecting the vein walls and valves, and as the condition aggravates 
inflammatory changes spread to the skin and the muscles, causing dermal changes, 
like hyperpigmentation, subcutaneous tissue fibrosis (lipodermatosclerosis), and 
ulceration (Meissner et al., 2007a; Raju et al., 2012; Sandor, 2004, 2010) and tissue 
necrosis, in the most severe cases (Bergan et al., 2008). 
Venous obstruction occurs because of the triad: blood stasis, changes in the 
vessel wall, and hypercoagulability (Lopez et al., 2004). This may occur as a 
phlebitis (obstructions of superficial venous system) or as deep venous thrombosis 
(obstructions of deep venous system), and can be diagnosed as acute or chronic 
(Labropoulos et al., 2009). The acute deep venous thrombosis may cause nociceptive 
pain, swelling and tenderness, and both phlebitis and deep venous thrombosis must 
be confirmed by venous ultrasonography (Meissner et al., 2007a). Hypertension that 
ensues opposes venous return, leading to luminal hypoxemia and vein wall 
distension, which impairs perfusion and causes endothelial hypoxia and leukocyte 
invasion of the wall (Lopez et al., 2004). A progressive aggravating remodeling 
process is then triggered consisting of hypoxemia-related venous/capillary wall 
injury, leukocytes accumulation and adhesion, progressive blockage of capillary 
blood flow, and ongoing damage of subcutaneous tissues and skin 
(lipodermosclerosis and skin ulceration) (Malone & Agutter, 2009).  
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Usually, venous reflux and obstruction occur together (Meissner et al., 
2007a). Following venous obstruction recanalization occurs and blood flow through 
the vein is restored (Lopez et al., 2004). However, lysis of the clot or thrombus is 
usually only partial and the residual thrombus might undergo fibrosis and completely 
obstruct of the lumen of the vein, for example involving leaflets (Lopez et al., 2004). 
Then collateral blood circulation develops, and obstruction may be overcome 
(Meissner et al., 2007a). Sometimes, calf perforating veins may be an important 
collateral venous path when the popliteal vein is involved, causing CVD of a 
secondary etiology (Meissner et al., 2007a). 
The initial hypertension in CVD may also be caused by valvular 
incompetence alone (Bergan et al., 2008). Varicose veins may result from endothelial 
changes (reduced elastin and smooth muscle content together with increased 
collagen) associated with hypoxia, causing weakened venous tone (Bergan et al., 
2008). Other changes include downregulated apoptosis (Ascher et al., 2001), 
decrease energy for cells’ metabolism and increased lysossomal activity (Stvrtinova 
& Ferencikova, 1992). 
Also, venous hypertension in CVD (because of obstruction or reflux) may 
cause extravasion of macromolecules and red blood cells, leading to endothelial cell 
activation, leucocyte diapedesis, extracellular matrix alterations, and intensive 
collagen deposition (Amato et al., 2013; Serra et al., 2014). Changes in skin and 
other tissues interstitium also cause the release of growth factors and pro-
inflammatory factors that stimulate increases in synthesis and deposition of collagen 
and other extracellular matrix components, while also affecting tissue remodeling by 
the metalloproteinases (Amato et al., 2013; Lowell et al., 1992; Sayers et al., 1993; 
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Serra et al., 2014). Also, numerous mast cells are present in venous ulcers, 
suggesting that this cells may also contribute to cytokine activation, tissue 
remodeling, and ulceration (Serra et al., 2014). 
As a cause of CVD, the venous stasis hypothesis that postulates that venous 
blood pooling within dilated veins in the skin causes anoxia and cell death, and the 
arteriovenous shunting hypothesis, that postulates that abnormal arteriovenous 
communications may increase oxygen tension in varicose veins, were abandoned 
(Meissner et al., 2007a; Sandor, 2004).  
The fibrin cuff and the white cell trapping hypothesis are the most accepted 
explanations for the physiopathology of CVD (Sandor, 2004). The enlarged 
interendothelial pores, stretched by raised intraluminal pressure, allow the passage of 
fibrinogen into the interstitial space where it is polimerized into fibrin, causing 
hypoxia and tissue injury (skin and subcutaneous tissue) (Meissner et al., 2007a). 
Associated to this perivascular cuff is leucocyte infiltration (around capillaries and 
post-capillaries venules) and deposition of collagen, that create a barrier to oxygen 
and nutrient diffusion, causing fibrosis, chronic inflammation (Meissner et al., 
2007a), and damage of venous valves (Sandor, 2004).  
Low capillary flow rate in CVD facilitates white cells trapping, the pulling of 
the capillaries, and the potent initiation of leucocytes adherence to the endothelium 
(Bergan et al., 2008). Perhaps white cells cause occlusion of capillaries, but the cause 
of local hypoxia and tissue injury are presumed to be mediated by toxic products 
released by trapped white cells (Eberhardt et al., 2005; Sandor, 2004, 2010).  
The breakdown of the skin is also related to increased expression of tissue 
metalloproteinases, that also inhibits venous ulcer healing (Bergan et al., 2008; 
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Meissner et al., 2007a; Sandor, 2004). The mechanism responsible for wound healing 
is an orderly process that involves inflammation, re-epitalization, matrix deposition, 
and tissue remodeling, and these last two stages are controlled by reducing the 
activity of extracellular matrix metalloproteinases and by increasing inhibitors of 
these proteolytic enzymes (Amato et al., 2013; Serra et al., 2014). Matrix 
metalloproteinases are controlled by a diversity of signaling molecules, including 
pro-inflammatory cytokines and growth factors (TGF-β1, that cause excessive 
fibrosis and inflammation) (Meissner et al., 2007a). 
Also, varicose veins present reduced ability to undergo venoconstriction and 
show lessened compliance, which is explained by reduced amount of smooth muscle 
(Eberhardt et al., 2005; Sandor, 2004, 2010), reduced quantity of elastin, and 
increased collagen as the result of endothelial dysfunction in response to stasis and 
hypoxia (Lowell et al., 1992; Sayers et al., 1993). 
Changes in the venous hemodynamics of the large veins of the lower 
extremity are transmitted into the microcirculation and eventually result in the 
development of venous microangiopathy (elongation, dilation, and tortuosity of 
capillary beds, thickening of basement membranes with increased collagen and 
elastic fibers, endothelial damage with widening of interendothelial spaces, and 
increased pericapillary edema) (Eberhardt et al., 2005; Sandor, 2004, 2010). The 
increased permeability of capillaries and high venous pressure leads to the 
accumulation of fluid, macromolecules (i.e., proteins like fibrinogen and α2-
macroglobulin), and red blood cells extravasation into the interstitial space, causing 
injury to the subcutaneous tissue (Meissner et al., 2007a; Sandor, 2010; Smith, 
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2006), chronic inflammation with degradation of red blood cells, and sustained 
recruitment of leucocytes (Smith, 2006; Wilkinson et al., 1993). 
Tissue remodeling in CVD is greatly dependent on the balance between 
inflammation and tissue injury and the process of healing and repair (Meissner et al., 
2007a). The frequency and the intensity of triggering events will determine such 
balance and ultimately the severity of tissue injury (Meissner et al., 2007a). Risk 
factors have an important role in this inflammatory cascade (Vlajinac et al., 2012). 
In addition to changes in the blood vessels and connective tissue, alterations 
in the lymphatic network and nervous system may occur (Boisseau, 2007; Eberhardt 
et al., 2005). Fragmentation and destruction of microlymphatics may further impair 
drainage from the extremities, whereas dysfunction of local nerve fibers may alter 
regulatory mechanisms (Eberhardt et al., 2005). As the capillary pressure elevates the 
content of proteins within the interstitial space, the skin and subcutaneous tissues 
become damaged, such as in lipodermatoesclerosis (Meissner et al., 2007a; Smith, 
2006), and because of peripheral lymphatic system dysfunction, secondary 
lymphedema may occur, motivated by the high oncotic pressure in the interstitial 
space (Raju et al., 2012). 
2.2.3 Symptoms in CVD 
There are several symptoms that are associated with CDV, including pain, 
tightness, skin irritation, heaviness, muscle cramps, burning feelings, fatigue, 
soreness, tingling, restless leg, and feeling of swelling (Bradbury et al., 1999; 
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Campbell et al., 2007; Darvall et al., 2012; Eklof et al., 2009; Eklof et al., 2004; 
Gloviczki et al., 2011). 
The number of symptoms reported by patients with CVD varies but are 
usually several (Boisseau, 2007; Bradbury et al., 1999; Darvall et al., 2012). 
Importantly, the number and severity of symptoms are not strictly related with CVD 
severity and sometimes severe symptoms, and those that have the largest impact on 
HRQL, are present in less severe cases (Darvall et al., 2012).  
Despite indication for surgery for varicose veins following the clinical 
evaluation of one or more symptoms and of reflux in saphenous veins, some studies 
suggest that the majority of the symptoms in patients with varicose veins are non-
venous related (Bradbury et al., 1999). Indeed, it seems very difficult to separate 
venous from non-venous causes of symptoms in CVD (Campbell et al., 2007). 
Several studies show the presence of both neuropathic and nociceptive pain in 
patients with CVD (Boisseau, 2007; Shiman et al., 2009). In addition, and based on 
the physiopathology of chronic pain (Smart et al., 2011; Vranken, 2012), the 
possibility of patients with CVD presenting central sensitization of pain cannot be 
discarded.  
Nociceptive pain announces a potential threat caused by noxious stimuli of 
chemical (inﬂammatory), mechanical or thermal nature, that activate primary afferent 
slow-conducting neurons (Aδ and C ﬁbres) (Fornasari, 2012). Neuropathic pain is 
related to a primary lesion or dysfunction of the nervous system resulting from 
infection, trauma and other causes (Fornasari, 2012), that changes the function of 
neural circuitries (neural plasticity) (Vranken, 2012). Neuropathic pain involves 
several mechanisms, including the action of soluble mediators (e.g., cytokines, H
+
, 
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nerve growth factor), alterations in calcium channels, sodium channels, 
hyperpolarisation-activated nucleotide-gated ion channels, potassium channels, 
phenotypic switches and sprouting of nerves endings, and the involvement of the 
sympathetic nervous system (Vranken, 2012). 
The progress from acute to chronic pain is related to changes in the central 
nervous system and with the altered transmission and modulation of pain sensation 
following a lesion (Fornasari, 2012). Peripheral sensitization of sensory nerve fibers 
cause hypersensitivity to pain, and may be present in inflammatory and neuropathic 
pain as due to CVD, however central sensitization are not described in this patients 
(Fornasari, 2012; Shiman et al., 2009; Vranken, 2012). 
In CVD, the adhesion of the leucocytes to the endothelial cells trigger an 
inflammatory process (Boisseau, 2007; Nicolaides, 2005). Leucocytes leave 
circulation because of inflammation (vascular media or intima), pre-inflammatory 
endothelial cell activation (hypoxia in lumen or wall vessel), or altered 
hemodynamics (decreasing or abnormal blood flow), damaging the microcirculation 
and enlarging the veins (Boisseau, 2007; Meissner et al., 2007a; Sandor, 2004). This 
may occur in deep vein thrombosis or venous reflux (Boisseau, 2007). Both 
leucocyte adhesion and its products, acting as signaling molecules, and the 
hypertension (decreased venous blood flow), acting as a mechanical factor, increase 
the permeability of capillaries, leading to CVD and edema (Boisseau, 2007; Meissner 
et al., 2007a; Nicolaides, 2005; Sandor, 2004). The abundant biochemical mediators 
released by leucocytes into vein and venule walls and into the interstitial space are 
presumed responsible for stimulating the nerve endings and causing nociceptive pain 
in CVD, rather than venous dilation per se, which seems to be painless (Boisseau, 
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2007). Unlike skin, veins possess only few nociceptive nerve endings (Boisseau, 
2007). First, the mechanical stimulation of Aβ nerve fibers after priming stimulation 
of both Aδ e C nerve fibers by chemical stimuli, gives rise to a truly painful 
sensation followed by a diffuse and sustained pain (Boisseau, 2007). The pain 
transmitted by C fibers are more visceral-like, meaning that it is more sustained, 
diffuse, while also causing anxiety, and the readiness to feel pain may interfere with 
this subjective sensation of symptoms (Boisseau, 2007).
 
With time, the nociceptors 
might become sensitized and pain pathway might suffer facilitation due to 
morphological (e.g., nerve endings sprouting) and/or neurophysiological changes 
causing peripheral neuropathy and neuropathic pain (Boisseau, 2007; Newland et al., 
2009).
 
CVD may cause tissue damage in the leg, including the peripheral nerves 
(Reinhardt et al., 2000). Patients with CVD present a higher motor latency, a reduced 
vibration threshold, and diminished warm and cold perception, resulting from 
disturbances of Aα, Aβ, Aδ and C fibers (Reinhardt et al., 2000) and denervation 
(Shiman et al., 2009). Patients with venous ulcer and varicose veins present a 
decreased number of nerve fibers at the epidermis (Guest et al., 2004). Also, the 
fewer number of epidermal nerve fibers in chronic ulcers suggests that skin 
innervation may be important for healing (Guest et al., 2004). On the other hand, the 
application of nerve growth factor is associated with improved venous ulcer healing, 
suggesting that changes in these kinds of growth factors may be at the origin of 
CVD-associated peripheral neuropathy and neuropathic pain (Shiman et al., 2009).  
Nevertheless, patients with CVD may present other comorbidities that make 
only the CVD-related pain difficult to assess (Shiman et al., 2009). For example, 
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peripheral neuropathy and pain might be due not to CVD, at least exclusively, but 
rather associated with comorbidities, like diabetes (Reinhardt et al., 2000). 
2.2.4 Signs of CVD 
Several signs are recognized to be associated with CVD, like telangiectasias 
and reticular veins, varicose veins, venous edema, skin pigmentation, corona 
phlebectatica, inflammation (eczema, cellulitis, dermatitis, for example), induration 
like lipodermatoesclerosis and atrophie blanche, and ulcer (healed or active), 
associated or not with symptoms of venous origin (Eklof et al., 2009; Eklof et al., 
2004; Gloviczki et al., 2011). Nevertheless, CVD might exist without the presence of 
signs (Eklof et al., 2009; Eklof et al., 2004; Gloviczki et al., 2011). The signs are the 
consequence of the physiopathology of CVD, and are caused by hypertension, 
inflammation, and injury of the microcirculation, the skin or the subcutaneous tissue 
(Meissner et al., 2007a). 
Reticular veins, also called blue veins, subdermal varices, and venulectasias, 
are dilated subdermal veins, usually 1 mm to less than 3 mm in diameter and with 
tortuous paths (Eklof et al., 2004). Telangiectasias, also called spider veins, hyphen 
webs, and thread veins, represent the confluence of dilated intradermal venules less 
than 1 mm in caliber (Eklof et al., 2004). 
According to the latest guidelines, varicose veins (also called varix, varices, 
and varicosities (Eklof et al., 2004)) should be palpable in an upright position and 
represent abnormal veins with at least 3 mm in diameter, (Eklof et al., 2009; Eklof et 
al., 2004; Gloviczki et al., 2011). Varicose veins can be present as a result of 
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hypertension caused by reflux and/or obstruction, as discussed before (Labropoulos 
et al., 2009; Meissner et al., 2007a). The development of varicose veins most 
frequently involves the saphenous veins, saphenous tributaries, or nonsaphenous 
superficial leg veins (Eklof et al., 2004). Varicose veins are usually tortuous, but 
tubular saphenous veins with demonstrated reflux may be classified as varicose veins 
(Eklof et al., 2004).  
Corona phlebectatica, also called malleolar flare and ankle flare, is commonly 
viewed as an early sign of CVD, and designates the accumulation of numerous small 
intradermal veins packed together on the medial or the lateral aspects of the ankle 
and foot (Eklof et al., 2004).  
Venous edema occurs when there is imbalance between venous filtration, 
venous reabsorption and lymphatic reabsorption (Mortimer, 2000). About 90% of the 
venous filtration is reabsorbed again in to the venous system, and the remaining 10% 
of the venous filtration (proteins, plasma, and other components) is reabsorbed by the 
lymphatic circulation (Morgan, 2008; Raju et al., 2012). In CVD, the venous 
filtration is increased by means of venous hypertension and raised permeability due 
to inflammation (Morgan, 2008; Mortimer, 2000). In these conditions venous edema 
may occur (Mortimer, 2000; Raju et al., 2012). This is a pitting edema that get worse 
through the day and improves at night with resting and leg elevation, and that usually 
is accompanied with venous symptoms and signs (Mortimer, 2000; Raju et al., 
2012). When edema is at the dorsum of the foot, is associated to squaring of the toes, 
to thick skin, and is of non-pitting edema type, it is assumed that a lymphatic 
compromise exists (Gloviczki et al., 2011). The lymphatic circulation may 
compensate for the excessive filtration, but lymph vessels also suffer damaged with 
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time (microlymphoangiopahty), because of chronic inflammation and accompanying 
subcutaneous and skin lesions (Eberhardt et al., 2005; Raju et al., 2012). Therefore, 
venous edema becomes compound with signs of lymphedema, with non-pitting 
edema and with hyperkeratosis, and is now associated with lymphatic insufficiency 
(Mortimer, 2000). Clinically, venous edema is perceived as an increase in volume of 
fluid in the skin and subcutaneous tissue, characteristically diminished by pressure 
(Eklof et al., 2004). Venous edema usually occurs around the ankle region, but may 
extend to the leg and foot (Eklof et al., 2004). 
The presence of pigmentation means that the skin becomes darker and 
brownish (Eklof et al., 2004). This results from extravasation of red blood cells into 
the interstitial space (Meissner et al., 2007a). Blood extravasation and skin 
pigmentation is most noticed around the ankle, but may also be visible in the leg and 
foot (Eklof et al., 2004; Vasquez et al., 2010). 
Atrophie blanche (white atrophy) is an induration of tissues. This skin 
alteration, that should not be confused with healed venous ulcers, is usually well 
localized and has the shape of a circular white and atrophic skin surrounded by 
dilated capillaries and sometimes hyperpigmentation (Eklof et al., 2004; Vasquez et 
al., 2010).  
Lipodermatosclerosis is also a clinical sign of tissue induration, characterized 
by local chronic inflammation and fibrosis of skin and subcutaneous tissues at the 
lower region of the leg (also compromising the Achilles tendon), sometimes 
preceded by diffuse inflammatory edema of the skin, which may be painful and 
which often is referred to as hypodermitis (Eklof et al., 2004; Vasquez et al., 2010). 
Clinically, lipodermatosclerosis must be differentiated from lymphangitis, erysipelas, 
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or cellulitis by their characteristically different local signs and systemic 
characteristics (Eklof et al., 2004).  
The eczema, is an inflammation process, erythematous dermatitis, which may 
progress to blistering, weeping, or scaling eruption of the leg skin, and may be 
located anywhere in the leg (Eklof et al., 2004; Vasquez et al., 2010). Eczema is very 
frequent in uncontrolled CVD, but may also be associated to sensitization to local 
therapy (Eklof et al., 2004). 
Venous ulcers are the worst clinical sign of CVD and represent the loss of 
integrity of the skin, with a full-thickness defect and occur most frequently near the 
ankle region (Eklof et al., 2004), at the site of major perforating veins and the 
greatest hydrostatic pressure (Eberhardt et al., 2005). Venous ulcers are also 
characterized by failure to heal spontaneously and are sustained by CVD (Eklof et 
al., 2004). 
2.3 CVD diagnosis 
The diagnosis of CVD is based on history and physical examination of 
patients with the assistance of non-invasive tests, such as duplex ultrasound scanning 
(Eberhardt et al., 2005; Meissner et al., 2007a; Min et al., 2003; Nicolaides, 2000). 
Duration and valve closure time calculated by duplex ultrasound scan are used to 
diagnosis veins with insufficiency (Magnusson et al., 1995). The diagnose using the 
reflux time has been shown to be reproducible (Asbeutah et al., 2005). 
With B-mode ultrasonography, veins’ lumen should be imaged at transversal 
or/and longitudinal view, and the transducer should be adjusted for correct vein 
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imaging and to assess the presence/absence of acute or chronic thrombosis 
(Coleridge-Smith et al., 2006). Pulsed-waved spectral or color Doppler are used to 
assess the velocity and direction of venous flow and should be performed with a 
recommended Doppler range of 5-10 cm/s, with the wall filter at its lowest setting, 
and with the angle of insonation at 45-60º (Coleridge-Smith et al., 2006). During the 
examination (reflux and diameter), patients are at upright position and several 
methods are used to elicit reflux: release after calf squeeze, for proximal veins, and 
after foot squeeze, for calf veins, manual compression of vein clusters, pneumatic 
calf cuff deflation (the more reproducible method), active foot dorsiflexion and 
relaxation, and Valsalva maneuver, in this case to demonstrate saphenofemoral 
incompetence (Coleridge-Smith et al., 2006). Reflux is generally considered 
abnormal when its duration attains a cutoff time of 0.5 seconds in the case of the 
saphenous, tibial, deep femoral, and perforating veins, and 1 second, in the case of 
the femoral and popliteal veins (Eberhardt et al., 2005; Gloviczki et al., 2011; Min et 
al., 2003; Nicolaides, 2000). One study concludes that veins are normal if reflux time 
is less than 0.5 seconds, with sensitivity of 90%, and are insufficient when reflux 
increases to above 0.7 seconds, with specificity greater than 90% (Lurie & Pevec, 
2000). The same study reports good reliability of reflux time measures, with 
correlation coefficients of r = 0.97 and r = 0.85, for immediate and late test-retest, 
respectively. Nevertheless, studies disagree whether this method allows to 
distinguish between different levels of venous insufficiency severity (Lurie et al., 
2000).  
On the other hand, the volume reflux index (the percentage of antegrade 
blood volume that flows backwardly (reflux) after a muscle calf 
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compression/contraction (Lurie et al., 2000)) is an accurate measure to evaluate the 
severity of venous insufficiency. This index is calculated by duplex ultrasound 
scanning taking into account the veins’ cross-sectional area and blood mean velocity 
(Lurie et al., 2000). 
Air-plethysmography can also be used to complement the diagnosing of CVD 
when duplex scanning is unable to provide definitive information about its 
physiopathology, also being a good test to assess CMPF (Gloviczki et al., 2011). 
Other imaging studies, such as computed tomography venography, magnetic 
resonance venography, ascending and descending contrast venography, and contrast 
ultrasonography are used selectively (Meissner et al., 2007a), such as in cases of 
endoluminal or extraluminal venous obstructions (like post-thrombotic syndrome and 
deep venous thrombosis, and pathologies as tumors, traumas, and some medical 
interventions). However, routinely, the duplex ultrasound scanning is the most 
economic, valid and reliable non-invasive method for diagnosing CVD (Gloviczki et 
al., 2011). 
2.4 Calf muscle pump function 
The venous blood return from periphery to heart via the venous system is 
linked to the action of a central pump (heart and respiratory cycle), periphery venous 
pump, a pressure gradient, and competent veins and/or venous valves (Shiman et al., 
2009). 
The calf muscle pump has an important role for the effective venous return 
and relies on dynamic interaction between the ankle joint, muscle fascia, muscles of 
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the calf and venous valves (Meissner et al., 2007a; Shiman et al., 2009). During 
muscle contractions, the venous blood is forced in direction to the heart and the 
valves prevent reflux during relaxation (Kan et al., 2001; Meissner et al., 2007b; 
Recek, 2013). As deep veins are tethered to surrounding tissues, muscle relaxation 
causes the veins to open, lead to a sudden drop in pressure within these vessels 
(Cavalheri et al., 2008; Clarke Moloney et al., 2006; Ibegbuna et al., 2006). The large 
pressure gradient that develops forces the blood to flow from superficial to deep 
veins trough perforator veins, decreasing venous pressure and allowing arterial flow 
(Meissner et al., 2007a; Shiman et al., 2009).  
2.4.1 The three venous muscle pumps of the lower limb 
There are three venous muscle pumps: foot, calf and thigh (Ludbrook, 1966; 
Meissner et al., 2007a). 
The calf muscles, and possibly the thigh muscles, act as a pump, also called 
as ‘‘peripheral heart”, which can generate pressures of up to 300 mm Hg during 
exercise (Gaweesh, 2009). Nevertheless, it has been suggested that thigh muscle 
pump has a minor effect in venous return, compared to calf muscle pump (Ludbrook, 
1966; Meissner et al., 2007a; Shiman et al., 2009). Calf muscles contraction can 
elevate the pressure to approximately 140 mm Hg and increase venous blood flow 
through the popliteal and the femoral veins (Recek, 2013).
 
In competent veins, the 
centrifugal component during muscle relaxation lasts approximately 200 to 300 
milliseconds and represents the physiological reflux, in incompetent veins the 
duration exceeds 500 milliseconds (Recek, 2013). 
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During gait, venous pressure in the leg decreases from around 100 mm Hg to 
around 22 mm Hg, due to combined action of the muscle contractions and plantar 
compression (Rowland, 2001). The plantar venous plexus is compressed during gait, 
increasing venous flow through the posterior tibial venous system into the popliteal 
vein (Meissner et al., 2007a; White et al., 1996). Despite these observations, it has 
been suggested that foot muscle pump has two possible mechanisms that operate 
during stance: firstly the weight bearing compression of the plantar veins, and 
secondly the contraction of the foot muscles (e.g., the abductor digiti minimi, 
abductor hallucis, extensor digitorum brevis, flexor digitorum brevis, and flexor 
hallucis brevis) around these veins. The two mechanisms, however, do not work 
synchronously, with plantar compression acting first then followed by the action of 
the muscle contractions at the foot (Corley et al., 2010). These two different foot 
pump mechanisms may both be present during the stance phase of the gait cycle, but 
would be active at slightly different moments (Corley et al., 2010). Also, certain 
clinical conditions of CVD could be explained by a conflict between the mechanisms 
of the foot pump and the leg pumps (Ricci et al., 2014). The knowledge about the 
interaction of the lower limb muscle pumps during contraction/relaxation as a 
mechanism for venous return is still quite poor (Meissner et al., 2007a). 
The calf muscle pump contraction is assumed as the most important muscle 
pump of the lower limb (Alimi et al., 1994; Meissner et al., 2007b). Less efficient 
CMPF (involving especially the gastrocnemius and soleus muscles) has also been 
related with muscle inflammation, reduced muscle oxygen supply, muscle necrosis, 
myofibril atrophy (muscle fibers type I and II) and muscle denervation (Qiao et al., 
2005; Yamaki et al., 2010). A study by Araki et al. (Araki et al., 1994) concluded 
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that venous insufficiency cannot fully explain venous ulceration, pointing to deficient 
calf muscle pump as a primary factor in CVD-related skin and tissue damage. 
Several studies show that early treatment, by exercising the muscle pump, can 
prevent the most severe forms of CVD (Nullen, 2010; Padberg et al., 2004). The 
important role of CMPF in the progression of CVD is well established, but in many 
individual cases impaired calf pump function may go undetected until most severe 
changes become evident (Bradbury, 2010). Therefore, assessable, accurate and non-
invasive methods to evaluate CMPF are needed (Bradbury, 2010; Nicolaides, 2000; 
Padberg et al., 2004; Panny et al., 2009; Sandor, 2010). 
2.4.2 Impairment of calf muscle pump and functional capacity 
Calf muscle pump dysfunction might be caused by weakness of calf muscles, 
but may also be related to decreased range of motion around the ankle joint during 
walking and other movements (Back et al., 1995; Cavalheri et al., 2008; Panny et al., 
2009; Yang et al., 1999), neuropathy, muscle denervation or muscle atrophy, or gait 
abnormalities (de Moura et al., 2012; Qiao et al., 2005; Shiman et al., 2009). 
Ankle function plays an important role in mobility (de Moura et al., 2012). 
Distal leg muscles may exhibit reductions in strength and power with aging, and 
these affects walking, balance, and increases the risk of falling (Webber & Porter, 
2010). Impaired ankle muscles strength has been associated with falls (Suzuki et al., 
2001). Dorsiflexion power has been found to be closely associated with function in 
community-dwelling older women in terms of their ability to get up from and sit 
down on a chair and climb stairs (Suzuki et al., 2001). Plantarflexion strength has 
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been shown to be positively related to both preferred gait speed and fast gait speed 
(Suzuki et al., 2001). Patients with CVD present limited ankle range of motion (Back 
et al., 1995; Cavalheri et al., 2008; de Moura et al., 2012; Dix et al., 2003; van Uden 
et al., 2005). Diminished ankle mobility tends to aggravate as CVD progresses and is 
parallel with increasing severity of symptoms, thus further contributing to a poor 
CMPF (Back et al., 1995; Cavalheri et al., 2008). Together with decreased ankle 
range of motion, there is also decreased muscle strength of dorsi and plantarflexors 
(Panny et al., 2009; Yang et al., 1999), with decreased peak torque, power ability (de 
Moura et al., 2012), muscle resistance (number of heel rises) (van Uden et al., 2005), 
and total work performed by the ankle plantarflexors (Yang et al., 1999). Other 
functional alterations associated with CVD include decreased gait speed (de Moura 
et al., 2012; van Uden et al., 2005), decreased number of steps per week (in venous 
ulcer patients) (Clarke-Moloney et al., 2007), and generally impaired functional 
capacity and mobility (de Moura et al., 2012). Also, changes in ankle function alters 
foot pressure distribution during gait that becomes higher at the midfoot and lower at 
the toes (Shiman et al., 2009). 
These functional alterations, specially the decreased strength of the calf 
muscles and reduced ambulation, contribute to venous hypertension (Back et al., 
1995; Dix et al., 2003; Meissner et al., 2007a; Newland et al., 2009; Panny et al., 
2009; Shiman et al., 2009). Dysfunction of the muscle pumps leads to venous blood 
not being effectively emptied out of the distal extremity (Panny et al., 2009). This 
rarely occurs as a “primary” disorder with neuromuscular conditions or muscle 
wasting syndromes; however, clinically significant muscle pump dysfunction often 
occurs in severe reflux or obstruction (Nicolaides, 2000). Muscle pump dysfunction 
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appears to be a major mechanism for the development of superficial venous 
incompetence and its complications, such as venous ulcers, and around 70% of 
patients with venous ulcer present calf muscle pump dysfunction (Araki et al., 1994; 
Bradbury, 2010; Eberhardt et al., 2005; Kan et al., 2001; O'Brien et al., 2012).  
2.4.3 Air-plethysmography: the gold standard assessment of calf muscle 
pump  
Venous hypertension usually results from reflux, obstruction, and poor 
ejection, and air-plethysmography is capable of defining the contribution of each of 
these components (Nicolaides, 2000).  
Although duplex ultrasound scanning is the method most used to diagnose 
CVD, the evaluation of calf muscle pump is usually done by air-plethysmography 
(Asbeutah et al., 2005). This is carried out by assessing the ability of the calf muscle 
pump to eject blood from the leg veins after ten consecutive calf muscle contractions 
during tip-toe/heel-rise movement (Nicolaides, 2000). However, other studies used 
vascular ultrasound to estimate the capacity of muscle contraction to eject venous 
blood as an estimation of CMPF (Hitos et al., 2007; Moloney et al., 2007; 
Staubesand et al., 1995). 
Calf air-plethysmography has been the gold standard measure to evaluate 
CMPF in venous insufficiency, showing good reproducibility (Asbeutah et al., 2005). 
This method is used for calculating the ejection fraction (the percent of blood volume 
expelled in one muscle contraction) and residual volume fraction (the percent of 
blood volume remaining within the calf at the end of ten tip-toe movements) 
(Nicolaides, 2000). A poor ejection fraction (< 40%) and a high residual volume 
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fraction (> 20/30%) are related to the most severe stages of CVD (Cavalheri et al., 
2008; Nicolaides, 2000; Padberg et al., 2004). Also, the complications and severity 
of CVD, such as ulceration, have been shown to correlate with the severity of reflux 
assessed by vascular ultrasound (de Moura et al., 2012; Eberhardt et al., 2005). This 
technique provides quantitative information about several aspects of global venous 
function (Eberhardt et al., 2005). It may be used in the selection of interventions and 
for assessing the response to interventions directed to CMPF and to provide an 
overall measure of the efficacy of CVD treatments (Owens et al., 2000; Padberg et 
al., 2004). 
2.4.4 Ultrasound assessment of hemodynamic component of calf muscle 
pump  
Despite there being no strong correlation with CVD severity, the capacity to 
increase venous blood flow (flow velocities and flow volume) through the veins 
during a calf muscle contraction has been assessed in several studies that evaluate 
CMPF (Moloney et al., 2007; Sochart & Hardinge, 1999; Staubesand et al., 1995).  
The reproducibility of venous volume flow (mean flow velocity × cross-
sectional area of the vein) measurements by vascular ultrasound scanning improves 
with the use of sampling volumes that cover the entire venous lumen at points where 
the veins’ profile is roughly circular, by using an incident angle of the ultrasound 
beam of 60 degrees, and measuring for 40-second intervals or longer (Lurie et al., 
2002; Ogawa et al., 2002). 
At rest, flow volume can reach [mean (standard deviation)]147 (70.2) 
mL/min in the superficial femoral vein, 86 (40.8) mL/min in the deep femoral vein, 
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and 38 (16.8) mL/min in the GSV (Ogawa et al., 2002). During contractions of lower 
limb muscles, it is possible to assess the increase in flow velocity and flow volume in 
the respective veins (Hitos et al., 2007; Moloney et al., 2007).  
With ultrasonography, it is possible to separately assess the effect of 
plantarflexion and dorsiflexion during both active and passive movements (Table 1) 
(Hitos et al., 2007; Moloney et al., 2007). 
2.4.5 Ultrasound assessment of muscle component of calf muscle pump 
Muscle pump function relies on muscle ability to contract and generate 
pressure against the deep veins, pulling venous blood through these vessels 
(Meissner et al., 2007a; Shiman et al., 2009). Macroscopic arrangement of muscle 
fibres is known as a muscle’s architecture (Lieber & Friden, 2000), also known as 
the arrangement of muscle fibres within a muscle relative to the axis of force 
generation (Lieber & Friden, 2001). Because muscle architecture is a primary 
determinant of muscle function, understanding this structure-function relationship is 
of great practical importance, by, for example, clarifying the physiological basis of 
force production (Lieber et al., 2000, 2001). Muscle force generation ability is 
related to the amount of muscle mass and in particular to its cross-sectional area 
(Lieber et al., 2000, 2001). In this case, ultrasound imaging can be employed to 
determine muscle thickness, which is an indicator of muscle mass and muscle cross-
sectional area (Chi-Fishman et al., 2004; Lieber et al., 2000, 2001). Also, ultrasound 
imaging provides data of muscle fascicles orientation either in relaxed or contracted 
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conditions, a parameter that is a determinant of the amount of muscle force (Chi-
Fishman et al., 2004). 
In ultrasound imaging, muscle fibres themselves are hipoechogenic, but the 
perimysium, that covers muscle fascicles, and the epimysium, covering the whole 
muscle, are hyperechogenic and are used, together with the aponeurosis and tendons, 
as references for defining the muscle architecture (Woodhouse & McNally, 2011). 
The parameters most used of muscle architecture are the muscle length (distance 
from origin of the most proximal muscle fibres to the insertion of the most distal 
fibres), fibre length (expression on number of sarcomeres in series, and in most 
studies measured as the fascicle length), pennation angle (i.e., the fibre angle relative 
to force-generating axis, that usual range from 0º to 30º for the gastrocnemius 
muscle) and physiological cross-sectional area (the sum of the cross-sectional areas 
of all the muscle fibres within the muscles) (Lieber et al., 2000, 2001). The muscle 
fascicle length plays a role in force generation during high-speed muscle 
contractions, while fascicle pennation angle and muscle thickness are important 
factors for overall force generation ability. These parameters can be reliably 
evaluated with ultrasound (Raj et al., 2012). Gastrocnemius muscle, one of the most 
important muscles of the CMPF, is a relatively thick muscle with short muscle 
fascicles, showing high capacity to produce force with low muscle excursion during 
activity (Lieber et al., 2000, 2001). During gastrocnemius contraction, muscle 
fascicles shorten from around 126 to 67 mm and the pennation angle increases from 
20º to 45º (Lieber et al., 2000, 2001). 
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Table 1 - Assessment of venous blood flow during calf muscle pump  
VEIN 
ASSESSED 
MOVEMENT VENOUS BLOOD FLOW MEASURES/RESULTS 
Popliteal 
vein 
During active plantar 
flexion of patients with 
venous ulcer (Moloney 
et al., 2007). 
Increased peak flow velocity to a median of 70.08 (28.73 - 206.2) 
cm/s. 
 After exercise of calf 
and foot muscles (Hitos 
et al., 2007). 
Increased venous flow velocity (7.3 - 20.2 cm/s) and flow volume 
(7.7 - 21.5 mL/s), calculated with formula: π × (diameter of 
popliteal vein)2 ÷ 4, when compared to rest not using any 
compression or active movement (5.8 - 15.6 cm/s and 6.6 - 16.3 
mL/s), at sitting position in healthy subject with risk of deep 
venous thrombosis by steadiness during an airplane travel. 
 During active tip-toe 
movement at upright 
position (Breen et al., 
2007). 
Increased mean and peak flow velocity and flow volume during an 
active tip-toe movement at upright position, with accurate 
measures when automatic assessment of hemodynamic variables 
are achieved. 
Great 
saphenous 
vein 
After a series of passive 
and active dorsiflexion-
plantarflexion of ankle 
(Staubesand et al., 
1995). 
Increased peak flow velocity (21.28 - 30.62 cm/s and 21.01 - 
43.12 cm/s, respectively) comparing with rest blood flow velocity 
(12.28 - 14.30 cm/s), in patients with CVD. 
 
Femoral vein At lying position during 
(Sochart et al., 1999): 
Increased peak flow velocity, in healthy subjects: 
 
  Passive 
dorsiflexion-
plantarflexion  
31.2 cm/s and 53.8 cm/s, respectively; 
 
  Active 
dorsiflexion-
plantarflexion 
35.6 cm/s and 59.0 cm/s, respectively; 
 
  Passive inversion-
eversion 
31.5 cm/s and 53.5 cm/s, respectively; 
 
  Active inversion-
eversion  
35.5 cm/s and 61.6 cm/s, respectively; 
 
  Passive 
combination for 
rotation of ankle  
Reach 58.0 cm/s; 
 
  Active combination 
for rotation of 
ankle 
Reach 70.2 cm/s. 
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There is scarce data relating muscle architecture with CMPF in healthy 
subjects and CVD patients. In one study, the volume of calf muscles of patients with 
venous ulcer was shown to be unrelated with the increase in venous blood peak flow 
velocity in popliteal vein during maximal plantar flexion contractions (Moloney et 
al., 2007). No other features of calf muscles architecture was evaluated in patients 
with CVD, despite existing changes in gastrocnemius muscles in these population, 
including disseminated myofibril atrophy (especially in fiber type I, accompanied by 
moderate to severe atrophy in fiber type II, associated to denervation and 
reinnervation of the gastrocnemius muscle), cell necrosis, inflammatory cell 
infiltration, proliferation and dilation of interfascicular veins (Qiao et al., 2005). 
2.5 Manual lymphatic drainage  
2.5.1 Brief history of manual lymphatic drainage 
There are four recognized techniques of MLD: the Földi (Tan et al., 2011), 
Vodder (Kasseroller, 1998), Casley-Smith (Casley-Smith et al., 1998) and Leduc 
(Leduc et al., 1998). 
Back in the nineteenth century, A. T. Still (1828-1917), the founder of 
Osteopathy, drew attention to the importance of the lymphatic system and of its 
connection with the venous circulation, but it was Winiwater, in 1890’s, an Austrian 
Physician from Vienna, that described for the first time a lymphatic massage 
(drainage), associated to leg elevation, compression and exercise (Kasseroller, 1998; 
Morgan, 2008). After these initial approaches, the theme of lymphatic drainage and 
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of its application in the treatment of edema remained relatively abandoned, 
undergoing further developments later by Vodder, Asdonk, and Leduc, and more 
recently by Földi (Casley-Smith et al., 1998). 
In 1920, Miller proposed a so-called thoracic pump technique that would 
presumably generate fluctuations in intrathoracic pressure and thus increasing lymph 
flow (Morgan, 2008).  
In 1930, Vodder and his wife developed the technique that was called manual 
lymph drainage (Morgan, 2008), that was originally directed to an essentially normal 
lymphatic system (like traumatic edema) (Casley-Smith et al., 1998). In 1960, 
Asdnok, a German physician, tested the Vodder technique of MLD, establishing the 
indications, contraindication, and the effects of the technique (Morgan, 2008). 
Földi combined Vodder’s MLD with bandaging, exercise, and skin care and 
named such therapeutic approach the “complete decongestive physiotherapy”, later 
renamed to as “complete decongestive therapy” (Coleridge-Smith et al., 2006; 
Morgan, 2008). His work, together with the knowledge about the physiology and 
pathophysiology of microcirculation and the development of the benzopyrone group 
of drugs, were one of the most important contributions for lymphedema treatment 
(Coleridge-Smith et al., 2006). The emphasis in self-care advocated by Casley-
Smith, complemented the complete decongestive therapy with techniques of deep 
breath and self-drainage. (Casley-Smith et al., 1998). 
Leduc in 1970’s started to publish his research, giving a novel and scientific 
understanding about the effects of MLD on the lymphatic and venous systems, and 
about the two basic mechanisms that MLD and other treatments must address: the 
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reabsorption and evacuation of the lymph, respecting the physiology and 
pathophysiology of lymphatic system (Leduc et al., 1988; Leduc et al., 1998).  
In February 1988, in New York, Földi, Leduc, Vodder and Casely-Smith 
agreed on the term “decongestive lymphatic therapy” as a suitable name to this group 
of treatment techniques.  
The four methods of MLD show some differences, but the major basic 
principles are very similar. In short, the maneuvers should be applied softly (with 
specific exceptions), should consist of a skin-stretching form of massage (not 
sliding), should comply with the direction of lymph flow, should be done using the 
entire hand or exceptionally with fingers, and should begin at the proximal regions of 
the extremity (Casley-Smith et al., 1998; Foldi, 1998a, 1998b; Kasseroller, 1998; 
Leduc et al., 1998). 
2.5.2 Manual lymphatic drainage - Leduc method 
MLD is used as a conservative treatment of lymphedema, independently of 
the specific method (Koul et al., 2007). In the case of the Leduc method, MLD 
consists of a skin-stretching (Koul et al., 2007) form of massage that applies low 
pressure (<40 mm Hg) to the underlying tissues (Leduc et al., 1998) along the 
anatomical distribution of the superficial lymphatic vessels and ganglions, 
stimulating lymph flow (Leduc et al., 2011; Lee et al., 2011) and the reabsorption of 
interstitial fluid and macromolecules through the lymphatic circulation (Leduc et al., 
2011; Leduc et al., 1998; Lee et al., 2011). At the lower extremity, the call-up 
maneuver, a technique belonging to the Leduc method, initiates with inciting (or call-
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up) maneuvers in the inguinal region (ganglionar stimulation) and then progresses 
distally along the lower extremity down to the edematous region, again employing 
call-up maneuvers, in order to stimulate lymph flow by enhancing the contractility of 
lymphagions of lymph collectors (Leduc et al., 2011; Lee et al., 2011). The 
reabsorption maneuver, another Leduc technique, is then applied over the edema to 
drain the interstitial fluid and soluble macromolecules through the lymphatic 
circulation (Leduc et al., 1988; Leduc et al., 2011; Lee et al., 2011) by stretching the 
leak filaments (connections between connective tissue to endothelial cell of 
lymphatic capillaries) when the skin is mobilized (Leduc et al., 1988; Leduc et al., 
2011; Lee et al., 2011). The whole procedure ends with a second round of call-up 
maneuvers which are then applied in the reverse direction, ending at the groin region, 
in the case of the lower limb (Leduc et al., 2011; Lee et al., 2011). Technically, the 
call-up maneuver initiates with the most proximal part of the hand and ends with the 
hands touching the skin while producing skin-stretching and is applied to promote 
the increase of lymph flow (Leduc et al., 2011; Lee et al., 2011). The reabsorption 
maneuver initiates with the most distal part of hand and ends with hands touching the 
skin while applying skin-stretching (Leduc et al., 2011; Lee et al., 2011).  
2.5.3 Therapeutic efficacy of manual lymphatic drainage 
There are several indications for the use of MLD other than lymphedema, like 
CVD, post thrombotic syndrome, chronic wounds, traumatic edema (iatrogenic, post-
surgical, musculoskeletal injury), complex regional pain syndrome, and lypedema 
(Morgan, 2008).  
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The evidence of MLD for the treatment of edema (related to cancer or 
traumatic during sport activity) (Huang et al., 2013; Vairo et al., 2009) and in 
improving functional status (related to total knee arthroplasty) (Ebert et al., 2013) is 
unclear, but has been considered minor. Nevertheless, MLD might have an important 
role in CVD by improving HRQL, symptoms (Kim et al., 2012; Lasinski et al., 
2012), and range of motion (Ebert et al., 2013) when edema/lymphedema is present. 
In palliative treatment, MLD improves pain and dyspnea (Huang et al., 2013). 
Based on a systematic review, the importance of MLD for preventing the 
incidence of lymphedema is unclear (Huang et al., 2013). A meta-analysis shows that 
MLD does not provide further therapeutic benefit in reducing lymphedema related to 
breast cancer, when compared to the standard treatment or with compression therapy 
(Huang et al., 2013), but another study has demonstrated a benefit when employing 
MLD in these cases (McNeely et al., 2011). However, the small benefit of MLD 
must be evaluated together with its cost in terms of time and money spent by patients 
and health care systems and such cost-benefit evaluation favours the option for 
compression therapy by using multilayer bandages or compression hosiers and 
considering adding MLD only if the response to treatment is unsatisfactory 
(McNeely et al., 2011). 
A simple lymphatic drainage, more simple in sequence, but using the same 
principles as MLD, in a way that can be applied by patients, with self-drainage (de 
Godoy et al., 2001; Williams et al., 2002) is less effective than MLD in reducing 
limb volume or lymphedema related to breast cancer, but can be used as a more 
economical MLD option (Huang et al., 2013). 
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It has been also suggested that MLD, despite the augmentation of lymph flow 
(increasing lymphagion contraction and lymphatic reabsorption), might also be 
responsible for increasing arteriolar blood flow, venous flow, redirection of flow 
towards collateral vessels, anastomoses, and perhaps stimulating angionesis, but this 
hypothetical effects of MLD need scientific evidence (Morgan, 2008). 
Younger patients, those heavier in weight and higher in body mass index are 
more likely to show poor lymphedema treatment outcome after intensive 
decongestive therapy (Huang et al., 2013). When an elastic sleeve and multilayer 
bandaging are associated to MLD, there is a higher chance that the lymphedema 
treatment is successful (Huang et al., 2013). 
2.5.4 Decongestive lymphatic therapy 
Decongestive lymphatic therapy is the physical treatment for lymphedema by 
combining MLD with other treatments, like low-stretch bandaging and compression 
garments, exercise, and skin care, and sometimes also with intermittent pneumatic 
compression (Foeldi et al., 1989; Koul et al., 2007; 2009). This method may reveal 
itself as effective in the treatment of lymphedema of the lower limb as it is for that 
affecting the upper limb as a result of cancer (Devoogdt et al., 2010; Lasinski et al., 
2012). 
Most often, decongestive lymphatic therapy is applied along two phases: the 
first, is the edema reduction and intensive one, the second one, is the maintenance 
phase ("The diagnosis and treatment of peripheral lymphedema: 2013 Consensus 
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Document of the International Society of Lymphology," 2013; Fialka-Moser et al., 
2013; Koul et al., 2007).  
The first phase is composed of skin care, exercises, MLD (for approximately 
1/2 hour), low pressure intermittent pneumatic compression therapy (one hour at a 
compression of 20 to 40 mm Hg), and multilayer bandages (worn day and night) 
("The diagnosis and treatment of peripheral lymphedema: 2013 Consensus 
Document of the International Society of Lymphology," 2013; Leduc, 2008). In 
breast cancer-related lymphedema, the patients remain active and proceed with 
normal activities, but should avoid sport activities (Leduc, 2008). Also, a treatment 
frequency of five times per week for two to three weeks or, if necessary, four weeks 
is recommended (Fialka-Moser et al., 2013; Koul et al., 2007; Leduc, 2008). 
In the second phase of treatment, that aims to conserve and optimize the 
results obtained in the first phase, is to recommended that patients receive MLD (1/2 
hour), low pressure intermittent pneumatic compression therapy (1 hour), 
compression hosiery (Leduc, 2008), with low-stretch elastic stocking or sleeve, skin 
care, and continued exercise ("The diagnosis and treatment of peripheral 
lymphedema: 2013 Consensus Document of the International Society of 
Lymphology," 2013). Sometimes, other components, such as self-drainage, might be 
added (Fialka-Moser et al., 2013; Koul et al., 2007). The treatment is initially 
commenced daily for 2-3 weeks and depending on clinical evolution can be reduced 
to once a week (Leduc, 2008). 
Sometimes, long term treatment is needed in the presence of some resistant, 
chronic edemas ("The diagnosis and treatment of peripheral lymphedema: 2013 
Consensus Document of the International Society of Lymphology," 2013). This 
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treatment requires regular MLD (1 session per week), education about the practice of 
sports, and wearing compression hosiery ("The diagnosis and treatment of peripheral 
lymphedema: 2013 Consensus Document of the International Society of 
Lymphology," 2013). 
Decongestive lymphatic therapy is often prescribed for patients with venous 
ulcer and when CVD are associated with mixed edema (lymphatic and venous 
origin), now combining MLD, compression bandages and stocking, physical therapy 
to improve calf muscle performance, and in few cases, intermittent pneumatic 
compression (Steins et al., 2000). In the case of CVD, wearing compression 
garments is essential for treatment efficacy ("The diagnosis and treatment of 
peripheral lymphedema: 2013 Consensus Document of the International Society of 
Lymphology," 2013; Steins et al., 2000). 
2.5.5 Contraindications/Precautions  
There are several contraindications and precautions for MLD and 
decongestive lymphatic therapy. It is suggested that cardiac, pulmonary and renal 
functions should be monitored because of temporary increase in blood flow and 
circulatory loading (Morgan, 2008). 
As for the contraindications, the literature describes erysipelas, lymphatic 
systemic infection and lymphangitis, meaning inflammation of the lymphatic system, 
as absolute contraindications for MLD and decongestive lymphatic therapy 
(Lymphoedema Framework. Management of Lymphoedema. International 
consensus, 2006). Severe renal and heart failure are also contraindications for the use 
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of multilayer bandages and intermittent pneumatic compression (Leduc, 2008), 
whereas caution should be enforced when employing MLD in patients with severe 
cardiac insufficiency (Leduc, 2008; Leduc et al., 2011; Lymphoedema Framework. 
Management of Lymphoedema. International consensus, 2006). Unstable 
hypertension, thyroid dysfunction, hepatic cirrhosis with abdominal fluid (ascites), 
superior vena cava obstruction, untreated tuberculosis or malaria, are also 
contraindications for physical treatment (Leduc, 2008; Lymphoedema Framework. 
Management of Lymphoedema. International consensus, 2006). If swelling occurs 
for a long time after initial breast surgery, medical examination should be sought and 
any physical treatment will be stopped if inflammation occurs (Leduc, 2008). Also, 
Crohn disease, recent surgery, and diabetes are some additional clinical conditions 
that may be monitored for precaution (Morgan, 2008). 
2.5.6 Manual lymphatic drainage in CVD 
MLD has also been used as a conservative treatment for CVD, (Steins et al., 
2000), mostly when venous lymphedema is present (Mortimer, 2000; Raju et al., 
2012). In this case, MLD is recommended to be applied at the level of the root of 
superficial veins, like GSV (medial aspect of the lower limb) (Leduc et al., 2000; 
Molski et al., 2009; Peyre et al., 2000). 
MLD applied before surgery in patients with CVD improves the clinical class 
of CEAP classification, HRQL, depression, anxiety, edema and symptoms (Molski et 
al., 2013; Molski et al., 2009). Nevertheless, foot volumetry and reflux volume index 
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only improve when MLD is associated to surgery and compression stockings (Molski 
et al., 2013; Molski et al., 2009). 
There is also the assumption that MLD has an effect on blood flow in 
superficial veins, especially through the call-up maneuver (Leduc et al., 2000). 
However, the real impact of MLD in hemodynamics is unclear, although it has been 
suggested as being insignificant (Leduc et al., 2011). One study concluded that 5 to 
15 minutes of MLD does not change cardiac output in patients with heart failure 
despite the near 100% increase in venous return after 5 minutes of MLD (Leduc et 
al., 2011). 
However, there is little information about the acute effect of MLD on blood 
flow in the superficial and the deep veins of the lower extremity and if there are, in 
fact, differences in such effect between alternative MLD maneuvers, like between the 
call-up and reabsorption maneuvers. 
2.6 The role of conservative treatments of CVD 
The treatment of patients with CVD might focus on both the symptoms and 
secondary changes of the disease, such as, for instance, edema, skin and 
subcutaneous changes or ulcers (Gloviczki et al., 2011). Usually, initial treatment of 
CVD patients involves a non-invasive conservative treatment to reduce symptoms 
and help prevent the development of secondary complications and the progression of 
the disease (Eberhardt et al., 2005). Complementary, or posteriorly, some 
interventional or surgical treatments can be undertaken (Eberhardt et al., 2005; 
Gloviczki et al., 2011). 
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Behavioral education, like giving advices to raise the legs to minimize edema 
and reducing intra-abdominal pressure, for exercising, for using compressive 
stockings and proper care of the skin and wounds, together with pharmacological 
therapy, are the most common referred conservative treatments (Eberhardt et al., 
2005; Gloviczki et al., 2011). The conservative pharmacological treatment with 
venoactive drugs may be indicated for patients with pain and edema and should be 
implemented in association with compression for healing venous ulcers (Gloviczki et 
al., 2011). If conservative treatment is unsuccessful or provides an unsatisfactory 
response, then further treatment, including surgery, should be considered based on 
anatomic and pathophysiological features (Eberhardt et al., 2005). 
Interventional treatments, like sclerotherapy, ablative therapy with 
endovenous radiofrequency and laser, endovascular therapy, are less invasive than 
surgery for treating CVD (Eberhardt et al., 2005). It has been recommended to use 
these techniques to treat superficial incompetence (endovenous thermal ablation, as 
laser and radiofrequency) and varicose veins (sclerotherapy) (Gloviczki et al., 2011). 
Surgical treatments are recommended in severe forms of CVD, like venous 
ulcers that did not heal after 6 months of treatment (Eberhardt et al., 2005). There are 
several surgical procedures described in the literature, like ligation, stripping and 
venous phlebectomy, subfascial endoscopic perforator surgery or valve 
reconstruction (Eberhardt et al., 2005). 
In CVD, the compression, like that provided by stockings, is recommended as 
a primary treatment, except when patients are candidates for vein ablation, in which 
case compression is also suggested as an adjuvant treatment, particularly to prevent 
ulcer recurrence (Gloviczki et al., 2011). Compression therapy is recommended as a 
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complement to surgery (like stripping), and to venoactive drug treatment, in order to 
control edema and pain, and to enhance venous ulcer healing (Gloviczki et al., 2011).  
MLD is also recommended to be used before venous surgery, and should be 
complemented with compression stockings (Molski et al., 2013; Molski et al., 2009). 
There are several conservative treatments described in the literature other 
than MLD and compression to treat and prevent complications associated with CVD, 
like exercise (Kahn et al., 2011; Padberg et al., 2004), intermittent pneumatic 
pressure (Lurie et al., 2008), kinesio taping (Aguilar-Ferrandiz et al., 2013a; Aguilar-
Ferrandiz et al., 2013b), electrical muscle stimulation (Clarke Moloney et al., 2006; 
Izumi et al., 2010), transcutaneous electrical nerve stimulation (Izumi et al., 2010), 
hydrotherapy (Carpentier et al., 2014; Carpentier & Satger, 2009), health education 
(Knapp et al., 2011). Most of these techniques are complementary to compression 
therapy or pharmacological treatment. 
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3 SCOPE OF THE THESIS AND HYPOTHESIS 
Despite the literature assuming that MLD might be a potential conservative 
treatment for CVD, in association with surgery (Molski et al., 2013; Molski et al., 
2009), or combined with other physical therapy treatments (Steins et al., 2000), the 
real efficacy of MLD alone remains unknown. The exact mechanisms underlying the 
therapeutic effects of MLD are doubtful, and may be associated with increased 
lymph flow (Leduc et al., 2011; Lee et al., 2011) or with increased venous flow 
(Leduc et al., 2011). 
Also, there is little information about the acute effect of the MLD maneuvers 
(reabsorption and call-up of the Leduc technique, both a low pressure, skin-stretching 
form of massage maneuver) on blood flow in the superficial and the deep veins of the 
lower extremity and if there are, in fact, differences between these two techniques in 
their effects. As for the lymphatic circulation, these MLD maneuvers may have an 
impact on venous blood flow both on superficial and deep veins of the lower 
extremity, but this effect is assumed to be mild (Leduc et al., 2011).  
In addition, the best anatomical regions of the lower limb where of MLD 
maneuvers should be applied remains unknown, despite the indication that they 
should be applied along the route of GSV (Leduc et al., 2000; Molski et al., 2009; 
Peyre et al., 2000). 
The major importance of CMPF in CVD physiopathology is well known 
(Panny et al., 2009; Shiman et al., 2009; Yamaki et al., 2010; Yang et al., 1999), but 
the efficacy of MLD in improving this function was not evaluated yet. 
Notwithstanding, several studies use the vascular ultrasound to estimate the capacity 
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of ejection of venous blood during muscle contractions (Hitos et al., 2007; Moloney 
et al., 2007; Staubesand et al., 1995) a dynamic characterization of CMPF in CVD 
patients is still missing. In particular, the relationship between calf muscles 
architecture and muscle pump function in CVD patients has not been established. 
Although the volume of calf muscles in patients with venous ulcer was shown not to 
be related with the capacity to increase venous blood flow velocity in popliteal vein 
during a maximal plantar flexion contraction (Moloney et al., 2007), there are several 
other muscle morphological features that determine muscle performance and that 
could be affected in CVD patients (Qiao et al., 2005). 
The efficacy of CMPF is usually evaluated using air-plethysmography 
(Nicolaides, 2000). However, this method requires equipment not readily available in 
most clinical settings and the development of alternative method to accurately assess 
CMPF could stimulate further investigation about the role of muscle pump function 
in CVD (Bradbury, 2010; Nicolaides, 2000; Padberg et al., 2004; Panny et al., 2009; 
Sandor, 2010). 
3.1 Objectives of the study 
The objectives addressed in this thesis were the following: 
1- To evaluate CMPF in CVD patients using ultrasound imaging and to relate 
this function with gastrocnemius muscle architecture. 
2- To assess the effect of the two low-pressure manual skin-stretching 
maneuvers of MLD: the call-up and the reabsorption on both deep and 
superficial venous blood flow in patients with CVD. 
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3- To verify whether the effect of MLD on venous blood flow differs if 
applied to different anatomical regions of the lower limb or between deep 
and superficial veins. 
4- To assess the long term effect of MLD in the conservative treatment of 
CVD. 
3.2 Hypothesis  
We defined the following hypothesis: 
1- Calf muscles architecture is altered in CVD patients when compared with 
healthy subjects and these changes are related with the efficacy of the 
CMPF. 
2- Call-up and reabsorption maneuvers of MLD technique will enhance 
venous blood flow to a similar extent and in both the superficial and the 
deep veins of the lower extremity. 
3- Higher venous blood flow enhancement occurs when MLD techniques are 
applied to the medial aspect of the thigh and of the leg, thus in coincidence 
with the course of GSV.  
4- MLD will improve HRQL, clinical and functional status of patients with 
CVD and that this effect will remain at the end of a short-term follow-up. 
We also anticipate that the effect of MLD on CVD severity and symptoms 
are enhanced by compliance to compression stockings. 
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4 INSTRUMENTS AND METHODS 
4.1 Studies outline 
This thesis is based on four separate studies, which are outlined in Table 2. 
The studies addressed each of the problems stated in Section 3. Three of the studies 
were of a cross-sectional design, including CVD and healthy control participants 
(one to assess reproducibility of the CMPF assessment, and two to assess 
hemodynamic effects of MLD), whereas the fourth study followed a prospective, 
single-blind randomized controlled trial (RCT) design, aimed at assessing the 
efficacy of MLD for the treatment of CVD. 
The first study (Study I) was performed to assess CMPF dynamically in a 
group of CVD patients and healthy controls using ultrasound. This study also aimed 
to assess the relationship between architecture of the two heads of the gastrocnemius 
muscle and the blood pumping function of calf contractions. 
The second study (Study II), was performed to assess the effect of the two 
low-pressure manual skin-stretching maneuvers: the call-up and the reabsorption on 
both deep and superficial venous blood flow in patients with CVD. Vascular 
ultrasonography was used to measure the cross-sectional area and blood velocity at 
the femoral vein (FV) and GSV during MLD maneuvers applied to the medial aspect 
of the thigh in CVD (patients with varicose veins, edema, skin and trophic changes) 
and healthy participants. 
The third study (Study III) was performed to verify if venous blood flow 
enhancement is the same when MLD is performed over different anatomical regions 
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of the lower limb. MLD applied to the medial versus the lateral aspect of the thigh 
and of the leg. Vascular (veins’ cross-sectional area) and hemodynamics changes 
(flow velocity and flow volume) in the FV, GSV, popliteal vein (PV), and small 
saphenous vein (SSV) were assessed with ultrasound imaging in CVD (edema, skin 
and trophic changes and healed ulcer) and healthy participants. 
The fourth study (Study IV) was performed to assess the long term effect of 
MLD (10 sessions, during four weeks) in the conservative treatment of CVD, having 
as outcomes HRQL, severity of disease, symptoms (heaviness and fatigue), leg 
volume, calf muscle strength (torque, torque/body weight, total work, and average 
power for dorsiflexors and plantarflexors muscle), and ankle dynamic range of 
motion in patients with CVD. Also, how adherence to compression stockings 
moderates the effect of MLD in this group of patients was also evaluated, as using 
such stockings is a primary conservative treatment for CVD. 
4.2 Ethics 
Before study enrolment, all participants were informed about the purpose and 
procedures of the study and signed an informed consent (Appendix 1 to 4). All 
studies received ethical approval from the Ethics Council of Faculdade de 
Motricidade Humana da Universidade de Lisboa. Our randomized controlled trial 
was registered with ClinicalTrials.gov registry (register number: NCT01899482). 
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Table 2 - Objectives and Procedures of the studies 
OBJECTIVES PROCEDURES 
Study I 
Respond to Hypothesis 1. 
 
To evaluate CMPF in CVD patients 
using ultrasound imaging and to 
relate this function with 
gastrocnemius muscle architecture. 
 
Design:  
Cross-sectional design with a CVD and a healthy control group of 
participants. 
 
Outcomes and intervention: 
- Clinical class of CEAP Classification; 
- Severity of disease: VCSS; 
- Vascular ultrasound of popliteal vein for assessing CMPF, during 10 
tip-toe movements (assessed twice with one week apart); 
- Gastrocnemius muscle architecture evaluated, with the ankle in 
plantarflexion, dorsiflexion and neutral position. 
Study II 
Respond to Hypothesis 2. 
 
To assess the effect of the two low-
pressure manual skin-stretching 
maneuvers: the call-up and the 
reabsorption on both deep and 
superficial venous blood flow in 
patients with CVD.  
Design:  
Cross-sectional design with a CVD and a healthy control group of 
participants. 
 
Outcomes and intervention: 
- Clinical class of CEAP Classification; 
- Severity of disease: VCSS; 
- Venous hemodynamic in GSV and FV during MLD (call-up and 
reabsorption maneuver) applied at medial aspect of thigh. 
Study III 
Respond to Hypothesis 3. 
 
To verify whether the effect of 
MLD on venous blood flow differs 
when applied to different 
anatomical regions of the lower 
limb and between deep and 
superficial veins. 
Design:  
Cross-sectional design with a CVD and a healthy control group of 
participants. 
 
Outcomes and intervention: 
- Clinical class of CEAP Classification; 
- Severity of disease: VCSS; 
- Venous hemodynamics in GSV and FV during MLD applied at the 
medial and lateral aspects of the thigh, and in SSV and PV during MLD 
applied at the medial and lateral aspects of the leg. 
Study IV 
Respond to Hypothesis 4. 
 
To assess the long term effect of 
MLD in the conservative treatment 
of CVD. 
Design:  
A single blind randomized controlled trial with patients with CVD  
 
Outcomes and intervention: 
- CEAP Classification; 
- Severity of disease: VCSS; 
- Health-related quality of life and symptoms quantification; 
- Leg volume; 
- Ankle isokinetic dynamometer assessment; 
- The intervention in experimental group was one educational session 
and 10 MLD sessions during 4 weeks; 
- The intervention in control group was one educational session. 
CVD: chronic venous disease. CMPF: calf muscle pump function. MLD: manual lymphatic 
drainage. VCSS: Venous Clinical Severity Score. CEAP: Clinical Etiological Anatomical 
Pathological classification. GSV: great saphenous Vein. SSV: small saphenous vein. FV: 
femoral vein. PV: popliteal vein. 
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4.3 Participants 
For Study I, participants were recruited from Lisbon area, whereas for the 
other three studies, participants were recruited from Castelo Branco area. In our 
studies, participants were excluded because of few contraindications/precautions of 
MLD. Therefore, the exclusion criteria included: 1) the presence of severe cardiac 
insufficiency, 2) acute venous or arterial obstruction, 3) renal insufficiency, 4) 
uncompensated thyroid dysfunction, 5) neoplastic pathology, 6) systemic or limb 
infection, 6) age over 65 years. Because other conditions may influence the severity 
and functional status of CVD, participants were also excluded if they presented 
recent musculoskeletal injury of the lower limb, arterial insufficiency, peripheral 
neuropathy in the lower limb, and pregnancy. 
In Study I, 15 healthy control participants (10 women and 5 men), and 16 
participants (13 women and 3 men) with a diagnosis of CVD (CVD group), were 
enrolled. All CVD participants presented venous blood reflux in at least one vein of 
the lower extremity with a minimum duration of 0.5 sec, and CEAP clinical 
classification in the range C1-4.  
For Study II, 23 participants (13 women and 10 men) with a diagnosis of 
CVD (CVD group), most of whom were outpatients in a local health unit, and 18 
healthy control participants (10 women and 8 men), were recruited. All CVD 
participants presented pathological venous blood reflux in the lower extremity and 
CEAP clinical classification in the range C1-5. Seven subjects were excluded: two 
participants presented active ulcer (C6), two participants were diagnosed with cardiac 
insufficiency, and three participants had severe arterial insufficiency. Three 
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participants from the CVD group had their GSV not evaluated due to previous 
surgery of this vein. In three other participants from this group, the FV was not 
evaluated because of time constraints. 
In Study III, 57 participants were included, 28 patients (21 women and 7 
men) with CVD, and 29 healthy control participants (17 women and 12 men). All 
CVD participants presented pathological venous blood reflux in the lower extremity 
and a CEAP classification in the range C3-5. Twenty two participants were excluded: 
11 participants presented a clinical CEAP classification below C3, 2 participants 
presented active ulcer (C6), 3 participants suffered from cardiac insufficiency, 3 
participants had arterial insufficiency, and 3 participants were over 65 years of age. 
In 6 participants with CVD, data was not collected from the GSV due to previous 
surgical treatment. For the same reason, the SSV was also excluded from data 
collection in 5 participants of this group. 
Study IV, a single blind randomized controlled clinical trial, was conducted 
in patients recruited from a school-based health community attendant service 
between October 2011 and July 2012. All the participants had CVD with C3-5, 
according to the clinical class of CEAP classification. Out of the 125 prospective 
candidates, 50 met the eligibility criteria and were randomly allocated to the 
experimental (N = 25) or to the control group (N = 25). During the first visit, the 
participants were informed that they would be expected to complete 10 treatment 
sessions over a period of 4 weeks, and another 3 sessions for assessments, starting 
within the following 2 months. Those conducting the assessments were blinded to 
group allocation, and the physical therapists applying the treatment were unaware of 
the results of the assessments. After the first round of testing [Time 0 (T0)], all 
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participants attended an educational session. Participants in the control group did not 
receive any further treatment during the time of the study. All participants were 
instructed to maintain their habitual CVD-management scheme as well as their 
habitual daily-life activities during the study. Participants in CVD group were 
reassessed at the end of the MLD-treatment program [Time 1 (T1)], and after 4 
weeks of follow-up [Time 2 (T2)]. Participants in the control group were tested with 
4-weeks intervals between T0-T1, and T1-T2. The timeline of the study, including 
sampling, testing and intervention, is depicted in Figure 1. Participants in the control 
group were also provided with the MLD treatment after T2. 
The demographic and clinical data of the participants are presented in Table 3 
to 9. Some participants were assessed in more than one study.  
4.4 Diagnose and Severity of disease 
The presence of CVD relies on patient’s history and physical examination 
(Gloviczki et al., 2011). It is recommended that the clinical evaluation (signs and 
symptoms) is carried out by the CEAP classification and the venous clinical severity 
score (VCSS) (Gloviczki et al., 2011; Kakkos et al., 2003). Complementary 
diagnostic testing, like duplex scanning, is also recommended (Gloviczki et al., 
2011). Patients’ health history is important because several comorbidities, like 
diabetes, arterial insufficiency, lower limb injury, may influence the clinical status of 
CVD patients, and is important also to assess the history of vascular or lower limb 
surgery, medication, and other treatments. Also, the presence of symptoms was 
always registered.  
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4.5 Duplex scanning: diagnose of CVD 
Duplex scanning is a safe, non-invasive, cost-effective, and reliable exam, 
recommended as the first diagnostic test for all patients with suspected CVD 
(Gloviczki et al., 2011). The test includes three components: visibility, 
compressibility, venous flow, including duration of reflux and augmentation 
(Gloviczki et al., 2011). A colour duplex ultrasound is usually recommended using a 
high-frequency linear array transducer of 7.5 - 13MHz, for superficial veins 
(Coleridge-Smith et al., 2006) and 4 - 7 MHz, for deep veins (Gloviczki et al., 2011). 
In case of very edematous regions, a 3.5 - 5 MHz curvilinear array can be useful 
(Coleridge-Smith et al., 2006). At B-mode the image of lumen should be evaluated, 
at transversal or/and longitudinal view, and the scanning parameters should be 
adjusted for correct identification of acute or chronic thrombosis (Coleridge-Smith et 
al., 2006). Pulsed–waved spectral or colour Doppler to assess the velocity and 
direction of venous flow, should be undertaken with a recommended Doppler range 
of 5 - 10 cm/s with the wall filter at its lowest setting, and the angle of insonation 
should be at 45 - 60º (Coleridge-Smith et al., 2006). During the examination (reflux 
and diameter), patients are at upright position and several methods are used to elicit 
reflux: release after calf squeeze for proximal veins, and foot squeeze for calf veins 
(used during our studies), manual compression of vein cluster, calf pneumatic cuff 
deflation (the more reproducible method), active foot dorsiflexion and relaxation, 
and Valsalva maneuver, which is useful to demonstrate saphenofemoral 
incompetence (also used in our study when manual compression did not allowed to 
asses this outcome) (Coleridge-Smith et al., 2006). A reflux value of 0.5 seconds is 
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considered a reliable indication of presence of CVD (Coleridge-Smith et al., 2006) 
(employed in Study I using ultrasound equipment HI VISION 8500, Hitachi, with a 
L53 linear array-transducer, scanned at 9 MHz), but recent guidelines suggest s a 0.5 
seconds cutoff values for saphenous, tibial, deep femoral, and perforating vein 
incompetence (also with vein diameter > 3.5 mm), whereas a value of 1 second is 
considered a cutoff value for femoral and popliteal veins incompetence (Gloviczki et 
al., 2011) (criteria employed in Study II-IV, using the ultrasound equipment 
ESAOTE mylab 30 cv, with 7 mm linear array-transducer, scanned at 6 - 12 MHz). 
4.6 CEAP classification 
The CEAP classification was created to facilitate communication about CVD 
severity and for scientific research (Eklof et al., 2004). The CEAP classification was 
based on 1) clinical manifestations (C), 2) etiologic factors (E), described as 
congenital, primary, secondary (post-thrombotic), 3) anatomical distribution of 
disease (A), that can be located at superficial, perforator or deep veins, and 4) 
underlying pathophysiological findings (P), such as reflux, obstruction or both reflux 
and obstruction (Eklof et al., 2004). Subscripts are applied to designate S 
(symptomatic) from A (asymptomatic) limbs (Padberg, 2005). According to CEAP, 
there are six CVD categories that range from C0 to C6 (Eklof et al., 2004; Padberg, 
2005). Also, the N subscript indicates no evidence of disease and is applicable to E, 
A, and/or P of CEAP (Eklof et al., 2004; Padberg, 2005).  
The C0 represents those individuals with objective evidence of venous disease 
(i.e., E, A, and/or P), but with no clinical manifestations. The C1 is characterized by 
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the presence of telangiectasia or reticular veins (< 3mm in diameter). In the C2 class, 
varicose veins (> 3 mm in diameter) are present. The C3 distinguishes itself from the 
preceding categories by the presence of edema of venous etiology. In the C4 class, 
there are now skin trophic changes, like C4a, for pigmentation and/or eczema, and 
C4b, for lipodermatosclerosis and/or white atrophy. Classes C5 and C6 are associated 
with the occurrence of venous ulcers: the C5 corresponds to cases of prior ulceration 
that healed, and C6 to cases with active venous ulcers (Eklof et al., 2004; Padberg, 
2005). 
The CEAP classification is the gold standard for classification of chronic 
venous disorders today and its use is recommended by the relevant guidelines 
(Gloviczki et al., 2011). Nevertheless, for proper use of CEAP some facts have to be 
taken into account: the CEAP classification is limited as a severity classification, C2 
summarizes all kinds of varicose veins, in C3 it may be difficult to separate between 
venous and other reasons for edema, and corona phlebectatica is not included in the 
classification (Rabe & Pannier, 2012). Further revisions of the CEAP classification 
may help to overcome the still-existing deficits (Rabe et al., 2012). Complementary 
to this classification system, some concepts were defined to give consistency to the 
scientific terms, like the CVD concept that designates any venous disorder associated 
to every clinical class, and the concept of chronic venous insufficiency, which 
represents the more severe stages of the disease (C3-6) (Eklof et al., 2004; Padberg, 
2005). For the sake of consistency and simplicity, in this thesis we opted not to use 
the term chronic venous insufficiency even in the cases where its use would be 
correct, such as in Study IV, in which all CVD participants were in the severity range 
C3-5. Hence, the term CVD was used at all times in this thesis.  
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Figure 1- Flow diagram for Study IV 
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4.7 Severity of disease: Venous Clinical Severity Score 
The CEAP clinical score assesses the severity of CVD. The severity is given 
by a global score in the range 0 - 18 (best to worst) obtained by summing the items 
1) pain, 2) edema, 3) venous claudication, 4) pigmentation, 5) lipodermatoesclerosis, 
6) ulcer size, 7) ulcer duration, 8) ulcers number, and 9) ulcer recurrence, each item 
scored as 0-2 (Kakkos et al., 2003). 
The procedure VCSS, that might be used in substitution of CEAP clinical 
score, was employed in all studies comprising this thesis. The VCSS was developed 
to supplement the CEAP classification and to give an additional weight to the more 
severe consequences of CVD (Rutherford et al., 2000). The VCSS score has shown 
good intra and inter-observer reliability and responsiveness to change (Kakkos et al., 
2003; Ricci et al., 2003; Rutherford et al., 2000). This is a score that quantifies 10 
items using the range: 0 (none), 1 (mild), 2 (moderate), and 3 (severe), with a total 
range score of 0-30 (best to worth) (Kakkos et al., 2003; Ricci et al., 2003; 
Rutherford et al., 2000; Vasquez et al., 2010). In CEAP classes C0 to C6, the VCSS 
score is reported to range between of 3-18 (Lozano Sanchez et al., 2012). A 
worthwhile clinical improvement for patients with CVD can be observed with a 
relative improvement of 70% in VCSS score (Kakkos et al., 2003) or with an 
absolute improvement of 4 points (Cesarone et al., 2010). Differences between 
clinical classes are 1-2 points of VCSS below C3, and 2-5 points above C3 (Lozano 
Sanchez et al., 2012). The items of the VCSS are: 
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- Pain or discomfort (i.e., aching, heaviness, fatigue, soreness, burning, 
with presumed venous origin), patients are asked to describe for each 
leg the category that best describes this item;  
- Varicose veins (with diameter ≥ 3 mm in standing position); 
- Venous edema (presumed venous origin, i.e., pitting edema present in 
every days and with significant effect of standing/limb elevation or 
evidence of venous etiology, like varicose veins or history of deep 
vein thrombosis) - clinical staff must exam both legs and should ask 
patients about the extent of edema experienced; 
- Skin pigmentation (presumed of venous origin and not including focal 
pigmentation over varicose veins or pigmentation due to other chronic 
diseases) - clinical staff must exam each leg; 
- Inflammation (more than just recent pigmentation, like erythema, 
cellulitis, venous eczema, dermatitis); 
- Induration (presumed of venous origin with secondary skin and 
subcutaneous changes, such as chronic edema with fibrosis, 
hypodermitis, white atrophy, and lipodermatoesclerosis); 
- Active ulcers number; 
- Active ulcers duration (patients are referred to describe the duration of 
the longest unhealed ulcer); 
- Active ulcers size (score according the size of the largest active ulcer); 
- Use of compression therapy (patients should be asked about their 
compliance to compression therapy). 
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The assessment of the items of VCSS score should be carried out for both 
legs. 
Demographic, CEAP and VCSS data were registered in one single 
characterization questionnaire (Appendix 5). The leg self-reported as presenting the 
worst symptoms and clinical signs and the dominant leg were chosen for subsequent 
measures in, respectively, the participants of CVD groups and the healthy-control 
groups. 
4.8 Health-related quality of life and symptoms quantification  
Health professionals-reported outcomes, such as VCSS and CEAP 
classification, are convenient, easily evaluated, and relevant. However, they remain 
biased by the observers’ expectations. Patient-reported outcomes are recognized by 
medical authorities as the ultimate outcome for health-care interventions, and for 
chronic venous disorders self-reported assessment of symptoms and HRQL is 
recommended (Guex, 2012). 
HRQL was assessed by the Chronic Venous Insufficiency Questionnaire 
(CIVIQ-20) (Annex 3), translated and culturally validated to Portuguese. 
Psychometric validations confer relevance, acceptability, reliability, construct 
validity and sensitivity to CIVIQ-20 questionnaire (Launois et al., 2013). The 
dimensions composing the CIVIQ-20 are physical (4 items), psychological (9 items), 
social (3 items), and pain (4 items) (Launois et al., 2010). In our studies, the scores 
for each dimension and for the global HRQL index were obtained using the scale 0-
100 (best to worse). The global score and the score for each dimension is around 60-
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70 points for patients with CVD of classes C0s-2, and around 50-60 points for classes 
C3-4 (Launois et al., 2010), decreasing in C5-6 to a median score value of 52.4 points 
(Lozano Sanchez et al., 2012). An improvement higher than 8-10 points in CIVIQ-20 
score represents a worthwhile clinical improvement for patients with CVD (Launois 
et al., 2010). 
Authorization for using the Portuguese version of CIVIQ-20 was given and a 
memorandum of agreement was signed with authors Robert Lounois and Les 
Laboratoires Seveier (Neuilly-sur-Seine, France). 
4.9 Symptoms  
Additionally to HRQL, symptoms (fatigue and heaviness, very frequent 
symptoms in CVD) (Bobridge et al., 2010; Launois et al., 2010) were quantified by 
visual analogue scale (Launois et al., 2010). The visual analogue scale for fatigue 
and heaviness is completed by the respondent, which is asked to place a line 
perpendicular to the visual analogue scale line at the point that represents their 
symptom intensity. The quantification is made with a score of 0-10 (best to worse), 
using a ruler that measures the distance on the 10-cm line. The visual analogue scale 
presents good acceptability, validity, reliability, and sensitivity to detect changes in 
symptoms, such as pain in chronic conditions (Hawker et al., 2011), and is used to 
assess symptoms related to CVD (Bobridge et al., 2010; Launois et al., 2010). An 
improvement higher than 1.8-2.1 points in visual analogue scale score represents the 
minimum clinically important difference for patients with CVD (Launois et al., 
2010). 
 65 
4.10 Vascular ultrasound assessments for venous hemodynamic  
Although previously employed in many studies (Breen et al., 2007; Hitos et 
al., 2007; Staubesand et al., 1995), ultrasound-measured venous blood peak velocity 
alone seems not to be an accurate measure of CMPF (Breen et al., 2007). However, 
calculating blood volume, or its variation, using vascular ultrasound looks otherwise 
to be a suitable procedure to assess CMPF (Breen et al., 2007). Measuring 
hemodynamic parameters, like volume flow (cross-sectional area X time average 
mean velocity) (Hitos et al., 2007) is also possible, and the measures are reproducible 
when the method is optimised by choosing a sampling volume that covers the entire 
venous lumen, using a probe incidence angle of 60 degrees, and measuring venous 
blood flow for a period of 40 seconds or longer (on pulse-wave imaging) (Ogawa et 
al., 2002). The vein’s cross-sectional area can also be measured accurately by 
ultrasound (in B-mode imaging), after defining the vein’s contour (Lurie et al., 
2002).  
Nevertheless several studies use venous blood peak flow velocity of lower 
limb veins to assess the effect of treatments on venous hemodynamics (Clarke 
Moloney et al., 2006; Izumi et al., 2010; Lurie et al., 2008). 
4.10.1 Popliteal vein assessment for calf muscle pump function 
After five minutes rest, the cross-sectional area of the popliteal vein was 
measured at the level just below the sapheno-popliteal junction (Figure 2) with 
subjects in prone position and using a linear array transducer (HI VISION 8500, 
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Hitachi, with a L53 linear array-transducer, scanned at 9MHz). Next, baseline mean 
and peak blood flow velocities in the popliteal vein were measured in standing 
position. Blood flow velocity was measured during a 10-seconds interval using an 
automatic time integral calculation. After completing the baseline measures, subjects 
performed a protocol of calf muscle contractions similar to that commonly used to 
assess the efficacy of CMPF by air-plethysmography and composed by three sets of 
ten repetitions of tip-toe movements (Figure 3) (Nicolaides, 2000; Padberg et al., 
2004). A metronome set the timing of the tip-toe movement that took 2 seconds to 
rise to the tip-toe, 2 seconds to get down to the initial position and 1 second interval 
to the next repetition. The ultrasound probe was manually held at the lower margin of 
the popliteal fossa with adequate orientation to measure blood flow velocity in 
popliteal vein, while subjects performed the tip-toe movement. Between sets, 
subjects rested for five minutes in sitting position. Mean and peak blood volume 
flowing through the popliteal vein at baseline were calculated. Dynamic peak (at first 
and tenth contraction) and mean (at first contraction) blood flow velocity were 
calculated using the integral of the blood flow-time curve. To avoid the effect of the 
foot sole impact with the ground on venous blood flow, only the time interval 
corresponding to heel rising was selected to analysis. During tip-toe movements, 
flow velocity data was normalized against baseline popliteal vein flow velocity to 
calculate flow velocity augmentation using the following equation: 
 
Augmentation (%) =  [(flow velocity during contraction (cm/s) – flow  
    velocity during baseline (cm/s)) ÷ flow velocity during 
    baseline (cm/s)] × 100 
 67 
The percentage augmentation in flow velocity was calculated using both the 
peak flow velocity registered during the first and tenth tip-toe movement in each set. 
To assess reliability of ultrasound measures, 17 subjects (CVD group, N = 9; 
control group, N = 8) visited the laboratory for a second session. During this visit 
subjects repeated the tip-toe protocol in order to assess reproducibility of ultrasound 
measures of blood pumping by calf muscles, using test-retest reliability and 
calculating the absolute agreement intraclass correlation coefficient (ICC) (Schuck, 
2004), and by agreement analysis using Bland and Altman plot analysis. For each 
participant, tests were carried out at the same time of day and at the same ambient 
temperature. Also to evaluate the bias eventually caused by probe unsteadiness 
during the movement repetitions, few subjects performed actual and simulated tip-toe 
movements. The simulated movements were done with subjects standing on a 
platform with the foot of the measured side hanging off the platform and performing 
active plantarfexions of the ankle joint by contracting the calf muscles. During this 
task, leg movement is minimal and the probe can be kept rather stationary. 
This methodological procedure was used in Study I. 
Figure 2 - Assessment of cross-sectional area and flow velocity at popliteal vein with 
vascular ultrasound 
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4.10.2 Venous hemodynamics during manual lymphatic drainage 
Four veins were assessed using venous duplex ultrasound with ultrasound 
equipment ESAOTE mylab 30 cv, with 7 mm linear array-transducer, scanned at 6-
12 MHz. These included two superficial veins, the GSV, insonated immediately 
below confluence of the superficial inguinal veins, and the SSV, insonated 
immediately below the saphenopopliteal junction, and two deep veins, the FV, 
insonated below confluence of the superficial inguinal veins, and the PV, insonated 
just below saphenopopliteal junction.  
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Figure 3 - Venous ultrasound assessment at popliteal vein during first and tenth calf 
contraction, during tip-toe movement for both control and CVD group 
 
 
Popliteal vein blood flow velocity during: A) the first and B) the last (tenth) repetition of the 
tip-toe movement task in a CVD participant and popliteal vein blood flow velocity during C) 
the first and D) the last (tenth) repetitions of the tip-toe movement task in a healthy subject 
Also shown are the automatic tracings of the blood flow velocity curve envelope and of the 
calculated mean (dark trace). 
The veins were scanned in B-mode for 4 seconds to measure the vein cross-
sectional area, using tracings of vein’s contour in the ultrasound scan, and selecting 
the highest cross-sectional area corresponding to expiratory moment of respiratory 
cycle. Venous peak and mean flow velocities were measured during 4-second 
intervals (during approximately a respiratory cycle), using the time integral 
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calculation. Three measurements of cross-sectional area and of blood flow velocity 
were taken for veins and the average was computed for analysis (Figure 4). 
Before measurements, the participants rested for 5 minutes in a supine 
position. Blood flow volume in the FV, GSV, PV, SSV was calculated based on 
measurements of cross-sectional area and blood flow velocity. 
In Study II, to compare the effect of call-up and reabsorption maneuvers of 
MLD, ultrasound measurements were taken from FV and GSV first at baseline (with 
no maneuver) and thereafter during randomly applied call-up and reabsorption 
maneuvers to the medial aspect of the thigh. Measurements were taken with 
participants in a supine position (Figure 5 and Figure 6 ). 
Figure 4 - Representative ultrasound images showing the effect of MLD  
Cross-sectional area at A: baseline and B: with manual lymphatic drainage and blood flow 
velocity at C: baseline and D: with manual lymphatic drainage, for popliteal vein. 
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Figure 5 - Randomization for duplex ultrasound assessment 
 
 
In Study III, to assess the hemodynamic effect of MLD in different regions of 
lower limb, ultrasound measurements were first taken at baseline (without MLD) and 
during the MLD applied to the medial and to the lateral aspect of the thigh for FV 
and GSV, and to the medial and to the lateral aspect of the leg for PV and SSV. To 
assess the flow velocity in FV and GSV, participants stayed in the supine position, 
whereas to assess PV and SSV participants were in prone position. The order of the 
blood flow measurements was randomized following a hierarchical procedure (see 
Figure 7 and Figure 8). 
Cross-sectional area and venous hemodynamics (peak and mean flow velocity 
and flow volume) percent augmentations were calculated using the following 
relation:  
 
Augmentation (%) = (Maneuver – Baseline) ÷ Baseline) × 100. 
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The operator collecting the ultrasound data was kept blind with regard to the 
application of MLD by staying behind an opaque screen. The MLD technique was 
executed with two hands placed onto the thigh or the leg and then by applying 
pressure just sufficient to stretch the skin. The stretching of the skin was maintained 
for at least 4 seconds. The MLD technique was started and ended by orders of the 
operator collecting the ultrasound data and therefore synchronized with ultrasound 
recording, and taking into account the respiratory cycle.  
Figure 6 - Vascular ultrasound evaluation context with curtain separating 
sonographer, therapist and participant, during manual lymphatic drainage maneuvers 
Assessment of the cross-sectional area and blood flow of femoral vein and great saphenous 
vein during baseline and during call-up maneuvers (A, B and C sequence) and reabsorption 
maneuvers (D, E and F sequence) in Study II. 
The call-up maneuver initiates with the most proximal part of the proximal 
hand and ends with both hands touching the skin, while producing a skin-stretching 
(and was used in both studies II and III to assess hemodynamic effect of MLD). The 
reabsorption maneuver initiates with the most distal part of the distal hand and ends 
with both hands touching the skin while applying skin-stretching (this maneuver was 
 73 
only used to compare the hemodynamic effect with that of the call-up maneuver, in 
Study II). Skin-stretching was applied in the two maneuvers in a proximal direction 
respecting the course of the lymph and venous flow.  
The veous blood flow parameters and percentage augmentation can easily be 
assessed with ultrasound assessment by venous duplex scanning and have been used 
in many studies which evaluate venous hemodynamics in the lower limb in response 
to treatments (Breen et al., 2007; Morris & Woodcock, 2004). Also, venous flow 
volume calculation based on cross-sectional area and flow velocities measurements 
is accurate (Lurie et al., 2002).  
Figure 7 - Randomization for vascular ultrasound assessments during leg and thigh 
manual lymphatic drainage 
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To assess test-retest reliability of these evaluations, 9 healthy participants 
repeated the tests after a one week interval. The cross-sectional area, mean and peak 
flow velocities and flow volume of FV, GSV, PV, and SSV were assessed during 
baseline and during the application of MLD to the lower extremity with venous 
duplex ultrasound. 
Figure 8 - Vein assessments during manual lymphatic drainage in lateral and medial 
aspect of thigh and leg 
 
Femoral vein and great saphenous assessments at (A) baseline and during MLD (B-D) at 
medial and (E-G) lateral aspect of thigh. Popliteal and small saphenous vein assessments at 
(H) baseline and during MLD at (I-K) medial and (L-N) lateral aspect of leg. 
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4.11 Calf muscles architecture  
The medial and lateral gastrocnemius muscles were imaged at 10 MHz and at 
a scan depth of 65 mm (HI VISION 8500, Hitachi, L53 linear array-transducer). The 
two muscle bellies were imaged at the upper third of the distance between the 
peroneal head and the lateral malleoulus with subjects lying prone with hip and knee 
at neutral position, and at three ankle joint positions: 1) foot at 90º (anatomical 
neutral position); 2) at maximal active plantarflexion; and 3) at maximal active 
dorsiflexion. The distance between the proximal and distal aponeurosis in both 
medial and lateral gastrocnemius muscles was traced to obtain the muscle thickness. 
In the medial gastrocnemius muscle, the direction of the muscle fascicles was also 
traced to derive the pennation angle for each ankle joint position. Pennation angle 
was defined as the angle between the load axis of the muscle and the axis of muscle 
fascicle. Muscle fascicle length, defined as the length of the fascicle between the 
deep and superficial aponeuroses, was directly measured for ankle plantarflexion 
position and using values of muscle thickness and pennation angle for ankle neutral 
and dorsiflexion positions (Figure 9), according to the following equation:  
 
Fascicle length (mm) = muscle thickness (mm) ÷ sine of pennation angle  
 
It has been suggested that B-mode ultrasonography can be used with 
confidence, revealing good reliability when investigating changes in muscle 
architecture in groups of older adults, but its use is limited in showing changes in 
individuals over time (Raj et al., 2012). The immediate (in the same day) test-retest 
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reliability between the three measures of lateral and medial gastrocnemius muscle 
thickness, pennation angle and fascicle length at neutral ankle position was assessed 
by calculating the absolute agreement ICC (Schuck, 2004). 
This methodological procedure was performed in Study I. 
Figure 9 - Calf muscle architecture assessment with ultrasound 
 
Ultrasound assessment for muscle thickness (a), pennation angle (α) and fascicle length (b) 
for lateral gastrocnemius muscle at neutral position (A), and for medial gastrocnemius 
muscle at plantarflexion (B), neutral position (C), and dorsiflexion of the ankle (D). 
4.12 Leg volume 
Although water displacement is considered a more reliable method to asses 
volumetric changes for treatment of edema (Rabe et al., 2010), the perimeter can also 
be used to estimate a segment volume, with manual circumference-based volume 
measures comparing well with those determined by water displacement (Mayrovitz 
et al., 2007). Edema volume and its changes during the course of treatment 
(Mayrovitz et al., 2000) are often assessed clinically using limb circumferences, 
which are used to estimate limb volume changes employing suitable geometric 
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models of the limb (Mayrovitz et al., 2007; Mayrovitz et al., 2000). For the lower 
limb, circumferences measured from a set of 8-12 cm-long leg segments are 
appropriate to assess the leg volume (Mayrovitz et al., 2007; Mayrovitz et al., 2000). 
The segmental volume from two adjacent limb perimeter (P) values (P1 and P2 
separately by length = 10 cm intervals) was calculated from the equation for a 
truncated cone model as:  
 
Segmental Volume (mL/s) = Length × (P1
2
 + P1 × P2 + P2
2) ÷ 12π 
 
In our study, leg perimeter was measured in standing using a standard tape at 
the level of the malleolus (P0), and 10 cm (P1), 20 cm (P2) and 30 cm (P3) above the 
lateral malleolus. The leg volume was calculated according to the equation, which is 
the sum of three volume cones estimated between P0 and P1, P1 and P2, and P2 and 
P3:  
 
Leg Volume (mL/s) = 10 × (P0
2
 + P0 × P1 + P1
2) ÷ 12π +  
   10 × (P1
2
 + P1 × P2 + P2
2) ÷ 12π +  
   10 × (P2
2
 + P2 × P3 + P3
2) ÷ 12π 
 
This procedure was performed in Study IV. 
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4.13 Ankle isokinetic dynamometer assessment 
Ankle muscles strength and active range of motion was measured with an 
isokinetic dynamometer (Biodex system 3 pro, Biodex Medical Systems, Inc., New 
York, USA). This method has been described to be reliable to assess dorsiflexor and 
plantarflexor muscles strength and ankle range of motion (Karnofel et al., 1989; 
Padberg et al., 2004). Participants were seated on the dynamometer’s chair with 70-
85º seatback tilt, with the knee flexed at 20-30º and with the trunk and thigh 
restrained by fastened seatbelts and a strap placed around the thigh. The foot rested 
in neutral position on a footplate and the ankle joint axis was aligned with the 
rotational axis of the dynamometer. Muscle concentric contractions started from full 
dorsiflexion and were performed at slow (60 º/sec) and fast (120 º/sec) speeds. Each 
participant completed 2 sets of five repetitions at the slow speed, 60 seconds of rest, 
followed by 15 repetitions at the fast speed. Participants were instructed to exert near 
maximal effort during the first set followed by maximal exertion during the second 
set. A 5 to 10-min rest separated the two sets. Average peak torque (Nm), peak 
torque per unit body weight (Nm.Kg
-1
), total work (J), average power (Watt), and 
ankle active range of movement [i.e., the maximal range of motion in which there is 
torque generation by ankle muscles] were obtained. Peak torque per body weight is a 
normalized form for reporting muscle strength that allows comparison between 
subjects. Total work is the area under the peak torque. Average power is the work 
divided by time, and it is influenced by both strength and speed, i.e., is the product of 
force and velocity. This procedure for assessing isokinetic strength of the ankle 
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muscles was used in Study IV and was found reliable, with ICC higher than 0.7 
(Padberg et al., 2004). 
4.14 Educational session 
The participants in Study IV attended a single group (experimental and 
control participants together) educational session soon following T0 (baseline 
assessments). This session addressed the characterization of CVD, including general 
mechanisms of the disease, predisposing and aggravating factors, and the importance 
of general care, such as skin care, leg elevation, exercise, diet, as well as the 
importance of wearing compression stockings (Knapp et al., 2011). The session was 
organized in two parts: the first one was to present the information (approximately 40 
minutes), and the second one for open discussion centered on the major concerns, 
questions, and experiences among participants (all CVD patients).  
The objective of this session was providing all participants with basic 
information about the disease and care. However, it was not the purpose of the 
educational session to intervene on CVD prevention or treatment. So, no booklet 
compiling this information, or other matters regarding counseling about CVD care, 
was given to the participants. Also, no specific incentives for adopting prophylactic 
behaviors related to CVD were yielded during the educational session. 
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4.15 Manual lymphatic drainage sequence and method 
The MLD technique was executed by two fully trained physical therapists in 
Study IV. The manual technique was performed placing the two hands side by side 
on the skin, like in the call-up maneuver (supposedly the best maneuver to improve 
venous flow) (Leduc et al., 2000), initiating with the most proximal part of the 
proximal hand and ending with both hands touching the skin while producing a skin-
stretching. The pressure applied by the hands to the skin and underlying soft tissue 
was carefully adjusted to remain soft and just enough to stretch the skin for at least 4 
seconds. Both legs were treated and the whole session took approximately 40-45 
minutes. The duration and the number of sessions in the present study are similar to 
those used in previous studies assessing the role MLD in CVD patients (Molski et 
al., 2013; Molski et al., 2009). During four weeks, patients completed 10 sessions of 
MLD. The sequence of the maneuvers complied with that commonly used for 
lymphedema, firstly following from proximal to distal and secondly from distal to 
proximal (Leduc et al., 2011; Lee et al., 2011). The maneuvers were applied in the 
following sequence: inguinal region (10 MLD maneuvers), progressing downwards 
through the thigh (30 MLD maneuvers at medial and 30 at lateral aspect of thigh), 
the popliteal region (MLD maneuvers were applied 10 times immediately above and 
10 times immediately below popliteal fossa), downwards to the leg (30 MLD 
maneuvers at medial and lateral aspect of leg), and finishing in the dorsal aspect of 
the foot (30 MLD maneuvers). Next, the maneuvers were carried out in the reverse 
order upwards: 15 maneuvers on the dorsal aspect of the foot, 15 maneuvers both on 
lateral and medial aspect of the leg, 5 maneuvers both below and above popliteal 
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fossa, 15 maneuvers above the lateral and above the medial aspect of the thigh, and 5 
maneuvers on the inguinal region (Figure 10). 
Figure 10 - Scheme of manual lymphatic drainage maneuvers sequence applied in 
lower extremity 
 
With patient in supine position, manual lymphatic drainage (MLD) starts at the (A) inguinal 
region (10 MLD maneuvers); progressing downwards through the thigh, with 30 MLD 
maneuvers at medial (B) and 30 at lateral (C) aspect of thigh; after that MLD maneuvers 
were applied (gray in the scheme) 10 times immediately above (D) and 10 times 
immediately below (E) popliteal fossa; then 30 MLD maneuvers were applied in a 
downward direction at medial (F) and lateral (G) aspect of the leg and finishing the 
downward sequence with 30 MLD maneuvers on the dorsal aspect of the foot (H).Then the 
MLD maneuvers were initiated in reverse order: further 15 repetitions of MLD maneuvers 
applied to the dorsum of the foot (H), 15 repetitions of MLD maneuvers again on the lateral 
(G) and on the medial side of the leg (F) and 5 repetitions of MLD maneuvers both below 
(E) and above (D) the popliteal fossa. Further 15 repetitions of MLD maneuvers are applied 
both to the lateral (C) and medial (B) sides of the thigh. The sequence ends with 5 MLD 
maneuvers over the inguinal region (A). 
Before initiating the study, the physical therapists received specific training in 
the MLD technique. This training focused on learning how to apply a strong pull to 
the skin yet without excessively pressing the underlying tissues, and to practice the 
maneuver sequence along the entire lower limb. Vascular ultrasound was employed 
to provide feedback to the training therapists about the immediate effect of their 
 82 
manual technique on the rise of venous blood flow (the desired effect and a 
demonstration of a correctly performed technique) or vein collapse (undesired effect 
and a demonstration of an incorrectly applied technique).  
When inflammation was present in the lower limb, the entire set of 
maneuvers was done up to the place of inflammation and reverse sequence was 
initiated in that moment. For example, if inflammation is present in the lower third of 
leg, the sequence is reversed immediately before touching the inflamed aspect of the 
leg, and maneuvers on the foot are not performed. 
In Study IV, patients with CVD were randomly allocated to an experimental 
group and to a control group. The experimental group received a total of 10 MLD 
sessions, along four weeks. The control group received no MLD treatments but 
participants in this group were given the opportunity to receive MLD at the end of 
the study. 
4.16 Statistical analysis 
All statistical tests were performed with the help of the statistical software 
package SPSS Inc. v.17 (SPSS Inc., Chicago, USA).  
In Study I, group differences were tested with Mann-Whitney U test. The 
differences between peak flow velocity (second session) at baseline, first and tenth 
contractions were calculated with Wilcoxon Signed-Rank test. The relationship 
between CVD severity and the gastrocnemius muscle and hemodynamic parameters 
was calculated using Spearman coefficient of correlation. Reproducibility was 
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assessed by test-retest reliability by calculating the absolute agreement ICC and by 
agreement analysis using Bland and Altman plot analysis.  
In Study II, III and IV, the normal distribution was checked using Shapiro-
Wilk Test. 
In Study II, group differences were tested with two-tailed Student’s T-test, 
while differences between maneuvers and between maneuvers and baseline were 
tested by repeated-measures ANOVA. The Bonferroni correction was used to correct 
for multiple comparisons. The relationship between the magnitude of the effect of the 
maneuvers, in terms of percentage augmentation from baseline, and CVD severity, in 
terms of CEAP and VCSS classification, was calculated using Spearman coefficient 
of correlation.  
In Study III, a mixed factorial ANOVA with three factors: group (two levels: 
CVD groups vs. control group), body region (three levels: baseline vs medial side vs. 
lateral side), and type of vein (two levels: deep vein vs. superficial vein) was used to 
test the effects of the dependent variables and interactions. Statistical analysis using 
this model was carried out separately for the thigh and the leg. The Bonferroni 
correction was used to correct for multiple pairwise comparisons. The relationship 
between the magnitude of the effect of the MLD techniques, in terms of percentage 
augmentation from baseline, and CVD severity, in terms of VCSS classification was 
calculated using the Spearman coefficient of correlation. The test-retest reliability 
was assessed by calculating the absolute agreement using the ICC.  
In Study IV, baseline variables were compared between groups using 
Independent Sample T-test. A mixed model ANOVA for repeated measures (2×2×3) 
with two between-subjects (Group; two levels: experimental and control; Stocking; 
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two levels compressive stockings use vs. non use) and one within-subjects variable 
(Time; three levels: T0, T1 and T2) was used to assess the effect of MLD on the 
outcome measures [CIVIQ-20, symptoms, leg volume, severity of disease (VCSS), 
and ankle muscles isokinetic strength]. The interactions are expressed with Group vs. 
Time, for interaction of both groups with the times (T0, T1 and T2) and Group vs. 
Stocking vs. Time to assess interaction of both group with use or not use of 
compressive stockings and time. Effect size was reported as partial eta squared (η2ρ) 
and was considered low when η2ρ ≤ 0.05, medium with η
2
ρ = ]0.05; 0.25]; high with 
η2ρ = ]0.25; 0.50]; very high η
2
ρ > 0.50. The Bonferroni correction was used to 
correct for multiple pairwise comparisons. The results of pairwise comparisons are 
reported by P-value and the 95% interval of confidence (IC) = [min; max].  
Descriptive data is presented as mean (standard deviation) unless otherwise 
stated. The significance level was set at P < 0.05. 
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5 RESULTS 
The demographic and clinical data pertaining to the participants of Study I are 
presented in Table 3 and Table 4. All subjects in the CVD group presented 
pathologic venous reflux but were free of venous obstruction. No differences in age, 
height, weight and body mass index were found between the groups. 
Regarding Study II, participants’ demographic and clinical data are presented 
in Table 5. No differences in age, height, weight, and body mass index were found 
between the CVD and control group. 
Demographic and clinical data pertaining to the participants of Study III are 
presented in Table 6 and Table 7. No differences in height, weight and body mass 
index were found between CVD and control groups. Nevertheless, the CVD group is 
slightly older than the control group [47.07 (12.22) yrs and 39.31 (13.76) yrs, CVD 
and control groups respectively, P = 0.029]. 
The demographic and clinical data of the participants of Study IV are 
presented in Table 8 and Table 9. No differences in height, weight and body mass 
index were found between the experimental and control groups. Participants in 
experimental group were slightly older than in control group [54.60 (11.30) years 
and 46.81 (11.10) years, experimental and control group respectively; P = 0.032, 
mean difference = 7.79 years, 95% IC = (0.72, 14.87)]. In addition, the experimental 
group was composed by a slightly higher number of C5 patients, but the severity of 
disease (VCSS) was similar in both groups, [7.80 (3.49) and 8.86 (2.94), 
experimental and control group, respectively; P = 0.354, mean difference = 0.94, 
95% IC = (1.09, 2.98)]. All participants using compression stockings reported 
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unchanged adherence to such use during the time of the study. At baseline, all 
outcomes were similar in experimental and control groups. 
Table 3 - Demographic and clinical data of Study I 
 
 
CVD group 
 
Control group 
 
P# 
 
P## 
 
All 
Participants 
     
  
Entire 
Group  
Subgroup 
with retest 
 
Entire 
Group  
Subgroup 
with retest 
   
N  16 9  15 8      31 
Age (years)  44.1(12.3) 45.7(14.2)  36.1(10.0) 35.8(11.4)  0.086  0.139  40.3(11.8) 
Height (cm)  162.8(7.3) 162.0(5.4)  166.3(9.6) 162.8(11.0)  0.281  0.114  164.5(8.5) 
Weight (Kg)  71.2(13.4) 73.1(15.0)  66.1(15.2) 60.5(13.5)  0.247  0.936  68.8(14.3) 
Body mass index (Kg/m2)  27.4(6.0) 28.1(7.1)  23.6(3.0) 22.5(3.0)  0.281  0.114  25.4(5.0) 
Gender             
Female  13(81.2) 7(77.8)  10(66.7) 6(75.0)  -  -  23(74.2) 
Male  3(18.8) 2(22.2)  5(33.3) 2(25.0)  -  -  8(25.8) 
Comorbidities             
Diabetes  1(6.25) 0(0.0)  0(0.0) 0(0.0)  -  -  1(3.2) 
Treated thyroid 
dysfunction (controlled) 
 2(12.5) 1(11.1)  1(6.7) 1(12.5)  -  -  3(9.7) 
Uterus malignant 
carcinoma (operated) 
 1(6.25) 1(11.1)  0(0.0) 0(0.0)  -  -  1(3.2) 
Knee surgery 
(contralateral leg > 6 
months ago) 
 2(12.5) 2(22.2)  0(0.0) 0(0.0)  -  -  2(6.5) 
Lupus erythematosus,  1(6.25) 1(11.1)  0(0.0) 0(0.0)  -  -  1(3.2) 
Surgical removal of 
greater saphenous with 
recurrence 
 1(6.25) 1(22.2)  0(0.0) 0(0.0)  -  -  1(3.2) 
Quantitative variable: mean (standard deviation). Categorical variable: frequency (%). P#: 
differences between groups (entire group). P##: differences between subgroups (groups with 
retest with one week apart).  
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Table 4 - Clinical data of CVD group of Study I 
 
 
CVD group 
 
  Entire Group  Subgroup with retest 
N  16 9 
CEAP 
Clinical classification 
   
C1  3(18.8) 2(22.2) 
C2  2(12.5) 1(11.1) 
C3  10(62.5) 5(55.6) 
C4  1(6.3) 1(11.1) 
Anatomical reflux    
Superficial veins  9(56.3) 5(55.6) 
Deep veins  1(6.3) 0(0.0) 
Perforator veins  3(18.8) 3(33.3) 
Superficial+Perforator  2(12.5) 0(0.0) 
Superficial+Deep+Perforator  1(6.3) 1(11.1) 
VCSS  3.8(3.2) 3.33(3.5) 
Symptoms    
Fatigue  11(68.8) 6(66.7) 
Cramps  8(50.0) 4(44.4) 
Heavy legs  10(62.5) 5(55.6) 
Pain  5(31.3) 3(33.3 
Skin irritation  3(18.8) 2(22.2) 
Itching  2(12.5) 1(1.1) 
Without  4(25.0) 2(22.2) 
Quantitative variable: mean (standard deviation). Categorical variable: frequency (%). 
VCSS: Venous Clinical Severity Score, total scale range 0-30 (best to worst) assessed in 
CVD (chronic venous disease) group.  
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Table 5 - Demographic and clinical data of Study II 
  
CVD Group  
 
Control Group  
  
P 
 
All Participants 
N  23  18    41 
Age (years)  46.83(13.24)  38.72(15.96)  0.083  42.68(15.23) 
Height (m)  1.67(0.91)  1.64(0.97)  0.419  70.62(15.03) 
Weight (Kg)  74.04(14.63)  66.08(13.50)  0.082  1.66(0.10) 
Body mass index (Kg/m2)  26.53(4.01)  24.36(3.67)  0.081  25.58(4.11) 
Gender          
Female   13(56.5)  10(55.6)  -  23(56.1) 
Male   10(43.5)  8(44.4)  -  18(43.9) 
CEAP clinical classification         
C1   5(21.7)  -  -  - 
C2  3(13.0)  -  -  - 
C3  5(21.7)  -  -  - 
C4  6(26.1)  -  -  - 
C5  4(17.4)  -  -  - 
VCSS  5.65(3.6)  -  -  - 
Anatomical reflux         
Superficial veins  3(13.0)  -  -  - 
Deep veins  1(4.3)  -  -  - 
Superficial+Deep veins  7(30.4)  -  -  - 
Superficial+Perforator veins  6(26.1)  -  -  - 
Superficial+Deep+Perforator veins  4(17.4)  -  -  - 
Comorbidities         
Surgical removal of great saphenous vein  3(13.0)  -  -  - 
Lower limbs symptoms         
Fatigue  18(78.3)  -  -  - 
Cramps   9(39.1)  -  -  - 
Heavy legs   14(60.9)  -  -  - 
Pain   14(60.9)  -  -  - 
Skin irritation   8(34.8)  -  -  - 
Itching   11(47.8)  -  -  - 
Without symptoms   2(8.7)  -  -  - 
Quantitative variable: mean (standard deviation). Categorical variable: frequency (%). 
VCSS: Venous Clinical Severity Score, total scale range 0-30 (best to worst). CEAP: 
Clinical Etiological Anatomical Pathological Classification. 
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Table 6 - Demographic and clinical data of Study III 
 
 
CVD group 
 Control 
group 
   All 
Participants    P  
N  28  29    57 
Age (years)  47.07(12.22)  39.31(13.76)  0.029*  43.12(13.49) 
Height (cm)  163.89(9.57)  164.83(9.94)  0.719  164.37(9.68) 
Weight (Kg)  69.30(13.59)  65.90(13.61)  0.349  67.57(13.59) 
Body mass index (Kg/m2)  25.73(3.81)  24.12(3.50)  0.101  24.90(3.71) 
Gender          
Female   21(75.0)  17(58.6)    38(66.7) 
Male   7(25.0)  12(41.4)    19(33.3) 
Comorbidities          
Surgical removal of small and/or 
great saphenous vein  
 
6(21.4)  0(0.0)    6(10.5) 
Active ulcer (contralateral leg)  1(3.6)  0(0.0)    1(1.8) 
History of deep venous thrombosis 
(>1year) 
 
3(10.7)  0(0.0)    3(5.3) 
Diabetes  0(0.0)  1(3.5)    1((1.8) 
Arterial hypertension  0(0.0)  4(13.8)    4(7.0) 
Cardio-respiratory disease (treated)  2(7.1)  4(13.8)    6(10.5) 
Erysipelas (>1 year ago)  1(3.6)  0(0.0)    1(1.8) 
Quantitative variable: mean (standard deviation). Categorical variable: frequency (%). 
*Significant difference between CVD (chronic venous disease) and control (healthy) groups. 
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Table 7 - Clinical data of CVD group in Study III 
 
 
CVD group 
 
  
N  28  
CEAP clinical classification    
C3   13 (46.4)  
C4  11(39.3)  
C5  4 (14.3)  
Anatomical reflux    
Superficial veins  5(17.9)  
Superficial+Deep veins  6(21.4)  
Superficial+Perforator veins  12(42.9)  
Superficial+Deep+Perforator veins  5(17.9)  
VCSS  7.07(3.6)  
Symptoms    
Fatigue  24(85.7)  
Cramps   14(50.0)  
Heavy legs   21(75.0)  
Pain   19(67.9)  
Skin irritation   12(42.9)  
Itching   17(60.7)  
Quantitative variable: mean (standard deviation). Categorical variable: frequency (%). 
VCSS: Venous Clinical Severity Score, range 0-30 (best to worst). CEAP: Clinical 
Etiological Anatomical Pathological Classification for CVD (chronic venous disease) group. 
Table 8 - Demographic data in Study IV 
 
 
Experimental Group 
 
Control group 
 
P 
  
N  20  21   
Age (years)  54.60(11.30)  46.81(11.10)  0.032* 
Height (cm)  164.90(8.78)  162.62(6.26)  0.342 
Weight (Kg)  77.00(20.71)  71.53(13.42)  0.325 
Body mass index (Kg/m2)  28.14(6.13)  27.00(4.59)  0.506 
Gender        
Female   15(75.0)  20(95.2)  - 
Male   5(25.0)  1(4.8)  - 
Quantitative variable: mean (standard deviation). Categorical variable: frequency (%). 
*Significant difference between CVD (chronic venous disease) and control (healthy) groups. 
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Table 9 - Clinical data of Study IV 
 
 Experimental 
Group 
 Control 
group 
 
P 
  
N  20  21   
VCSS  7.80(3.49)  6.86(2.94)  0.354 
CEAP classification       
Clinical Class       
C3: edema  8(40.0)  17(81.0)  - 
C4: skin changes  7(35.0)  4 (19.0)  - 
C5: healed ulcer  5(25.0)  0(0.0)  - 
Etiological Class       
Ep: primary  20(100)  21(100)  - 
Anatomical Class       
As: superficial veins  6(30.0)  4(19.0)  - 
Ad: deep veins  1(5.0)  0(0.0)  - 
As,d: superficial+deep veins  7(35.0)  5(23.8  - 
As,p: superficial+perforator veins  1(5.0)  5(23.8)  - 
As,d,p: superficial+deep+perforator veins  5(25.0)  7(33.3)  - 
Pathological Class       
Pr: reflux  20(100)  21(100)  - 
Symptoms       
Fatigue  16(80.0)  18(85.7)  - 
Cramps   11(55.0)  12(57.1)  - 
Heavy legs   20(100)  17(81.0)  - 
Pain   16(80.0)  18(85.7)  - 
Skin irritation   10(50.0)  9(42.9)  - 
Itching   9(45.0)  6(28.6)  - 
Comorbidities        
Surgical removal of small and/or great saphenous 
vein  
 
5(25.0)  3(14.3)  - 
Sclerotherapy  2(10.0)  0(0.0)  - 
History of deep venous thrombosis (>1year)  4(20.0)  0(0.0)  - 
Diabetes  1(5.0)  3(14.3)  - 
Arterial hypertension  6(30.0)  1(4.8)  - 
CVD treatments       
Compression stocking  8(40.0)  10(47.6)  - 
Medication to chronic venous disease  9(45.0)  1(4.8)  - 
Quantitative variable: mean (standard deviation). Categorical variable: frequency (%). 
VCSS: Venous Clinical Severity Score total scale range 0-30 (best to worst). CEAP: Clinical 
Etiological Anatomical Pathological Classification.  
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5.1 The use of ultrasound in the evaluation of the efficacy of calf muscle 
pump function in primary chronic venous disease 
5.1.1 Venous dynamic blood flow 
During the first tip-toe movement, popliteal vein blood flow velocity 
increased significantly in both the CVD and control groups (P = 0.008 and P = 
0.012, respectively for CVD group and control group). However, in the CVD group, 
but not in the control group, peak velocity decreased from the first to the tenth calf 
muscles contraction (first contraction vs. tenth contraction: P = 0.028 and P = 0.093, 
respectively for the CVD group and the control group). Dynamic blood flow velocity 
in popliteal vein was lower in the CVD group compared to the control group during 
both the first (P = 0.021) and the tenth contraction (P = 0.024) of the tip-toe 
movement set (Figure 3 and Figure 11). Peak velocity, given as percentage 
augmentation, was lower in the CVD group compared to the control group during the 
first contraction [530.6 (115.2)% vs. 831.5 (353.4)%, P = 0.027]. However, mean 
velocity augmentation during the first contraction and peak velocity augmentation in 
tenth contraction did not differ between groups. No differences in venous baseline 
hemodynamics were found between the two experimental groups (Table 10). 
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Figure 11 - Venous peak flow velocity in the popliteal vein during baseline, first and 
tenth tip-toe contractions  
 
Mean and standard deviation of venous peak flow velocity in the popliteal vein during 
baseline, first and tenth tip-toe contractions in CVD (chronic venous disease) group and 
control (healthy) group obtained during retesting and showing the results from Wilcoxon 
Signed-Rank test: (*) significantly different from baseline, (#) significantly different from 
first contraction of control group; (§) significantly different from tenth contraction; and (&) 
significantly different from tenth contraction of control group. All significant differences at 
least at P < 0.05. 
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Table 10 - Popliteal vein hemodynamics in CVD and control groups  
The results were obtained during the retest trial performed one week after the first session for 
CVD (chronic venous disease) and control (healthy) groups. *Significant with P < 0.05 for 
Mann-Whitney U test. 
5.1.2 Gastrocnemius muscle architecture 
Table 11 presents the anatomical data for the gastrocnemius muscle in CVD 
and control groups. Muscle thickness, pennation angle and muscle fascicles’ length 
were similar in both groups at the three different ankle joint positions. 
 
 
Group N Mean(SD) P 
Baseline peak flow velocity (cm/s) 
CVD 9 6.6(2.3) 
0.370 
Control 8 6.9(1.3) 
     
Baseline mean flow velocity (cm/s) 
CVD 9 2.7(1.7) 
0.963 
Control 8 2.4(1.2) 
     
Baseline cross-sectional area of popliteal vein (cm2) 
CVD 9 0.6(0.2) 
0.673 
Control 8 0.5(0.2) 
     
Baseline peak flow volume (mL/s/s) 
CVD 9 3.5(1.4) 
0.743 
Control 8 3.5(1.4) 
     
Baseline mean flow volume (mL/s/s ) 
CVD 9 1.3(0.6) 
0.743 
Control 8 1.2(0.6) 
     
First contraction peak flow velocity (cm/s) 
CVD 9 40.6(11.8) 
0.021* 
Control 8 62.4(22.1) 
     
First contraction mean flow velocity (cm/s) 
CVD 9 17.1(5.0) 
0.083 
Control 8 26.7(12.5) 
     
Tenth contraction peak flow velocity (cm/s) 
CVD 9 30.4(9.1) 
0.024* 
Control 8 49.5(22.7) 
     
Peak flow velocity augmentation in first contraction (%) 
CVD 9 530.6(115.2) 
0.027* 
Control 8 831.5(353.4) 
     
Mean flow velocity augmentation in first contraction (%) 
CVD 9 721.5(532.2) 
0.124 
Control 8 1319.0(1234.7) 
     
Peak flow velocity augmentation in tenth contraction (%) 
CVD 9 379.0(123.9) 
0.068 
Control 8 623.5(302.4) 
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No relationship could be noted between clinical severity (measured by CEAP 
and VCSS) and gastrocnemius architecture, as well as between clinical severity and 
dynamic popliteal vein blood flow. In CVD patients, a relationship could be found 
between peak flow velocity during the first contraction and medial gastrocnemius 
muscle fascicles length (r = 0.63; P = 0.041) and pennation angle (r = -0.68; P = 
0.044) when both are measured with ankle dorsiflexion. Peak flow velocity during 
the last contraction of the tip-toe set also increased with medial gastrocnemius 
muscle pennation angle in neutral position (r = 0.73; P = 0.025) and with the range of 
change in pennation angle between ankle dorsiflexion and plantarflexion (r = 0.70; P 
= 0.025).  
5.1.3 Test-retest reliability of calf muscle pump and gastrocnemius 
architecture ultrasound measures 
Ultrasound measures of gastrocnemius muscle architecture were generally 
highly reproducible. High immediate test-retest reliability (ICC > 0.94) for 
ultrasound measures of muscle thickness was found for medial and for lateral 
gastrocnemius muscle, and for pennation angle and muscle fascicles’ length of 
medial gastrocnemius muscle in ankle neutral position. The reliability of popliteal 
vein blood velocity in the first and tenth contractions was low, with an ICC < 0.5. 
However, peak and mean flow velocity in the first contraction presented good 
immediate test-retest reliability, with an ICC > 0.74. None of the hemodynamics 
measures showed high test-retest reliability (i.e., ICC > 0.5) (Table 12). The Bland-
Altman plot analysis reveals a poor agreement for dynamic popliteal vein velocity 
measures (Figure 12). 
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For the estimation of probe movement bias, the peak velocity was 57.8(14.9) 
cm/s during the actual tip-toe movement and 52.8 (17.3) cm/s during the simulated 
tip-toe movement with an ICC = 0.85 [0.35; 0.98] and P = 0.005, and a bias = 4.9 
cm/s (lower bound: -10.7 cm/s; upper bound: 20.7 cm/s). 
5.2 Venous flow at superficial and deep venous system during manual 
lymphatic drainage  
5.2.1 Baseline measures of venous blood flow 
The cross-sectional area of the GSV was higher in the CVD group [0.14 
(0.06) cm
2
] than in the control group [0.09 (0.04) cm
2
, P = 0.007]. Nevertheless, the 
cross-sectional area of FV and the mean flow velocity, the peak flow velocity, and 
the flow volume of both FV and GSV at baseline were similar in CVD and in the 
control group (Table 13 and Table 14). 
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Table 11 - Differences between CVD and control group in gastrocnemius muscle 
architecture 
 
 
Group N Mean(SD) P 
Medial gastrocnemius muscle thickness in neutral (mm) 
CVD 16 18.0(2.5) 
0.890 
Control 15 17.8(2.7) 
     
Medial gastrocnemius muscle thickness in plantarflexion (mm) 
CVD 16 17.0(2.6) 
0.968 
Control 15 17.5(3.5) 
     
Medial gastrocnemius muscle thickness dorsiflexion (mm) 
CVD 16 19.1(2.2) 
0.654 
Control 15 19.7(3.2) 
     
Lateral gastrocnemius muscle thickness in neutral (mm) 
CVD 16 12.2(3.3) 
0.384 
Control 15 13.2(3.6) 
     
Medial gastrocnemius muscle pennation angle in neutral (degrees) 
CVD 16 19.5(2.3) 
0.664 
Control 15 19.1(1.3) 
     
Medial gastrocnemius muscle pennation angle in plantarflexion (degrees) 
CVD 16 42.2(8.8) 
0.165 
Control 15 46.3(5.4) 
     
Medial gastrocnemius muscle pennation angle in dorsiflexion (degrees) 
CVD 16 17.6(3.1) 
0.572 
Control 15 17.3(2.0) 
     
Δ Medial gastrocnemius muscle pennation angle (degrees) 
CVD 16 24.6(8.0) 
0.096 
Control 15 29.0(5.5) 
     
Medial gastrocnemius muscle fascicle length in neutral (mm) 
CVD 16 54.3(7.7) 
0.874 
Control 15 54.8(8.7) 
     
Medial gastrocnemius muscle fascicle length in plantarflexion (mm) 
CVD 16 25.0(4.8) 
0.580 
Control 15 24.7(6.4) 
     
Medial gastrocnemius muscle fascicle length in dorsiflexion (mm) 
CVD 16 65.3(15.8) 
0.477 
Control 15 66.5(11.2) 
Mean (SD: standard deviation). Δ Medial gastrocnemius muscle (angle between maximal 
active dorsiflexion and plantarflexion in medial gastrocnemius). Differences between CVD 
(chronic venous disease) group and control (healthy) group are significant with P < 0.05 for 
Mann-Whitney U test. 
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Table 12 - Test-retest reliability of venous hemodynamics and muscle 
architecture measures 
* Calculated with subgroup with retest; ** calculated with all subjects. Intraclass Correlation 
Coefficient (ICC) significant with P < 0.05, with range [lower bound ─ upper bound] at 95% 
confidence interval. Mean (SD: standard deviation): results from the three measurements in 
the same day for immediate test-retest reliability and from the measures of first and second 
week for delayed test-retest reliability. 
 
 
 
 
N 
 
Mean(SD) 
 
ICC[range] 
 
P 
Immediate test-retest reliability         
First contraction peak flow velocity (cm/s)*  17  50.9(20.2)  0.74 [0.52─0.88]  0.000 
First contraction mean flow velocity (cm/s)*  17  21.6(10.3)  0.78[0.58─0.90]  0.000 
Tenth contraction peak flow velocity (cm/s)*  17  39.4(19.1)  0.49[0.20─0.75]  0.000 
Medial Gastrocnemius thickness (mm)**  31  17.9(2.5)  0.98 [0.96─0.99]  0.000 
Lateral Gastrocnemius thickness (mm)**  31  12.7(3.5)  0.98[0.97─0.99]  0.000 
Fibre length of medial gastrocnemius muscle 
(ankle at 90 degrees) (mm)** 
 31  54.5(8.0)  0.94[0.87─0.97]  0.001 
Pennation angle of medial gastrocnemius  
muscle fascicles (ankle at 90 degrees) (º)** 
 31  19.3(1.8)  0.94[0.89─0.97]  0.000 
Delayed test-retest reliability         
First contraction peak flow velocity (cm/s)  17  53.7(7)  -0.06[-0.46─-0.40]  0.253 
First contraction mean peak flow velocity (cm/s)  17  21.7(6.1)  0.28[-0.47─-0.50]  0.487 
Tenth contraction peak flow velocity (cm/s)  17  48.1(33.1)  0.10[-0.39─-0.54]  0.722 
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Figure 12 - Bland and Altman Plot of the two measures of first contraction peak flow velocity, first contraction mean flow velocity and 
tenth contraction peak flow velocity 
 
Bounds and bias were set at 95% of confidence interval. 
 100 
Table 13 - Venous blood flow in femoral vein  
  
CVD group 
(N=20) 
 
Control group 
(N=18) 
 
P 
 
All Participants 
(N=38) 
Cross-sectional  
area (cm2) 
Baseline  0.47(0.16)  0.46(0.21)  0.992  0.45(0.18) 
Call-up  0.52(0.20)*  0.49(0.19)  0.661  0.50(0.19)* 
Reabsorption  0.60(0.19)*  0.53(0.19)*‡†  0.229  0.57(0.19)*‡† 
          
Peak flow  
Velocity (cm/s) 
Baseline  19.38(8.77)  21.37(9.36)  0.504  20.32(8.99) 
Call-up  24.85(10.92)*  25.67(8.82)*  0.803  25.24(9.85)* 
Reabsorption  25.96(10.32)*  25.04(6.83)  0.754  25.51(8.69)* 
          
Mean flow  
velocity (cm/s) 
Baseline  12.14(5.67)  14.20(7.47)  0.342  13.11(6.57) 
Call-up  16.62(8.27)*  17.12(7.15)  0.843  16.86(7.66)* 
Reabsorption  15.88(7.30)*  15.37(4.76)  0.807  15.63(6.12)* 
          
Flow volume (ml/s) Baseline  5.47(3.40)  6.05(4.22)  0.644  20.32(8.99) 
Call-up  8.20(4.72)*  7.99(3.87)*  0.883  25.24(9.85)* 
Reabsorption  9.42(4.73)*  7.98(3.89)*  0.320  25.51(8.69)* 
P-Value for differences between groups (P). * Significantly different from baseline (P < 
0.05). †Significantly different from call-up maneuver (P < 0.05). ‡Significantly different 
from call-up maneuver for percentage augmentation from baseline [(maneuver-
baseline)/baseline)*100, (P < 0.05). Results are presented as mean (standard deviation) for 
CVD (chronic venous disease) group and control (healthy) group, and all subjects. 
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Table 14 - Venous blood flow in great saphenous vein 
  
CVD group 
 (N=20) 
 
Control group 
 (N=18) 
 
P 
 
All Participants  
(N=38) 
Cross-sectional  
area (cm2) 
Baseline  0.14(0.06)  0.09(0.04)  0.007†  0.12(0.05) 
Call-up  0.16(0.07)  0.09(0.04)  0.001†  0.12(0.06) 
Reabsorption  0.16(0.06)  0.10(0.04)  0.001†  0.13(0.06) 
          
Peak flow  
Velocity (cm/s) 
Baseline  15.82(8.06)  21.09(17.52)  0.240  18.38(13.66) 
Call-up  26.22(13.65)*  33.31(28.96)*  0.313  29.45(22.61)* 
Reabsorption  28.58(15.66)*  35.19(29.05)*  0.393  31.84(23.10)* 
          
Mean flow  
velocity (cm/s) 
Baseline  10.05(4.63)  14.56(14.29)  0.194  12.22(10.72) 
Call-up  16.64(8.13)*  24.18(25.29)*  0.215  20.23(18.92)* 
Reabsorption  18.09(9.03)*  24.77(23.16)*  0.224  21.31(17.62)* 
          
Flow volume (ml/s) Baseline  1.35(0.82)  1.49(1.91)  0.784  1.42(1.45) 
Call-up  2.69(2.49)*  2.32(2.92)*  0.686  2.50(2.68)* 
Reabsorption  3.08(2.80)*  2.35(2.24)*  0.390  2.71(2.53)* 
* Significantly different from baseline (P < 0.05). 
†
Significant difference between CVD 
(chronic venous disease) group and control (healthy) group (P < 0.05). Results are presented 
as mean (standard deviation). 
5.2.2 Call-up and Reabsorption maneuver 
During the call-up maneuver, the FV blood flow volume increased 
significantly from baseline (P < 0.05; Figure 13). The FV peak flow velocity only 
increased during call-up maneuver in the control group (P = 0.032), and during 
reabsorption and call-up maneuvers in the CVD group (P < 0.001) and in both 
groups pooled together (P < 0.01). The FV mean flow velocity only increased during 
call-up and reabsorption maneuvers in the CVD group (P < 0.001 and P < 0.001, 
respectively) and in both groups pooled together (P < 0.001 and P < 0.01, 
respectively). The cross-sectional area of FV increased from baseline during the call-
up maneuver only in the CVD group (P < 0.01) and with all groups pooled together 
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(P < 0.01), and during reabsorption in both the CVD (P < 0.01) and the control group 
(P < 0.01) and with the two groups pooled together (P < 0.001).  
The GSV blood flow (peak and mean flow velocity and flow volume) 
increased significantly (P < 0.05) from baseline during call-up and reabsorption 
maneuvers (Figure 14). The cross-sectional area of GSV, however, remained 
unchanged during the maneuvers. 
The venous blood flow (mean and peak flow velocities and flow volume) and 
cross-sectional area augmentation from baseline for both FV and GSV were similar 
in both call-up and reabsorption maneuvers, with the exception of the cross-sectional 
area augmentation of FV that was lower during call-up maneuver when compared 
with reabsorption in the control group [12.45 (30.00)% and 23.05 (32.89)%, 
respectively; P < 0.01]), and with the two groups pooled together [12.70 (23.85)% 
and 34.76 (58.40)%, respectively; P < 0.05]). The cross-sectional area (in absolute 
values) of FV during call-up was also lower than during reabsorption maneuver in 
the control group [(0.49 (0.19) cm
2
, and 0.53 (0.19) cm
2
 for call-up and reabsorption 
maneuvers, respectively; P = 0.042]), and with the two groups pooled together [0.50 
(0.19) cm
2
 and 0.57 (0.19) cm
2
 for call-up and reabsorption maneuvers, respectively; 
P < 0.05]), but no differences were found between maneuvers in the CVD group. In 
addition, no differences in cross-sectional area for GSV, and in blood flow for FV 
and for GSV, were found were found between call-up and reabsorption maneuvers. 
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Figure 13 - Blood flow velocities and volume of femoral vein during baseline, call-up maneuvers and reabsorption maneuvers of MLD 
 
Left: image of blood flow velocities of FV during baseline, call-up maneuver and reabsorption maneuver of MLD. Right: mean and error (95% of 
confidence interval) of flow volume in femoral vein in the CVD group (patients with chronic venous disease) and the control group (healthy subjects) 
during baseline and MLD maneuvers (call-up and reabsorption), showing the results of Bonferroni-adjusted pairwise comparisons. (*) Significantly 
different from the baseline. 
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Figure 14 - Blood flow velocities and volume of great saphenous vein during baseline, call-up maneuvers and reabsorption maneuvers of 
MLD 
 
Left: image of blood flow velocities of great saphenous vein (GSV) during baseline, call-up maneuver and reabsorption maneuver of MLD. 
Right: mean and error (95% of confidence interval) of flow volume in the GSV in the CVD group (patients with chronic venous disease) 
and the control group (healthy subjects) during baseline and MLD maneuvers (call-up and reabsorption), showing the results from 
Bonferroni-adjusted pairwise comparisons. (*) Significantly different from the baseline. 
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5.2.3 Severity of CVD and MLD maneuvers 
The CVD group presents a higher cross-sectional area of the GSV than the 
control group during call-up (P < 0.001) and reabsorption maneuvers (P < 0.001), 
but the cross-sectional area augmentations were similar. No other differences were 
found between the CVD and the control group during the application of each 
maneuver. 
Blood flow (peak and mean flow velocity and the flow volume) 
augmentations in FV and as a result of applying the reabsorption maneuver 
decreased with the severity of CVD, as measured by VCSS (r = -0.51, P < 0.05 for 
peak flow velocity; r = -0.51, P < 0.05 for mean flow velocity; and r = -0.49, P < 
0.05 for flow volume). Again in the FV, flow volume augmentation also decreased 
with the severity of CVD, measured by CEAP clinical classification (r = -0.64; P < 
0.05). The GSV flow volume augmentation was not affected by the severity of the 
CVD disease.  
5.3 Venous flow during manual lymphatic drainage applied to different 
regions of the lower extremity.  
5.3.1 Manual lymphatic drainage at the thigh 
The cross-sectional area of FV increased when MLD was applied over the 
medial side of the thigh (P < 0.05) for all groups, but not when applied to its lateral 
side in control group. The cross-sectional area of GSV remains unchanged with 
MLD applied to the thigh. Irrespective of changes in cross-sectional area, peak and 
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mean blood flow velocity and flow volume increased during medial and lateral thigh 
MLD both in FV and in GSV (P < 0.001 for all variables). However, the increase in 
blood flow velocity and in blood flow volume was higher with medial thigh MLD, 
when compared with the lateral thigh MLD, in both FV and GSV (P < 0.001 for all 
variables). In addition, the increase in venous blood flow velocity and flow volume 
as a result of medial thigh MLD was greater in GSV than in FV (P < 0.05). No 
differences could be found in the effect of MLD in blood flow and in the cross-
sectional area in either veins between the CVD group and the control group (see 
Table 15).  
5.3.2 Manual lymphatic drainage at the leg 
The peak and mean flow velocity and flow volume of PV and SSV increased 
as a result of MLD applied to the leg (P < 0.001). The same procedure increased 
PV’s cross-sectional area (P < 0.001), but not that of SSV. These increases, however, 
were similar (P > 0.05) when the MLD technique was performed over the lateral and 
the medial aspect of the leg (Table 16). The amount of increase in blood flow 
velocity and blood flow volume as a result of leg MLD was similar in PV and SSV. 
Again, the effect of leg MLD on peak flow velocity was similar in the two groups. A 
significant interaction effect between the vein assessed (PV and SSV) and the 
experimental groups (CVD group and control group) was found for the increase in 
mean blood flow velocity (P < 0.01), which was higher for SSV in the CVD group, 
and for PV in the control group. 
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Table 15 - Venous blood flow during manual lymphatic drainage at the thigh 
Variables 
 CVD group  Control group  All Participants 
N   N   N  
Femoral vein          
Cross-sectional area (cm2) Baseline 27 0.41(0.14)  29 0.43(0.20)  56 0.42(0.17) 
Medial aspect 27 0.45(0.17)*  29 0.48(0.20)*  56 0.46(0.19)* 
Lateral aspect 28 0.46(0.17)*  29 0.44(0.18)  57 0.44(0.18) 
          
Peak flow velocity (cm/s) Baseline 28 21.07(10.70)  29 20.14(8.11)  57 20.60(9.40) 
Medial aspect 28 25.39(15.14)*  29 24.59(8.03)*  57 24.98(11.95)* 
Lateral aspect 28 22.81(14.67)*†   29 23.19(7.80)*†  57 23.00(11.65)*† 
          
Mean flow velocity (cm/s) Baseline 28 14.04(8.60)  29 13.02(6.48)  57 13.52(7.53) 
Medial aspect 28 17.58(12.53)*  29 15.86(6.44)*  57 16.70(9.86)* 
Lateral aspect 28 15.70(12.19)*†  29 14.93(5.63)*†  57 15.31(9.36)*† 
          
Flow volume (mL/s/s) Baseline 27 5.09(2.91)  29 5.28(3.60)  56 5.19(3.25) 
Medial aspect 27 6.82(3.69)*  29 7.22(3.68)*  56 7.03(3.65)* 
Lateral aspect 28 6.09(3.44)*†  29 6.22(3.31)*†  57 6.16(3.35)*† 
          
Great saphenous vein          
Cross-sectional area (cm2) Baseline 22 0.11(0.07)  29 0.09(0.04)  51 0.10(0.06) 
Medial aspect 22 0.11(0.08)  29 0.10(0.05)  51 0.10(0.06) 
Lateral aspect 22 0.10(0.07)  29 0.10(0.05)  51 0.10(0.06) 
          
Peak flow velocity (cm/s) Baseline 22 19.19(12.25)  29 20.71(14.43)  51 20.06(13.42) 
Medial aspect 22 28.82(19.97)*  29 32.81(24.77)*  51 24.98(11.95)* 
Lateral aspect 22 22.00(14.70)*†  29 25.68(19.78)*†  51 23.00(11.65)*† 
          
Mean flow velocity (cm/s) Baseline 22 13.41(9.18)  29 14.02(11.60)  51 13.76(10.53) 
Medial aspect 22 20.31(15.62)*  29 22.92(21.00)*  51 21.80(18.74)* 
Lateral aspect 22 15.66(11.01)*†  29 18.07(16.31)*†  51 17.03(14.20)*† 
† 
          
Flow volume (mL/s/s) Baseline 22 1.63(1.96)  29 1.34(1.56)  51 1.47(1.73) 
Medial aspect 22 2.41(2.66)*  29 2.26(2.47)*  51 2.33(2.53)* 
Lateral aspect 22 1.87(2.28)* †  29 1.72(1.80)* †  51 1.78(2.00)* † 
Manual lymphatic drainage technique at medial and lateral aspect of thigh. * Significantly 
different from baseline (P < 0.05). 
†
 Significantly different from technique applied at medial 
aspect of thigh (P < 0.05). Results are presented as mean (standard deviation) for CVD 
(chronic venous disease) group and control (healthy) group. 
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Table 16 - Venous blood flow during manual lymphatic drainage on the leg 
Manual lymphatic drainage techniques at the medial and lateral aspect of leg. * Significantly 
different from baseline (P < 0.05). Results are presented as mean (standard deviation) for 
CVD (chronic venous disease) group and control (healthy) group. 
 
Variables   
CVD group  Control group   
All 
Participants 
N   N   N  
Popliteal vein          
Cross-sectional area (cm2) Baseline 28 0.21(0.15)  29 0.19(0.12)  57 0.20(0.13) 
Medial aspect 28 0.27(0.19)*  29 0.23(0.15)*  57 0.25(0.17)* 
Lateral aspect 28 0.25(0.17)*  29 0.23(0.13)*  57 0.24(0.15)* 
          
Peak flow velocity (cm/s) Baseline 27 18.17(8.53)  29 19.69(9.78)  56 18.96(9.15) 
Medial aspect 28 37.12(20.38)*  29 42.00(20.48)*  57 39.60(20.40)* 
Lateral aspect 28 33.90(16.00)*  29 42.78(21.27)*  57 38.42(19.23)* 
          
Mean flow velocity (cm/s) Baseline 27 11.95(6.28)  29 12.30(7.89)  56 12.14(7.10) 
Medial aspect 28 23.45(14.21)*  29 27.90(16.73)*  57 25.71(15.57)* 
Lateral aspect 28 21.43(11.33)*  29 28.07(17.14)*  57 24.80(14.83)* 
          
Flow volume (mL/s/s) Baseline 27 2.31(2.74)  29 2.26(2.16)  56 2.28(2.44) 
Medial aspect 28 5.76(5.64)*  29 6.36(5.41)*  57 6.06(5.48)* 
Lateral aspect 28 4.99(4.38)*  29 6.88(6.15)*  57 5.95(5.39)* 
          
Small saphenous vein          
Cross-sectional area (cm2) Baseline 23 0.05(0.03)  29 0.05(0.03)  52 0.05(0.03) 
Medial aspect 22 0.06(0.04)  29 0.06(0.03)  51 0.06(0.03) 
Lateral aspect 23 0.05(0.03)  29 0.06(0.04)  52 0.05(0.03) 
          
Peak flow velocity (cm/s) Baseline 23 10.10(2.67)  29 11.86(5.25)  52 11.08(4.36) 
Medial aspect 23 12.74(4.66)*  29 14.59(5.98)*  52 13.77(6.89)* 
Lateral aspect 23 14.31(10.82)*  29 13.99(7.82)*  52 14.13(9.17)* 
          
Mean flow velocity (cm/s) Baseline 23 5.95(2.26)  29 7.20(3.94)  52 6.64(3.33) 
Medial aspect 23 7.88(3.57)*  29 9.28(5.98)*  52 8.66(5.06)* 
Lateral aspect 23 9.09(8.06)*  29 8.61(5.76)*  52 8.82(6.80)* 
          
Flow volume (ml/s) Baseline 23 0.30(0.28)  29 0.40(0.38)  52 0.35(0.34) 
Medial aspect 22 0.46(0.49)*  29 0.55(0.52)*  51 0.51(0.50)* 
Lateral aspect 23 0.55(0.95)*  29 0.52(0.52)*  52 0.53(0.73)* 
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5.3.3 Clinical severity of chronic venous disease and response to MLD 
No correlation could be found between percent increase in blood flow (i.e., 
peak and mean flow velocity and the flow volume) or cross-sectional area, and the 
degree of severity of CVD for any of the veins or MLD techniques investigated in 
this study.  
5.3.4 Reliability  
High to moderate test-retest reliability for vein cross-sectional area and 
venous blood volume measurements, taken at the baseline and during MLD, was 
confirmed in this study, excepting for measures of blood flow velocity during MLD, 
for which ICC values were below 0.50 (Table 17). 
Table 17 - Test-retest reliability for duplex ultrasound assessments 
Intraclass correlation coefficient (ICC), with range (lower bound; upper bound) at 95% 
confidence interval. 
Variables 
 Baseline (n=9)  MLD (n=9) 
 ICC (range)  ICC (range) 
Cross-sectional area (cm
2
)  0.97(0.84;0.96)  0.95(0.84;0.99) 
Peak flow velocity (cm/s)  0.47(-0.14;0.87)  0.14(0.15;0.54) 
Mean flow velocity (cm/s)  0.50(-0.13;0.89)  0.15(-0.13;0.54) 
Flow volume (mL/s/s)  0.90(0.58;0.98)  0.57(0.00;0.85) 
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5.4 Efficacy of manual lymphatic drainage in chronic venous disease 
patients 
The effect of 4-week MLD treatment on signs and symptoms of CVD was 
assessed in Study IV, a single blind randomized controlled trial. 
5.4.1 Health-related quality of life  
A significant interaction effect of Group versus Time was found for pain 
dimension of CIVIQ-20, with medium effect size [F (2,70) = 3.417; P < 0,05; η2ρ = 
0.089]. In the experimental group, but not in the control group, pain scores improved 
between T0 [55.75 (14.17)] and T1 [(47.11 (14.17)] (P < 0.05; 95% IC = [0.617; 
17.537]) and between T0 and T2 [(46.00 (15.27)] (P < 0.05; 95% IC = [0.181; 
17.546]). No differences between experimental and control were found for physical, 
psychological and social dimensions or in the global score of HRQL assessed with 
CIVIQ-20. 
No interaction effect between Group versus Stocking versus Time could be 
found for any of the CIVIQ-20 scores (Table 18). 
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Table 18 - Severity of chronic venous disease, symptoms and leg volume 
Variables 
 
Experimental Group 
 
Control group 
  
Severity of disease       
VCSS  T0  7.80(3.49)   6.86(2.94) 
T1  4.85(3.10)*   6.24(2.32) 
T2  5.25(3.21)*   6.43(3.20) 
Symptoms       
Fatigue  T0  5.21(2.43)   4.71(2.86) 
T1  2.19(2.18)*   3.89(2.89) 
T2  2.40(2.53)*   4.53(3.18) 
       
Heaviness T0  5.25(2.40)   4.71(2.86) 
T1  2.12(2.15)*   4.31(2.92) 
T2  2.24(2.53)*   4.20(3.31) 
       
Leg volume (mL/s) T0  2556.83(389.59)   2476.24(459.41) 
 T1  2485.57(399.74)   2502.10(451.23) 
 T2  2552.98(331.24)   2473.08(456.08) 
Health-related quality of life       
CIVIQ- Global score T0  48.05(12.53)   48.67(16.03) 
T1  44.84(14.89)   50.23(17.63) 
T2  44.50(12.88)   49.85(19.06) 
       
CIVIQ – Pain dimension T0  55.75(14.17)   55.71(16.22) 
T1  47.11(14.17)*   55.00(17.61) 
T2  46.00(15.27)*   56.75(19.28) 
       
CIVIQ – Physical dimension T0  54.00(16.27)   50.24(21.23) 
T1  48.68(19.85)   50.71(21.23) 
T2  48.25(17.41)   52.50(21.91) 
       
CIVIQ – Psychological dimension T0  37.22(11.07)   39.89(15.48) 
T1  42.22(41.43)   48.25(18.53) 
T2  41.43(11.25)   46.11(22.27) 
       
CIVIQ – Social dimension T0  52.00(19.77)   47.94(18.57) 
T1  44.56(18.20)   49.21(19.49) 
T2  45.65(17.98)   48.33(20.73) 
* Significantly different from T0 (P < 0.05). CIVIQ-20: Chronic Venous Insufficiency 
Questionnaire, range 0-100 (best to worth). VCSS: Venous Clinical Severity Score total 
scale range 0-30 (best to worst). Symptoms: assessed with visual analogue scale, range 0-
10(best to worth). Results are presented as mean (standard deviation). 
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5.4.2 Severity of the disease, symptoms and leg volume 
A significant Group versus Time interaction was found for clinical severity, 
with medium effect size [F (2; 74) = 3.025, P < 0.05, η2ρ = 0.117]. In the 
experimental group, clinical severity improved between T0 [7.80 (3.49)] and T1 
[4.85 (3.10)]; P < 0.001, 95% IC = [1.426; 4.324]) and between T0 and T2 [5.25 
(3.21)]; P < 0.001; 95% IC = [1.312; 3730]). In the control group, no changes in 
clinical severity were noticed during the study. For VCSS item, a significant Group 
versus Time interaction was found for the item “Venous Edema” [F (2; 72) = 3.308, 
P < 0.05, η2ρ = 0.084]. In the experimental group, edema improved between T0 
[1.97 (0.20)] and T1 [1.30 (0.21)] (P < 0.05, 95% IC = [0.012; 1.334]) but not from 
T0 and T1 to T2 [1.54 (0.17)]. 
A significant Group versus Time interaction effect could be found for 
symptom “fatigue”, with medium effect size [F (2; 74) = 4.390, P < 0.05, η2ρ = 
0.106], improving only in the experimental group between T0 [5.21 (2.43)] and T1 
[2.19 (2.18)] (P < 0.01; 95% IC = [1.148; 4.994]), and between T0 and T2 [2.40 
(2.53)] (P < 0.01; 95% IC = [0.677; 4.773]).  
A significant Group versus Time interaction effect was also observed for the 
symptom “heaviness”, with medium effect size [F (1.56; 57.72) = 9.710, P < 0.001, 
η2ρ = 0.208], improving only in the experimental group between T0 [5.25 (2.40)] and 
T1 [2.12 (2.15); P < 0.01; IC 95% IC = [1.334; 5.154]) and between T0 and T2 [2.24 
(2.53)], (P < 0.01; 95% IC = [0.791; 5.372]). Heaviness symptoms in the control 
group remained unaltered throughout the study.  
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No Group versus Time interaction effect was found for leg volume. Also, no 
Group versus Stocking versus Time interaction could be found for severity of 
disease, fatigue, heaviness and leg volume (Table 18). 
5.4.3 Ankle muscles strength 
Ankle muscles isokinetic strength and ankle range of motion were similar in 
experimental and control groups and did not vary across T0, T1 and T2 (Table 19 
and Table 20). 
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Table 19 - Calf muscle dynamometer isokinetic performance for ankle dorsiflexion 
 
 
Experimental Group 
 
Control group 
  
Dorsiflexion    
Peak torque 60º/sec (Nm) T0  30.87(17.90)   25.23(11.12) 
 T1  33.26(22.34)   24.37(8.94) 
 T2  35.68(20.04)   25.63(13.80) 
       
Peak torque 120º/sec (Nm) T0  26.27(13.57)   21.21(7.21) 
 T1  29.17(16.97)   21.35(5.88) 
 T2  30.29(15.84)   22.79(9.31) 
       
Peak torque/body weight 60º/sec  T0  0.40(0.21)   0.37(0.20) 
(Nm/Kg) T1  0.43(0.28)   0.36(0.17) 
 T2  0.47(0.22)   0.38(0.22) 
       
Peak torque/body weight 120º/sec  T0  0.35(0.11)   0.31(0.14) 
(Nm/Kg) T1  0.39(0.21)   0.31(0.12) 
 T2  0.40(0.18)   0.34(0.16) 
       
Total work 60º/sec (J) T0  67.35(33.47)   73.00(46.87) 
 T1  73.82(49.83)   58.57(21.84) 
 T2  66.21(40.92)   63.01(33.37) 
       
Total work 120º/sec (J) T0  177.99(113.03)   152.91(69.46) 
 T1  177.24(117.80)   148.69(69.28) 
 T2  171.64(89.60)   141.96(74.76) 
       
Average power 60º/sec (Watt) T0  15.52(7.83)   13.93(6.03) 
 T1  17.29(10.09)   14.45(5.08) 
 T2  18.12(9.33)   14.83(7.41) 
       
Average power 120º/sec (Watt) T0  19.29(11.74)   17.10(7.62) 
 T1  20.63(13.56)   17.19(7.78) 
 T2  20.72(10.66)   17.44(8.65) 
T0 (Baseline); T1 (4 weeks of MLD treatment for experimental group, and without MLD 
treatement for control group); and T2 (follow-up of 4 weeks after T1). 
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Table 20 - Calf muscle dynamometer isokinetic performance for ankle plantarflexion 
 
 
Experimental Group 
 
Control group 
  
Plantarflexion       
Peak torque 60º/sec (Nm) T0  42.44(24.35)   52.82(24.23) 
 T1  50.70(25.63)   65.22(25.20) 
 T2  51.87(25.48)   57.06(22.59) 
       
Peak torque 120º/sec (Nm) T0  34.30(20.30)   41.90(18.52) 
 T1  45.67(24.42)   52.96(21.46) 
 T2  40.88(21.28)   46.37(23.95) 
       
Peak torque/body weight 60º/sec  T0  0.61(0.39)   0.78(0.43) 
(Nm/Kg) T1  0.71(0.42)   0.94(0.38) 
 T2  0.74(0.44)   0.83(0.35) 
       
Peak torque/body weight 120º/sec  T0  0.49(0.34)   0.62(0.32) 
(Nm/Kg) T1  0.63(0.34)   0.76(0.32) 
 T2  0.58(0.33)   0.67(0.32) 
       
Total work 60º/sec (J) T0  100.57(69.47)   130.82(82.54) 
 T1  105.00(53.40)   140.97(66.08) 
 T2  100.78(54.32)   139.71(109.75) 
       
Total work 120º/sec (J) T0  222.89(193.03)   294.49(164.70) 
 T1  254.02(133.76)   354.78(174.30) 
 T2  238.97(154.50)   280.41(146.17) 
       
Average power 60º/sec (Watt) T0  19.37(10.41)   25.77(13.71) 
 T1  25.26(13.35)   31.30(13.90) 
 T2  25.99(13.44)   29.51(15.71) 
       
Average power 120º/sec (Watt) T0  23.81(18.81)   30.08(16.06) 
 T1  29.32(15.98)   38.41(20.41) 
 T2  27.16(16.76)   33.43(19.39 
       
Active range of motion 60º/sec (degrees) T0  57.86(13.64)   64.53(11.03) 
 T1  61.56(10.59)   59.43(7.84) 
 T2  53.19(6.82)   56.91(5.55) 
       
Active range of motion 120º/sec (degrees) T0  59.13(10.55)   64.93(10.17) 
 T1  61.02(9.71)   60.12(7.90) 
 T2  54.73(5.66)   56.31(6.57) 
T0 (Baseline); T1 (4 weeks of MLD treatment for experimental group, and without MLD 
treatement for control group); and T2 (follow-up of 4 weeks after T1). 
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6 DISCUSSION 
6.1 Ultrasound assessment of calf muscle pump function 
CMPF is impaired in CVD (Araki et al., 1994; O'Brien et al., 2012; Panny et 
al., 2009; Recek, 2013; Shiman et al., 2009; Simka, 2007). In addition to normal 
venous functioning, CMPF function relies on the contraction ability of the calf 
muscles and in a good ankle range of motion (Cavalheri et al., 2008; de Moura et al., 
2012; Panny et al., 2009; Shiman et al., 2009). Despite its importance in preventing 
venous stasis and hypertension, calf muscle pump is not commonly assessed in 
dynamic conditions. Likewise, the relationship between muscle pump efficacy and 
measures of muscle size and architecture has not been explored before. Hence, we 
hypothesized that calf muscles architecture is affected in CVD subjects and that this 
is related with the efficacy of the blood pumping function of this musculature, which 
could be assessed dynamically by means of duplex ultrasound. Despite that air-
plethysmography provides a non-invasive and accurate assessment of CMP, it does 
not allow examining individual veins (deep and superficial) during muscle 
contraction or ankle motion. These measures can be gathered using duplex scanning 
and might be important for understanding CVD physiopathology for guiding the 
treatment and perhaps used as a strategy to assess efficacy of CVD treatments for 
CMPF. 
Our results show a clear increase in venous blood flow caused by calf muscle 
contractions in individuals with CVD and control participants. Popliteal peak flow 
volume was maximal during the first contraction of the tip-toe set when the venous 
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reservoir is full, which has also been seen in other studies (Staubesand et al., 1995). 
In the CVD patients, but not in the healthy subjects, venous flow augmentation 
diminished during the muscle contraction set. Such apparent calf pump dysfunction 
might be related to weak calf muscles in CVD patients (Panny et al., 2009; Qiao et 
al., 2005) and is compatible with a lower ejection volume, such as has been measured 
before in this population with air-plethysmography (Nicolaides, 2000). In addition, 
abnormal venous blood reflux from deep to superficial venous system through 
incompetent perforator veins may blunt blood flow through the popliteal vein. 
As a result of CVD, distal leg muscles may exhibit reductions in strength and 
power, which then might contribute to aggravate the condition (Webber et al., 2010). 
In fact, patients with CVD present decreased ankle muscle strength (Panny et al., 
2009) with a decreased peak torque per kilogram of body weight, as well as 
diminished power ability (de Moura et al., 2012) and muscle resistance (van Uden et 
al., 2005). Accompanying muscle weakness, CVD patients are also characterized by 
decreased ankle range of motion (de Moura et al., 2012; Dix et al., 2003; van Uden et 
al., 2005), decreased gait speed (de Moura et al., 2012; van Uden et al., 2005), and 
impaired functional capacity and mobility (de Moura et al., 2012). 
Nonetheless, it seems that calf muscle size is not a strong indicator of the 
efficacy of muscles to pump venous blood during contractions, at least in patients 
with venous ulcer (Moloney et al., 2007). In our study, gastrocnemius thickness and 
some other muscle architectural features were similar in patients with low to 
moderate severity of CVD and healthy participants and were unrelated to the severity 
of CVD. Despite this fact, for the medial gastrocnemius, few morphological 
parameters were associated with the degree of increase in peak flow velocity in the 
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popliteal vein during tip-toe movement. Higher muscle fascicle length and a lower 
pennation angle in the medial gastrocnemius, and with the ankle in dorsiflexion, 
were associated with larger increase in peak flow volume in the popliteal vein during 
tip-toe. Likewise, higher gastrocnemius muscle fascicles pennation angle with ankle 
in neutral position, and a larger change in pennation angle between maximal active 
dorsiflexion and plantarflexion are accompanied by increased venous flow volume at 
the end of a whole set of calf muscle contractions. The exact meaning of these 
findings is unclear but lower pennation angle and longer muscle fascicles at ankle 
dorsiflexion may indicate higher ankle joint range of motion and improved blood 
pumping function by the calf muscles (Duclay et al., 2009; Manal et al., 2008; Morse 
et al., 2007; Rassier & Herzog, 2004). Improved ankle range of motion is likely 
important for muscle pump function during gait and patients with CVD show notable 
gait alterations (de Moura et al., 2012). In addition, increased tissue hydrostatic 
pressure and tissue edema in the lower leg likely restricts ankle dorsiflexion and 
gastrocnemius muscle lengthening and can be related to less efficient calf pump 
function (Back et al., 1995; Cavalheri et al., 2008; Meissner et al., 2007b; Panny et 
al., 2009; Shiman et al., 2009). 
In this study, the ultrasound measures of gastrocnemius muscle architecture 
were highly reproducible, which is in agreement with previous studies (Duclay et al., 
2009; Narici et al., 1996). In contrast, those of popliteal venous blood flow showed 
quite large variation when measured within a week interval (Breen et al., 2007; Lurie 
et al., 2002). Such somewhat low reproducibility might be related with probe 
unsteadiness, combined with short sampling time of venous velocity (Breen et al., 
2007; Lurie et al., 2002). We attempted to determine the error introduced by leg 
 120 
movement on probe steadiness and on the measures of blood flow volume by 
contrasting such measures with those collected with subjects performing similar foot 
movement while standing supported on the opposite limb. In this case, the measures 
of venous blood flow collected from the popliteal vein were highly reproducible and 
showed good agreement with measures collected during actual tip-toe movement. 
This suggests that probe movement relative to the underlying vein is not a strong 
limitation to the use of continuous-wave Doppler ultrasound in evaluating venous 
hemodynamics in the lower extremity during dynamical weight-bearing conditions.  
The poor test-retest reliability found for popliteal vein measures during tip-
toe movements points to the need for strict standardization regarding probe 
positioning and movement task conditions if the use of ultrasound techniques to 
assess CMPF is warranted. However, the high bias of this procedure might preclude 
its usefulness in assessing the response to treatment interventions. Hence, this 
methodology was not used in our study to assess therapeutic efficacy of MLD on 
treatment of the impaired calf muscle pump function in this patients. 
6.2 Hemodynamic effects of manual lymphatic drainage 
The hypothesis that MLD increases blood flow in superficial veins has 
already been proposed (Leduc et al., 2000), especially by means of the call-up 
maneuver (Leduc et al., 2000), but the evidence supporting such contention was not 
strong. In fact, data collected from patients with heart failure and lower limb edema 
point to small or even insignificant effects of MLD on venous hemodynamics (after 
applying sequentially call-up and reabsorption maneuvers) (Leduc et al., 2011) but 
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the direct effect of MLD in venous blood flow across the lower limbs was not 
evaluated. Despite the lack of strong evidence demonstrating its efficacy, MLD is 
commonly prescribed as a treatment for patients with CVD, especially when the 
lymphatic system is affected and edema is present (Raju et al., 2012). Before CVD 
surgery, MLD also appears to have an important role in improving the severity of the 
disease and the HRQL of these patients, as well as in improving hemodynamics 
parameters, such as the reflux volume index, an important marker of CVD (Molski et 
al., 2009). 
Based on this evidence we hypothesized that call-up and reabsorption 
maneuvers would enhance venous blood flow and that this would be apparent by an 
elevated blood flow in both the superficial and the deep veins of the lower extremity, 
a possibility based on the anatomical features of the venous system in the lower 
extremity. We also hypothesized that venous blood flow enhancement would be 
higher when the MLD technique (call-up maneuver) is applied to the medial aspect 
of the thigh and of the leg, thus in coincidence with the course of GSV. Such effects 
of MLD will then be translated into elevated blood flow in both the superficial and 
the deep veins of the lower extremity. 
6.2.1 Call-up versus Reabsorption maneuver 
The results we have obtained demonstrate that indeed MLD techniques, 
which are based on manual stretching of the skin and underlying soft tissues, 
increase venous blood flow along the superficial veins, as has already been suggested 
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(Leduc et al., 2000), but also along the deep venous system, which course beneath 
the deep fascia. That MLD enhances blood flow in deep veins is a novel observation. 
Current concepts regarding MLD indicate that each maneuver should take 
around 4 seconds from beginning to end (Lee et al., 2011). We strictly followed this 
recommendation when applying MLD techniques during the different studies 
comprising this thesis. Also, the two MLD techniques, the call-up and reabsorption 
maneuvers, presumably affect venous circulation differently. As commonly taught, 
the call-up maneuver is applied in a proximal to distal direction and enhances venous 
blood flow. The reabsorption maneuver instead begins distally and then moves 
proximally, stimulating lymph flow and fluid reabsorption (Lee et al., 2011). Our 
findings do not substantiate such differential effects between the two maneuvers. In 
fact, the two maneuvers enhanced venous blood flow to a similar extent and in both 
FV and GSV. The only difference between the two MLD maneuvers that could be 
pointed regarded changes in the cross-sectional area of the FV and only in non-CVD 
participants. In this case, the reabsorption maneuver produced a higher increase in 
vein’s size.  
The amount of strain applied to the skin and deeper tissues by MLD is not 
known. Although studies using radiolabelled tracers demonstrate the efficacy of 
MLD in stimulating lymph flow, the exact mechanisms by which these techniques 
work are not fully elucidated (Leduc et al., 1988; Tan et al., 2011). Skin and deep 
fasciae are connected by ligamentous structures at the level of the thigh, knee, 
popliteal fossa and leg, which give stability to the skin and act like an anchor during 
lower limb movements (Nash et al., 2004). The skin-stretching applied during MLD, 
such as that employed along this thesis, might produce enough increase in pressure 
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upon underlying structures to enhance venous flow in superficial and deep veins, as 
occurs during physiological skin-stretching accompanying movement (Benjamin, 
2009). 
At baseline, venous blood flow was found to be similar in CVD and healthy 
control participants, which is a common observation. Nevertheless, the cross-
sectional area of the GSV was found to be higher in the CVD group, which is in 
accordance with previous observations (Mendoza et al., 2013) and reveals that the 
diameter of GSV can be a good predictor of the presence and severity of CVD. 
6.2.2 The effect of manual lymphatic drainage when applied to different 
regions of the lower limb 
When applied to the medial aspect of the thigh, MLD results in a greater 
enhancement of venous blood flow in FV and GSV. In our study, the MLD technique 
was applied exactly along the course of the GSV (Meissner et al., 2007b) and over 
the medial compartment of the thigh, following the path of the FV (Toomayan et al., 
2005). This finding confirms that MLD should be applied over the trajectory of the 
GSV as is normally recommended (Felty & Rooke, 2005; Molski et al., 2009; Peyre 
et al., 2000). 
In turn, the effect of MLD in increasing the blood flow at the level of the PV 
and SSV was similar whether the MLD technique was applied over the medial or 
over the lateral aspect of the leg. Anatomically, the SSV lies posterior and laterally in 
the leg (Meissner et al., 2007b), while the PV is deeply and centrally placed within 
the posterior muscle compartment of the leg (Toomayan et al., 2005). Therefore, 
both the PV and the SSV are placed relatively equidistant from the medial and the 
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lateral aspects of the leg where the MLD maneuvers were applied. Also, the smaller 
size of the leg, at least compared with that of the thigh, makes it difficult to restrict 
the effect of the MLD technique to just one of the sides of this segment. These 
findings suggest that MLD must take into account venous anatomy and venous blood 
flow direction just like the lymphatic anatomy and the lymph flow directions, 
particularly when applied to larger body segments, such as the thigh (Leduc et al., 
2011; Lee et al., 2011; Martin et al., 2011).  
As previously said, the mechanisms explaining the increases in venous flow 
during MLD are still unknown. A likely mechanism would be that skin traction 
increases the pressure over superficial vessels reducing their caliber and leading to an 
increase in blood flow velocity. The increased blood flow in the superficial veins 
would result in higher blood flow across perforating veins and into the deep veins, 
thereby raising blood flow in the deep venous system as well. In addition, the 
pressure applied to the skin, as said before, would probably reach the muscles 
underneath, and pressure would also increase in deep seated structures including 
veins, further stimulating blood flow. Also, muscle tone might increase during the 
time MLD techniques are being applied. Although participants were instructed to 
remain as relaxed as they possibly could during the MLD maneuvers, unnoticed 
muscle contraction could have occurred either induced by the manual stimulation, or 
in response to the movement of the lower extremity, which could have contributed to 
the observed increase in venous blood flow. 
This results suggest that MLD should be applied as a low pressure, manual 
skin-stretching form of massage applied from distal to proximal throughout the lower 
limb, with the two hands of the physical therapist placed side by side and respecting 
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the anatomy and flow of venous vessels, in order to increase venous return from the 
lower limb in subjects with or without CVD (C1-5). The sequence of MLD maneuvers 
should be applied proximal to distal, followed by a sequence in reverse direction 
(i.e., from distal to proximal) such as recommended for lymphedema (Leduc et al., 
2011; Leduc et al., 1998). Because inflammation may be present in these patients, 
direct manual skin-stretching should be avoided in that specific anatomical place, as 
for local inflammation in lymphedema. 
6.2.3 The effect of chronic venous disease severity on manual lymphatic 
drainage efficacy in venous return 
CVD causes significant damage to the skin and underlying tissues. Persistent 
inflammation of the skin leads to disease complications such as lipodermatosclerosis, 
characterized by fibrosis and microcirculatory changes that together increase the risk 
of ulceration (Smith, 2006). Leg edema (Meissner et al., 2007b) and limited ankle 
range of motion (Panny et al., 2009) also restrain the normal movement of the skin 
and underlying soft tissues, thus contributing to blood stasis and CVD disease 
complications. Furthermore, the endothelium and the smooth muscle of vein walls 
also undergo structural changes as a result of chronic inflammation and venous 
hypertension, causing vein dilatation (Lim et al., 2009). During MLD (call-up 
maneuvers), the cross-sectional area and hemodynamic augmentations in superficial 
and deep veins were not associated with the severity of CVD. Nevertheless, more 
severe CVD was accompanied by diminished flow volume augmentations in FV 
during reabsorption. Also, MLD-related GSV’s cross-sectional area increase was 
correlated with CVD severity ranging between C1 and C5.  
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The severity of the disease is related with the difficulty of the peripheral 
venous system to evacuate the venous blood from the periphery in the direction of 
the heart (Gloviczki et al., 2011), resulting in venous stasis (Gloviczki et al., 2011; 
Lurie et al., 2000). Furthermore, it is assumed that there is a strict relation between 
blood ﬂow velocity and secondary deep vein thrombosis (Morris et al., 2004). The 
prevention of stasis is a main goal in CVD treatment and decisive in preventing 
venous complications, and is frequently done through conservative approaches. 
Conservative CVD treatment might include intermittent pneumatic compression 
(Lurie et al., 2008), compression stockings and bandages (Clarke Moloney et al., 
2006; Downie et al., 2008; Partsch et al., 2002), and muscle pump activation using 
electrical muscle stimulation (Clarke Moloney et al., 2006; Izumi et al., 2010), 
transcutaneous electrical nerve stimulation (Izumi et al., 2010), or active and passive 
movements (Izumi et al., 2010; Staubesand et al., 1995). In this regard, MLD 
maneuvers may be an alternative treatment to enhance venous flow. Nevertheless, 
this intervention needs specialized professionals and could be an expensive health 
care treatment. In addition, middle and long-term effects of MLD in venous flow are 
unknown. Teaching caregivers or patients simple lymphatic drainage, despite the 
lower efficacy showed in the treatment of lymphedema, when compared with MLD 
applied by professionals (Huang et al., 2013), could be an alternative. 
High pressures (> 40mmHg) reached by intermittent pneumatic compression 
or compression bandages and stockings, increase venous blood flow velocity 
(Downie et al., 2008; Lurie et al., 2000) but veins suffer compression and therefore 
their cross-sectional area decreases (Lurie et al., 2008; Partsch et al., 2002). Despite 
increased venous flow velocity in deep veins, pressures applied to the lower 
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extremity, within the range of 80-100 mmHg or higher, force the collapse of the 
superficial veins (Lurie et al., 2000; Morris et al., 2004). In contrast, and as we have 
demonstrated, the MLD maneuvers increase the cross-sectional area of both the 
superficial and the deep veins, most likely because the amount of pressure applied 
was adequate (Leduc et al., 1998). During the application of the MLD maneuver, 
vein enlargement was accompanied by the acceleration of the blood flow and 
therefore the volume of venous blood flowing through the scanned cross section of 
the deep and superficial veins increased substantially.  
The mean and peak flow velocity augmentations in FV during active and 
passive movements of the ankle (20 - 40%) (Staubesand et al., 1995) and in GSV 
(34.00 - 46.58 cm/s in healthy participants, and 21.02 - 43.12 cm/s in CVD 
participants) (Sochart et al., 1999) were very similar to the augmentations produced 
by MLD in our studies. Calf muscle electrical stimulation, and compression 
bandaging (Clarke Moloney et al., 2006) are all procedures that increase venous flow 
in PV. Compared to these procedures, which enhance venous blood flow mainly in 
the deep vein system, the MLD technique is able to increase blood flow in both 
superficial and deep veins. Moreover, the increase of venous blood flow during the 
tip-toe movements seems to be lower in patients with CVD, when compared to age-
matched healthy controls, as the results of our Study I suggest, whereas MLD 
efficacy seems to be the same in CVD patients and in subjects without vascular 
disease.  
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6.3 Therapeutic efficacy of manual lymphatic drainage for treatment of 
patients with chronic venous disease 
Since we have observed increased venous blood flow on deep and superficial 
veins of lower limb during MLD, and because previous studies reveal that this 
technique can improve HRQL, symptoms, severity of disease, edema following 
vascular surgery (Molski et al., 2013; Molski et al., 2009), we hypothesized that 
MLD alone (10 sessions during 4 weeks), would improve HRQL, clinical and 
functional status of patients with CVD and that this effect would still be noticed 
following a short-term follow-up (4 weeks). We also anticipated that the effect of 
MLD on CVD severity and symptoms could be enhanced by compliance to 
compression stockings. 
Our data reveals that a 4-weeks period of MLD treatment, comprising ten 40 
to 45 min-duration sessions, improves CVD clinical severity (mostly related to 
venous edema), symptoms (leg heaviness, fatigue), and pain-HRQL. Furthermore, 
this study shows that the positive effects of MLD on CVD can still be observed after 
4 weeks of follow-up. Nonetheless, leg volume, ankle muscles isokinetic 
performance, and ankle active range of motion were not affected by the MLD 
treatment. 
Previous studies show that MLD (10 sessions in 2 weeks) used in CVD 
patients who were referred to vascular surgery is effective in diminishing pain and 
edema and in improving HRQL (Molski et al., 2013). When employed for a longer 
period of time (14 sessions in 5 weeks), MLD also seems to effectively contribute, 
together with surgery, to improve CVD severity (Molski et al., 2009). However, such 
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effect of MLD could be explained by faster recovery during the post-operative time. 
Our results extend this evidence by showing that MLD has a real effect in improving 
CVD-related symptoms, pain-HRQL and clinical severity (mostly related to venous 
edema), independently from vascular surgery. 
When measured by VCSS, the severity of CVD has been shown to improve 
with surgery alone (relative improvement: 70%) (Kakkos et al., 2003), drug 
treatment (absolute improvement: 4 points) (Cesarone et al., 2010), and with 
conservative treatments, like kinesio taping (1.8 points) (Aguilar-Ferrandiz et al., 
2013a). In our study the improvement in clinical severity reached 37.8% or 3.05 
points at T1, and 32.7% or 2.55 points at T2, comparatively to baseline (T0). 
Therefore, in terms of clinical severity in CVD, our MLD intervention seems to 
provide a clinical effect that lies well within the range of effects offered by other 
conservative treatment modalities (Aguilar-Ferrandiz et al., 2013a). On the other 
hand, the improved overall VCSS score observed in the experimental group was the 
result of an effect of the MLD treatment on the item “venous edema”, thus cannot be 
ascribed to changes in self-reported measures. The venous edema item is defined as 
an augmented tissue volume of presumed venous origin, i.e., with significant 
changed magnitude due to standing or limb elevation, or with evidence of venous 
etiology, like varicose veins or history of deep vein thrombosis, and that is present in 
most if not every days (Passman et al., 2011; Vasquez et al., 2010). 
Our MLD treatment also improved pain-HRQL, heaviness and fatigue. An 
improvement of an 8-10 points and of 20-24 in CIVIQ scores represents a 
worthwhile improvement in signs and symptoms, respectively for drug (Launois et 
al., 2010) and compression (Andreozzi et al., 2005) therapy. In our study, pain-
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HRQL improved by approximately 8.6 points in T1, and 9.8 in T2; therefore such 
improvements might be regarded as clinically significant. Nevertheless, MLD was 
ineffective in changing the physical, social or psychological components of HRQL. 
For visual analogue scale, clinical meaningful changes require a minimum variation 
of 2.1-5 cm in the ratings (Aguilar-Ferrandiz et al., 2013a; Launois et al., 2010). Our 
observed improvement in fatigue and heaviness symptoms matched this range (2.84-
3.55), revealing an important improvement in patients with CVD after MLD 
treatment.  
The reason which explains pain and discomfort that accompanies CVD is not 
completely clear. Leg symptoms in CVD patients may not have an exclusive venous 
origin and may otherwise be related with adhesion of leucocytes to the endothelium 
(Boisseau, 2007). Leucocytes are believed to be the source of large amounts of 
inflammatory mediators that are released into the vein walls and the interstitial space 
(responsible for trophic skin changes), because of hypoxia and blunted venous flow 
(Boisseau, 2007). Such inflammatory mediators are presumed responsible for 
stimulating nociceptive nerve endings in the skin and other tissues and to cause pain 
and discomfort (Boisseau, 2007). It is possible that MLD, by improving venous flow, 
and also by stimulating lymphatic reabsorption (Leduc et al., 1998) and decreasing 
tissue edema, could blunt the leucocyte-endothelial inflammatory reaction (Boisseau, 
2007). Also, there is the possibility that stimulation of cutaneous, subcutaneous, and 
even muscle and other deep tissues afferents by MLD maneuvers may interfere with 
the transmission of discomfort and pain sensation, like other techniques, such as 
Kinesio taping that also stimulates the skin through straining (Aguilar-Ferrandiz et 
al., 2013a). In addition, a placebo effect, not measured in our study, may have an 
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important effect in reducing activity in central neural pathways associated with pain 
perception (Dobrila-Dintinjana & Nacinovic-Duletic, 2011). Nevertheless, changes 
in the severity of disease, specially decreased venous edema item (a sign evaluated 
by a blind evaluator) from T0 to T1, support a real effect of MLD in reducing venous 
stasis and improving the CVD condition conservatively. 
Nevertheless previous studies were unable to provide distinct demonstration 
of MLD efficacy in treating lymphedema (Huang et al., 2013) or sports injury-
associated edema (Vairo et al., 2009), as well as in improving functional status 
(Ebert et al., 2013). Nevertheless, MLD continues to be suggested as an adjuvant 
rehabilitative intervention following orthopedic surgery (Ebert et al., 2013), and it is 
efficacious in the treatment of lymphedema if applied in combination with other 
interventions, generally known as the complex decongestive therapy (Kim et al., 
2012). 
The important role played by the ankle range of motion and calf muscle 
strength in the efficacy of CMPF is now widely recognized (de Moura et al., 2012; 
Padberg et al., 2004; Panny et al., 2009; Shiman et al., 2009; van Uden et al., 2005). 
Likewise, altered CMPF seems to play a key role in the physiopathology of CVD (de 
Moura et al., 2012; Panny et al., 2009; Shiman et al., 2009; van Uden et al., 2005). 
However, we were unable to find any significant change in ankle muscles 
performance (either plantarflexors or dorsiflexiors) and ankle range of motion after 
MLD treatment. Physical exercise is nowadays widely recommended for CVD 
management (Kahn et al., 2011; Padberg et al., 2004). In previously conducted 
randomized controlled trials, exercise training in patients with CVD (Padberg et al., 
2004) or with post-thrombotic syndrome (Kahn et al., 2011) was shown to improve 
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calf muscles’ peak torque at slow (60º/s) and fast (120º/s) speeds (Padberg et al., 
2004), maximal heel rise repetitions (Kahn et al., 2011), CMPF (Padberg et al., 
2004), and HRQL (Kahn et al., 2011). However, the role of physical exercise in 
ameliorating the measures of clinical severity of CVD or in improving few 
performance features, such as joint range of motion or work and power ability of 
ankle plantarflexors could not be clearly demonstrated (Kahn et al., 2011; Padberg et 
al., 2004). However, we cannot rule out the possibility that MLD might improve 
ankle function during more natural activities, such as gait. Future work might assess 
whether MLD improves ankle function (improved ankle muscles recruitment and 
ankle range of motion) during gait in CVD patients. 
Finally, we also hypothesized that the effect of MLD would rely on using 
compression stockings. The rationale for this hypothesis was that MLD would 
decrease venous stasis, would diminish tissue edema and that the use of compressive 
stockings would prolong these effects of MLD. Despite the information and the 
advice given about the importance of wearing compression stockings to manage 
symptoms and complications of CVD, our study participants did not change their 
habitual behavior regarding such use. The adherence to compressive stockings 
treatment is usually decisive (Ziaja et al., 2010). In this our study, 23 out of the 41 
patients participants that completed the study were not wearing compression 
stockings and only four participants, two in each group, (2 participants from 
experimental group and 2 participants from the control group) fully adhere to this 
treatment. However, in our study wearing or not compression stockings had no effect 
on MLD efficacy. 
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7 CONCLUSION 
Assessing CMPF in an easy and assessable way is needed. By using 
ultrasound (vascular and muscular), hemodynamics in the popliteal vein and 
gastrocnemius muscle architecture, the two major components of calf muscle, can be 
measured. Such measures might then be employed to dynamically evaluate CMPF 
during tip-toe movements. Duplex ultrasound scanning demonstrated lower 
efficiency of calf muscles in patients with mild CVD when compared to a group of 
controls, which extends previous findings obtained with air-plethysmography. 
However, no differences in gastrocnemius muscle architecture and blood flow 
velocity of popliteal vein at baseline existed between the CVD group and the control 
group. Few associations were found between gastrocnemius muscle parameters and 
muscle pump efficacy but no relationship between these measures and CVD severity 
were founded. Ultrasound evaluation of CMPF shows good reliability if measures 
are in collected in the same testing session. However, reliability and agreement of 
this technique was poor when tests are repeated in separate days. Decidedly, further 
research is needed in order to improve ultrasound-based assessment of CMPF in 
CVD patients.  
Because the effect of MLD in venous hemodynamics is still unclear, we 
compared the two major MLD maneuvers (call-up and reabsorption). When these 
maneuvers were applied to the medial aspect of the thigh, both improved in a similar 
amount the venous blood flow in FV and GSV. When applied along the entire lower 
limb, MLD increases deep (FV and PV) and superficial (GSV and SSV) venous 
blood flow. The amount of blood flow augmentation within deep and superficial 
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veins is significantly higher when MLD maneuvers are applied along the course of 
veins, like on the medial aspect of the thigh, than when it is applied on the lateral 
side of this segment. In the leg, MLD shows equal efficacy in increasing venous 
blood flow when applied to the medial or the lateral side of this body segment, as a 
result of more central position of the leg veins (PV and SSV). These increases in 
venous blood flows occur to a similar extent in CVD patients (C1-5) and healthy 
participants. However, the efficacy of the reabsorption maneuvers in increasing 
venous blood velocity may decrease with CVD increased severity.  
To verify if the MLD techniques investigated in our more mechanistic studies 
would improve CVD (C3-5) severity, we undertook a single blind randomized 
controlled trial involving 10 sessions of MLD over 4 weeks. Patients with CVD 
improved their clinical severity, most related to venous edema, symptoms, like 
fatigue and heaviness, and pain-HRQL, after the treatment, and much of these effects 
were still observed after 4 weeks of follow-up. However, MLD seems unable to 
modify the majority of the components of HRQL, leg volume or ankle muscles 
isokinetic strength and ankle range of motion. Also, it seems that these effects of 
MLD on the treatment of CVD patients were not related with compliance to 
compression stockings usage. 
7.1 Clinical notes 
For treating patients with CVD, MLD should be applied as a low pressure, 
manual skin-stretching form of massage applied from distal to proximal, with both 
hands of physical therapist side by side, respecting the anatomy and flow of venous 
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vessels, in order to increase venous return of the lower limb in subjects with or 
without CVD (C1-5). Applying four weeks of MLD may be used as a strategy to 
relieve fatigue and heaviness symptoms related do CVD, improve pain dimension of 
HRQL, decrease clinical severity of disease and related edema with at least a short 
term effect (four weeks after treatment).  
The reliability of ultrasound assessment of muscular and hemodynamics 
components of calf muscle pump show only moderate reliability and are not sensitive 
to distinguish between different severity levels of CVD. 
7.2 Limitations 
The major limitation found in our studies was the poor test-retest reliability 
found for venous hemodynamics measures during tip-toe movements. This points to 
the need for strict standardization regarding probe positioning and movement task 
conditions if use of ultrasound techniques is warranted to assess calf muscle pump 
function. Also, no trigger was used to synchronize MLD techniques and ultrasound 
assessments, and some effect of respiratory cycle or other stimulant effects (not 
controlled) might have influenced venous flow. Because of this limitation, we use 
augmentations to reduce error. Also, the limitation due to the lack of information 
about placebo effect of MLD must be acknowledged and addressed in future studies.  
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7.3 Future directions 
In the future it will be important to address the effect of MLD in known 
physiopathology mechanisms of CVD. In particular, the effect of MLD on markers 
of tissue inflammation and microcirculation should be evaluated. From the technical 
side, there are also questions that should deserve attention. One of these questions 
regards the minimal amount of technique repetitions that are needed to exert an 
effect. This is particular important since the time cost of this type of treatment is 
considered high. Related with this question, is to know how efficacious self-drainage 
is in managing CVD. Because MLD still relies heavily on specialized health 
professionals, and because the costs to treat patients with venous ulcer are very high, 
future studies should evaluate the impact of MLD in this specific group of patients, 
as well as its cost-effectiveness. 
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9 APPENDIXES 
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9.1 Appendix 1 -Informed Consent of Study I 
 
CARTA DE EXPLICAÇÃO DO ESTUDO 
 
Doutoranda/investigadora: Rute Sofia dos Santos Crisóstomo 
(crisóstomo.rute@gmail.com; tm: 968584992) 
Orientador: Professor Doutor Paulo Armada da Silva (parmada@fmh.utl.pt) 
 
Este estudo, intitulado “Estudo piloto – avaliação da bomba muscular venosa 
da perna por ultrassonografia”, tem como objectivo avaliar a fiabilidade e validade 
de construção da avaliação por eco-doppler da velocidade do fluxo, durante a 
contracção da bomba muscular venosa da perna. 
Enquadra-se no programa de Doutoramento em Fisioterapia, da Faculdade de 
Motricidade Humana da Universidade Técnica de Lisboa e Centro Interdisciplinar 
para o Estudo da Performance Humana (CIPER). 
A cada elemento de estudo será feita entrevista para que possam ser 
recolhidos dados da história clínica e outros complementares e garantir que cada um 
deles está de acordo com os critérios de inclusão e exclusão (ficha de avaliação e 
ficha de caracterização). 
Será necessário deslocar-se às instalações da Faculdade de Motricidade 
Humana de Lisboa uma ou duas vez, onde serão avaliados: o refluxo venoso nos 
membros inferiores e os valores hemodinâmicos (por um Técnico de 
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Cardiopneumologia) durante a realização de exercício (elevação dos calcanhares), 
que terá a duração aproximada de uma hora. Após estes procedimentos existe a 
possibilidade de algum desconforto ou fadiga. 
Toda a informação recolhida pelo médico e doutoranda, será tratada de forma 
confidencial e conservada à responsabilidade da doutoranda. Os participantes terão 
acesso aos resultados do estudo, que por sua vez serão apresentados, sem que nunca 
sejam divulgados de forma individual. 
A escolha de participação no estudo é voluntária e caso seja esse o seu desejo 
poderá abandonar o mesmo em qualquer momento abandonar o estudo sem risco de 
represália ou de exigência de compensação. 
Com os melhores cumprimentos, 
A doutoranda, 
 
 
 
 
 
Com os melhores cumprimentos, 
A doutoranda, 
 
(Rute Sofia dos Santos Crisóstomo) 
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CONSENTIMENTO INFORMADO 
Eu, ____________________________________________________(nome), 
declaro que os procedimentos de investigação descritos na carta anexa me foram 
explicados e que todas as minhas questões foram esclarecidas. 
Autorizo que o médico e doutoranda recolham a informação constante nas 
fichas de avaliação e caracterização; e que sejam recolhidos os dados no Laboratório 
da Escola Superior de Saúde Dr. Lopes Dias constantes na carta de explicação do 
estudo. Autorizo igualmente, que todos estes dados fiquem com a doutoranda, para 
que possam constar no estudo. 
Compreendo os riscos de participação no estudo, e que não serei prejudicado 
ou beneficiado pela minha participação. 
Entendo que tenho o direito de colocar agora e durante o desenvolvimento do 
estudo, qualquer questão relacionada com o mesmo. Foi-me garantido que os meus 
dados pessoais, incluindo a minha identidade, serão guardados de forma 
confidencial. 
Sei que sou livre de, a qualquer momento, abandonar o estudo sem risco de 
represália ou de exigência de compensação. 
Pelo presente documento, eu consinto a minha participação no estudo em 
questão. 
Lisboa, ____ de______________ de 20___ 
Assinatura do Participante:  ______________________________________  
Assinatura do Investigador:  ______________________________________  
                                                            (Rute Sofia dos Santos Crisóstomo) 
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9.2 Appendix 2 -Informed Consent of Study II 
 
CARTA DE EXPLICAÇÃO DO ESTUDO 
 
Doutoranda/investigadora: Rute Sofia dos Santos Crisóstomo 
(crisóstomo.rute@gmail.com; tm: 968584992) 
Orientador: Professor Doutor Paulo Armada da Silva (parmada@fmh.utl.pt) 
 
Este estudo, intitulado “Drenagem linfática manual na doença venosa crónica: 
um estudo por ultrassonografia vascular”, tem como objetivo avaliar o fluxo venoso 
nas veias grande safena e femoral durante a aplicação das manobras de reabsorção e 
de chamada da técnica de drenagem linfática manual, em pessoas com e sem doença 
venosa crónica. Enquadra-se no programa de Doutoramento Motricidade Humana na 
especialidade de Fisioterapia, da Faculdade de Motricidade Humana da Universidade 
Técnica de Lisboa e Centro Interdisciplinar para o Estudo da Performance Humana 
(CIPER). 
Será necessário deslocar-se às instalações da Escola Superior de Saúde Dr. 
Lopes Dias uma única vez, onde será realizado uma entrevista para que possam ser 
recolhidos dados sociodemográficos, a história clínica e outros dados 
complementares (médico, doutoranda e técnico de cardiopneumologia) e garantir que 
cada um deles está de acordo com os critérios de inclusão e exclusão do estudo. Será 
ainda realizado um eco Doppler venoso aos membros inferiores para diagnóstico da 
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ausência/presença de Doença Venosa Crónica. Posteriormente será também aplicada 
as manobras de reabsorção e chamada (técnicas de drenagem linfática manual) ao 
nível da coxa e em simultâneo avaliado a hemodinâmica venosa das veias grande 
safena e femoral com o ecógrafo. Estes procedimentos terão a duração máxima de 
1hora e 30 minutos e poderão causar alguma fadiga e desconforto. 
Toda a informação recolhida pelo médico, técnico de cardiopnemologia e 
doutoranda será tratada de forma confidencial e conservada à responsabilidade da 
doutoranda. Os participantes terão acesso aos resultados do estudo, que por sua vez 
serão apresentados, sem que nunca sejam divulgados de forma individual. 
A escolha de participação no estudo é voluntária e caso seja esse o seu desejo 
poderá abandonar o mesmo em qualquer momento, sem risco de represália ou de 
exigência de compensação. 
 
 
 
 
 
Com os melhores cumprimentos, 
A doutoranda, 
 
(Rute Sofia dos Santos Crisóstomo) 
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CONSENTIMENTO INFORMADO 
Eu, _____________________________________________________(nome), 
declaro que os procedimentos de investigação descritos na carta anexa me foram 
explicados e que todas as minhas questões foram esclarecidas. 
Autorizo que o médico e doutoranda recolham a informação 
sociodemográfica e clinica relevante para o estudo, assim como ser avaliada por eco 
Doppler venoso aos membros inferiores, para diagnóstico e avaliação dos efeitos das 
manobras de reabsorção e chamada, e que sejam recolhidos os dados nos 
Laboratórios da Escola Superior de Saúde Dr. Lopes Dias constantes na carta de 
explicação do estudo. Autorizo igualmente, que todos estes dados fiquem com a 
doutoranda, para que possam constar no estudo. 
Compreendo os riscos de participação no estudo, e que não serei prejudicado 
ou beneficiado pela minha participação.  
Entendo que tenho o direito de colocar agora e durante o desenvolvimento do 
estudo, qualquer questão relacionada com o mesmo. Foi-me garantido que os meus 
dados pessoais, incluindo a minha identidade, serão guardados de forma 
confidencial. Sei que sou livre de, a qualquer momento, abandonar o estudo sem 
risco de represália ou de exigência de compensação. 
Pelo presente documento, eu consinto a minha participação no estudo em 
questão. 
Castelo Branco, ____ de______________ de 20___ 
Assinatura do Participante:  ______________________________________  
Assinatura do Investigador:  ______________________________________  
                                                            (Rute Sofia dos Santos Crisóstomo) 
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9.3 Appendix 3 -Informed Consent of Study III 
 
 
CARTA DE EXPLICAÇÃO DO ESTUDO 
 
Doutoranda/investigadora: Rute Sofia dos Santos Crisóstomo 
(crisóstomo.rute@gmail.com; tm: 968584992) 
Orientador: Professor Doutor Paulo Armada da Silva (parmada@fmh.utl.pt) 
 
Este estudo, intitulado “Efeito da drenagem linfática manual no fluxo venoso 
na insuficiência venosa crónica”, tem como objetivo avaliar o fluxo venoso nas veias 
grande safena e pequena safena (superficiais) e veias femoral e poplítea (profundas) 
durante a aplicação de drenagem linfática manual, em pessoas com e sem 
insuficiência venosa crónica. 
Enquadra-se no programa de Doutoramento em Motricidade Humana, na 
especialidade de Fisioterapia, da Faculdade de Motricidade Humana da Universidade 
Técnica de Lisboa e Centro Interdisciplinar para o Estudo da Performance Humana 
(CIPER). 
Será necessário deslocar-se às instalações da Escola Superior de Saúde Dr. 
Lopes Dias uma única vez, onde será realizado uma entrevista para que possam ser 
recolhidos dados sociodemográficos, a história clínica e outros dados 
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complementares (médico, doutoranda e técnico de cardiopneumologia) e garantir que 
cada um deles está de acordo com os critérios de inclusão e exclusão do estudo. Será 
ainda realizado um eco Doppler venoso aos membros inferiores para diagnóstico da 
ausência/presença de Insuficiência Venosa Crónica. Posteriormente será também 
aplicada drenagem linfática manual (massagem suave) nos membros inferiores e em 
simultâneo avaliado a hemodinâmica venosa das veias por eco Doppler. Estes 
procedimentos terão a duração máxima de duas horas e poderão causar alguma 
fadiga e desconforto. 
Toda a informação recolhida pelo médico, técnico de cardiopnemologia e 
doutoranda será tratada de forma confidencial e conservada à responsabilidade da 
doutoranda. Os participantes terão acesso aos resultados do estudo, que por sua vez 
serão apresentados, sem que nunca sejam divulgados de forma individual. 
A escolha de participação no estudo é voluntária e caso seja esse o seu desejo 
poderá abandonar o mesmo em qualquer momento, sem risco de represália ou de 
exigência de compensação. 
 
 
Com os melhores cumprimentos, 
A doutoranda, 
 
(Rute Sofia dos Santos Crisóstomo) 
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CONSENTIMENTO INFORMADO 
Eu, _____________________________________________________(nome), 
declaro que os procedimentos de investigação descritos na carta anexa me foram 
explicados e que todas as minhas questões foram esclarecidas. 
Autorizo que o médico e doutoranda recolham a informação 
sociodemográfica e clinica relevante para o estudo, assim como ser avaliada por eco 
Doppler venoso aos membros inferiores, para diagnóstico e avaliação da drenagem 
linfática manual, e que sejam recolhidos os dados nos Laboratórios da Escola 
Superior de Saúde Dr. Lopes Dias constantes na carta de explicação do estudo. 
Autorizo igualmente, que todos estes dados fiquem com a doutoranda, para que 
possam constar no estudo. 
Compreendo os riscos de participação no estudo, e que não serei prejudicado 
ou beneficiado pela minha participação.  
Entendo que tenho o direito de colocar agora e durante o desenvolvimento do 
estudo, qualquer questão relacionada com o mesmo. Foi-me garantido que os meus 
dados pessoais, incluindo a minha identidade, serão guardados de forma 
confidencial. Sei que sou livre de, a qualquer momento, abandonar o estudo sem 
risco de represália ou de exigência de compensação. 
Pelo presente documento, eu consinto a minha participação no estudo em 
questão. 
Castelo Branco, ____ de______________ de 20___ 
Assinatura do Participante:  ______________________________________  
Assinatura do Investigador:  ______________________________________  
                                                        (Rute Sofia dos Santos Crisóstomo) 
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9.4 Appendix 4 -Informed Consent of Study IV  
        
CARTA DE EXPLICAÇÃO DO ESTUDO 
 
Doutoranda/investigadora: Rute Sofia dos Santos Crisóstomo 
(crisóstomo.rute@gmail.com; tm: 968584992) 
Orientador: Professor Doutor Paulo Armada da Silva (parmada@fmh.utl.pt) 
Este estudo, intitulado “Avaliação da eficácia terapêutica da drenagem 
linfática manual na insuficiência venosa crónica”, tem como objetivo avaliar a 
eficácia terapêutica drenagem linfática manual em doentes com Insuficiência Venosa 
Crónica e encontra-se a ser realizado na Escola Superior de Saúde Dr. Lopes Dias.  
Enquadra-se no programa de Doutoramento em Fisioterapia, da Faculdade de 
Motricidade Humana da Universidade Técnica de Lisboa e Centro Interdisciplinar 
para o Estudo da Performance Humana (CIPER). 
A cada elemento de estudo será feita entrevista para que possam ser 
recolhidos dados da história clínica e outros complementares (médico, doutoranda e 
técnica de cardiopneumologia) e garantir que cada um deles está de acordo com os 
critérios de inclusão e exclusão (ficha de avaliação). 
Será necessário deslocar-se às instalações da Escola Superior de Saúde Dr. 
Lopes Dias 14 vezes: (I) três vezes, a fim de ser avaliado (com o intervalo de um mês 
entre cada), onde serão recolhidos dados quanto à qualidade de vida relacionada com 
 168 
a saúde, à funcionalidade, aos sintomas, à força muscular, à perimetria da perna e 
caracterização clínica e anatómica da doença, e terá a duração aproximada de uma 
hora; (II) uma outra vez de modo a participar numa sessão de educação para a saúde 
(durante uma hora); (III) e dez vezes a fim de ser aplicada a técnica de tratamento 
durante uma hora, por fisioterapeutas treinadas. Estes procedimentos poderão causar 
alguma fadiga e desconforto. 
Toda a informação recolhida pelo médico e doutoranda, será tratada de forma 
confidencial e conservada à responsabilidade da doutoranda. Os participantes terão 
acesso aos resultados do estudo, que por sua vez serão apresentados, sem que nunca 
sejam divulgados de forma individual. 
A escolha de participação no estudo é voluntária e caso seja esse o seu desejo 
poderá abandonar o mesmo em qualquer momento, sem risco de represália ou de 
exigência de compensação. 
 
 
 
 
 
Com os melhores cumprimentos, 
A doutoranda, 
 
(Rute Sofia dos Santos Crisóstomo) 
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CONSENTIMENTO INFORMADO 
Eu, _____________________________________________________(nome), 
declaro que os procedimentos de investigação descritos na carta anexa me foram 
explicados e que todas as minhas questões foram esclarecidas. 
Autorizo que o médico e doutoranda recolham a informação constante na 
ficha de avaliação; assim como ser tratada com drenagem linfática manual, e que 
sejam recolhidos os dados nos Laboratórios da Escola Superior de Saúde Dr. Lopes 
Dias constantes na carta de explicação do estudo. Autorizo igualmente, que todos 
estes dados fiquem com a doutoranda, para que possam constar no estudo. 
Compreendo os riscos de participação no estudo, e que não serei prejudicado 
ou beneficiado pela minha participação.  Entendo que tenho o direito de colocar 
agora e durante o desenvolvimento do estudo, qualquer questão relacionada com o 
mesmo. Foi-me garantido que os meus dados pessoais, incluindo a minha identidade, 
serão guardados de forma confidencial. 
Sei que sou livre de, a qualquer momento, abandonar o estudo sem risco de 
represália ou de exigência de compensação. 
Pelo presente documento, eu consinto a minha participação no estudo em 
questão. 
Castelo Branco, ____ de______________ de 20___ 
Assinatura do Participante:  ______________________________________  
Assinatura do Investigador:  ______________________________________  
                                                            (Rute Sofia dos Santos Crisóstomo)
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9.5 Appendix 5 - Characterization Questionnaire 
FICHA DE CARACTERIZAÇÃO Nº 
Nome: Contato telefónico: 
Morada 
Peso:               Género:   Masculino        Feminino                              
Altura: Profissão:                                                  Escolaridade: 
  
SINTOMAS  
 CLASSE CLINICA 
CEAP 
 COMORBILIDADES: 
Fadiga:   C1    
Sensação de peso:   C2    
Prurido:   C3    
Irritação da pele:   C4    
Cãibras:   C5    
 
 
CLASSIFICAÇÃO ANATÓMICA CEAP 
Insuficiência: MI. Direito M. Esquerda 
Veias Superficiais   
Veias Profundas   
Veias Perfurantes   
 
VCSS 
 Dor 
Veias 
varicosas 
Edema 
venoso 
Pigmentação da 
pele 
Inflamação Endurecimento 
Terapia 
compressiva 
Ausente  
(0) 
       
Suave 
(1) 
       
Moderado 
(2) 
       
Severo 
(3) 
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10.1 Annex 1 - Article: The use of ultrasound in the evaluation of the 
efficacy of calf muscle pump function in primary chronic venous 
disease 
 
Crisóstomo, R. S., Candeias, M. S., & Armada-da-Silva, P. A. (2014). The 
use of ultrasound in the evaluation of the efficacy of calf muscle pump 
function in primary chronic venous disease. Phlebology, 29(4), 247-256. doi: 
10.1177/0268355512471757 
Original article
The use of ultrasound in the evaluation of the efficacy
of calf muscle pump function in primary chronic
venous disease
R S S Criso´stomo*†‡, M S Candeias‡ and P A S Armada-da-Siva*†
*Laborato´rio de Biomecaˆnica e Morfologia Funcional (LBMF); †Centro Interdisciplinar para o Estudo da Performance
Humana (CIPER), Faculdade de Motricidade Humana, Universidade Te´cnica de Lisboa, Estrada da Costa, Lisboa,
Portugal; ‡Instituto Polite´cnico de Castelo Branco, Escola Superior de Sau´de Dr. Lopes Dias, Castelo Branco, Portugal
Abstract
Objectives: To evaluate popliteal vein blood flow during calf muscle contraction in chronic
venous disease (CVD) patients and healthy controls using ultrasound imaging and to
investigate the relationship between venous blood flow and gastrocnemius muscle (GM)
morphology.
Methods: Thirty-one subjects participated in this study (mean age: 40.3 [11.8] years),
15 healthy controls and 16 with CVD (clinical classification: C1–4). Popliteal vein cross-
sectional area and venous blood flow velocity (FV) were evaluated by Doppler ultrasound
at baseline and during three sets of 10 tip-toe movement repetitions. Muscle thickness,
muscle fascicle length and pennation angle of both medial and lateral GM were measured
by ultrasound. Measures were repeated a week later in 17 participants in order to assess
reproducibility with intraclass correlation coefficient (ICC) and Bland–Altman analysis.
Results: Peak FV was lower in CDV group compared with Control group for both first
(40.6 [11.8] versus 62.4 (22.1) cm2/second; P ¼ 0.021) and last (30.4 [9.1] versus 49.5
(22.7) cm2/second; P ¼ 0.024) contraction. In CVD group, peak FV during first contraction
increased with GM’s muscle fascicle length (r ¼ 0.63; P ¼ 0.041). Popliteal FV also increased
with rising range of muscle fascicles pennation change between ankle dorsiflexion and
plantar flexion (r ¼ 0.70; P ¼ 0.025). No associations were found between haemodynamics
and medial or lateral GM thickness. Calf muscular architecture was similar in both CVD
and control participants. Test–retest reliability of FV measured in the same session was high
(ICC≈0.70) for measures taken in the first contraction of the set but lowered when using the
last contraction (ICC,0.50). Reproducibility of ultrasound evaluation of calf pump is
acceptable within the same session but is unsatisfactory when testing in separate days.
Conclusion: Patients with moderate CVD have lower FV during calf muscles contraction but
similar muscle anatomical characteristics compared with healthy controls. Changes in calf
muscles flexibility and fatigue resistance may be investigated as possible causes of calf
pump dysfunction.
Keywords: calf muscle pump function; chronic venous disease; Doppler ultrasound; venous
flow
Introduction
Chronic venous disease (CVD) is an under-
estimated pathology affecting around 2.5 million
people in the USA1 that decrease patients’ ability
to engage in normal daily activities1 and has a
negative impact on the quality of life.2 In advanced
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stages, CVD is characterized by venous insuffi-
ciency, tissue oedema and trophic changes of the
skin, including skin ulcerations in severe cases.3
However, venous insufficiency alone does not
seem to explain venous skin ulceration and it has
been hypothesized that deficient calf muscle
pump function (CMPF) might be a primary factor
in CVD-associated skin and soft tissue damage4
and a cause of inflammation, reduced blood per-
fusion and scattered muscle cell necrosis.5,6
Muscle pump impairment is likely caused by
diminished calf muscle strength combined with
decreased ankle joint motion, particularly during
walking.7–10 In this sense, CMPF might be
related to changes in skeletal muscle architecture.
These can be readily evaluated using ultrasound
imaging, particularly the muscle thickness, which
is a major determinant of muscle strength. Ultra-
sound imaging can also measure muscle fascicle
length and pennation angle, morphological charac-
teristics also associated with the contractile force
produced by skeletal muscles.11
The efficacy of CMPF is usually evaluated using
air plethysmography.12 However, this method
requires equipment not readily available in most
clinical settings and the development of alternative
method to accurately assess CMPF could stimulate
further investigation about the role of muscle
pump function in CVD.9,12–15 Doppler ultrasound
is commonly employed as a diagnostic tool in
CVD. This technique provides measures of blood
flow velocity (FV) in given veins or arteries and
can potentially be adapted to be used during
dynamic conditions and to assess the blood
pumping function of the calf muscles.12 Therefore,
in this study we evaluated the potential of ultra-
sound to measure the efficacy of CMPF in a group
of CVD patients and healthy controls. Ultrasound
imaging was further employed to assess the archi-
tecture of the two heads of the gastrocnemius
muscle (GM) and the relationship between these
measures and the blood pumping function of the
calf contractions was investigated. We hypothesize
that calf muscles architecture is affected in CVD
subjects and that this is related with the efficacy of
the blood pumping function of this musculature.
Methods
Fifteen healthy control subjects (10 women and
5 men) and 16 subjects (13 women and 3 men)
with a diagnosis of CVD (CVD group) were
enrolled in this study (Table 1). All CVD subjects
presented venous blood reflux in at least one
lower extremity vein with a minimum duration of
Table 1 Demographic and clinical data
CVD group Control group
P P† All Subjects
Entire
group
Subgroup
with retest
Entire
group
Subgroup
with retest
N 16 9 15 8 31
Age (years) 44.1 (12.3) 45.7 (14.2) 36.1 (10.0) 35.8 (11.4) 0.086 0.139 40.3 (11.8)
Height (cm) 162.8 (7.3) 162.0 (5.4) 166.3 (9.6) 162.8 (11.0) 0.281 0.114 164.5 (8.5)
Weight (kg) 71.2 (13.4) 73.1 (15.0) 66.1 (15.2) 60.5 (13.5) 0.247 0.936 68.8 (14.3)
BMI (kg/m2) 27.4 (6.0) 28.1 (7.1) 23.6 (3.0) 22.5 (3.0) 0.281 0.114 25.4 (5.0)
Gender
Female 13 (81.2) 7 (77.8) 10 (66.7) 6 (75.0) – – 23 (74.2)
Male 3 (18.8) 2 (22.2) 5 (33.3) 2 (25.0) – – 8 (25.8)
Co-morbidities
Diabetes 1 (6.25) 0 (0.0) 0 (0.0) 0 (0.0) – – 1 (3.2)
Treated thyroid dysfunction (controlled) 2 (12.5) 1 (11.1) 1 (6.7) 1 (12.5) – – 3 (9.7)
Uterus malignant carcinoma (operated) 1 (6.25) 1 (11.1) 0 (0.0) 0 (0.0) – – 1 (3.2)
Knee surgery (contralateral leg
.6 months ago)
2 (12.5) 2 (22.2) 0 (0.0) 0 (0.0) – – 2 (6.5)
Lupus erythematosus 1 (6.25) 1 (11.1) 0 (0.0) 0 (0.0) – – 1 (3.2)
Surgical removal of greater saphenous
with recurrence
1 (6.25) 1 (22.2) 0 (0.0) 0 (0.0) – – 1 (3.2)
CVD, chronic venous disease; BMI, body mass index
Quantitative variable: mean (SD); categorical variable: frequency (%)
P: Differences between groups (entire group)
P†: Differences between subgroups (groups with retest with one week apart)
Differences are significant with P, 0.05 for Mann-Whitney U test
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0.5 seconds and CEAP (clinical, etiological, ana-
tomical, and pathological) clinical classification in
the range C1–4. Before study enrolment, subjects
were informed about the purpose and procedures
of the study and signed an informed consent. The
study received ethical approval by the review
board of the scientific council of Faculty of
Human Kinetics, Technical University of Lisbon.
The exclusion criteria in this study included the
presence of severe cardiac insufficiency, acute
venous or arterial obstruction, arterial insufficiency,
renal insufficiency, uncompensated thyroid dys-
function, pregnancy, neoplasic pathology, systemic
or limb infection, recent musculoskeletal injury of
the lower limb and peripheral neuropathy of the
lower limb. The clinical history, the symptoms
(fatigue, heavy sensation, hitching, cramps and
skin irritation), the severity of the disease according
to the clinical score of CEAP (CSCEAP) and
the venous clinical severity score (VCSS) were
collected.16
The anatomical location (i.e. superficial, per-
forating and/or deep vein system) and severity of
venous blood reflux were determined during the
first visit to the laboratory. The control subjects
also went through a thorough vascular ultrasound
of both lower extremities to confirm that they
were free from CVD. All ultrasound tests were per-
formed by a certified vascular sonographist and
with the same ultrasound equipment (HI VISION
8500, Hitachi, with a L53 linear array-transducer,
scanned at 9 MHz). The leg self-reported as present-
ing the worst symptoms and clinical signs and the
dominant leg were chosen for subsequent measures
in, respectively, the CVD group and the Control
group.
Baseline and dynamic popliteal vein blood flow
After five-minute rest, the cross-sectional area
(CSA) of the popliteal vein was measured at the
level just below the saphenopopliteal junction
with subjects in prone position. Next, baseline
mean and peak blood flow velocities in the popli-
teal vein were measured in standing position.
Blood FV was measured during a 10-second inter-
val using an automatic time integral calculation.
After completing the baseline measures, subjects
performed a calf muscle contractions protocol
similar to that commonly used to assess the efficacy
of CMPF by air-plethysmography and composed
of three sets of 10 repetitions of tip-toe move-
ments.12,14 A metronome set the timing of the
tip-toe movement that took two seconds to rise to
the tip toe, two seconds to get down to the initial
position and one second interval to the next
repetition. The ultrasound probe was manually
held at the lower margin of the popliteal fossa
with adequate orientation to measure blood FV in
popliteal vein while subjects performed the tip-toe
movement. In between the sets, subjects rested for
five minutes in sitting position. Mean and peak
popliteal vein blood volume at baseline were calcu-
lated by the following relation:17 Flow volume
(mean or peak) (cm3/second) ¼ popliteal CSA
(cm2) × flow velocity (mean or peak) (cm/second).
Dynamic peak and mean blood FV were calcu-
lated using the integral of the blood flow–time
curve. To avoid the effect of the foot sole impact
with the ground on venous blood flow, only the
time interval corresponding to heel rising was
selected to analysis. To evaluate the bias eventually
caused by probe unsteadiness during the move-
ment repetitions, few subjects performed actual
and simulated tip-toe movements. The simulated
movements were done with subjects standing on a
platform with the foot of the measured side
hanging off the platform and performing active
extension of the ankle joint by contracting the
Table 2 Clinical characteristics of CVD group
CVD group
(all subjects)
Subgroup
with retest
N 16 (100) 9 (56.3)
CEAP clinical classification
C1 3 (18.8) 2 (22.2)
C2 2 (12.5) 1 (11.1)
C3 10 (62.5) 5 (55.6)
C4 1 (6.3) 1 (11.1)
Anatomical reflux
Superficial veins 9 (56.3) 5 (55.6)
Deep veins 1 (6.3) 0 (0.0)
Perforator veins 3 (18.8) 3 (33.3)
SuperficialþPerforator 2 (12.5) 0 (0.0)
SuperficialþDeepþPerforator 1 (6.3) 1 (11.1)
VCSS 3.8 (3.2) 3.33 (3.5)
CSCEAP 2.9 (2.9) 2.7 (3.4)
Symptoms
Fatigue 11 (68.8) 6 (66.7)
Cramps 8 (50.0) 4 (44.4)
Heavy legs 10 (62.5) 5 (55.6)
Pain 5 (31.3) 3 (33.3
Skin irritation 3 (18.8) 2 (22.2)
Itching 2 (12.5) 1 (1.1)
Without symptoms 4 (25.0) 2 (22.2)
Quantitative variable: mean (SD); categorical variable: frequency (%)
VCSS (Venous Clinical Severity Score) total scale range 0–30 (best to
worst); CSCEAP (clinical score of clinical, etiological, anatomical,
and pathological) total scale range 0–18 (best to worst); CVD,
chronic venous disease
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calf muscles. During this task, leg movement is
minimal and the probe can be kept rather stationary.
During tip-toe movements, FV data were normal-
ized against baseline popliteal vein FV to calculate
FV augmentation using the following equation:
augmentation (%) ¼ ([FV during contraction (cm2/
second) – FV during baseline (cm2/second)]/FV
during baseline (cm2/second))100.
The percentage augmentation in FV was calcu-
lated using both the mean FVand the peak FVregis-
tered during the first and 10th tip-toe movement in
each set.
Muscle architecture
The medial gastrocnemius (MG) and the lateral
gastrocnemius (LG) were imaged at 10 MHz and
at a scan depth of 65 mm. The two muscle bellies
were imaged at the upper third of the distance
between the peroneal head and the lateral malleou-
lus with subjects lying prone and at three ankle joint
positions: (1) foot and leg at 908 (anatomical neutral
position), (2) at maximal active plantar flexion and
(3) at maximal active dorsiflexion. The distance
between the proximal and distal aponeurosis in
Figure 1 Popliteal vein blood flow velocity during: (a) the first and (b) the last (10th) repetition of the tip-toe
movement task in a chronic venous disease (CVD) participant and popliteal vein blood flow velocity during (c) the first
and (d) the last (10th) repetitions of the tip-toe movement task in a healthy subject. Also shown are the automatic
tracings of the blood flow velocity curve envelope and of the calculated mean (dark trace)
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both LG an MG was traced to obtain the muscle
thickness. In the MG, the direction of the muscle
fascicles was also traced to derive the pennation
angle for each ankle joint position. Pennation
angle was defined as the angle between the load
axis of the muscle and the axis of muscle fascicle.
Muscle fascicle length, defined as the length of the
fascicle between the deep and superficial apo-
neuroses, was directly measured for the ankle
plantar flexion position and using the values of
muscle thickness and pennation angle for the
ankle neutral and dorsiflexion positions, according
to the following equation: Muscle fascicle length
(mm) ¼muscle thickness (mm)/sin (pennation
angle).
One week later, 17 subjects (CVD group, n ¼ 9;
Control group, n ¼ 8) visited the laboratory for a
second session. During this visit subjects repeated
the tip-toe protocol in order to assess the test–
retest reliability of ultrasound measures of blood
pumping by calf muscles. For each participant,
tests were carried out at the same time of day and
at the same ambient temperature.
Statistical analysis
All statistical tests were performed with the help of
the statistical software package SPSS Inc. v.17 (SPSS
Inc., Chicago, IL, USA). Group differences were
tested with Mann-Whitney U test. The differences
between peak FV at baseline, first and 10th contrac-
tions were calculated with Wilcoxon signed-rank
test. The relationship between CVD severity
and the GM and haemodynamic parameters was
calculated using Spearman coefficient of corre-
lation. Reproducibility was assessed by test–retest
reliability by calculating the absolute agreement
intraclass correlation coefficient (ICC)18 and by
agreement analysis using Bland and Altman plot
analysis. The significance level was set at P, 0.05.
Results
Demographic and clinical data pertaining to the
participants are presented in Tables 1 and 2. All
subjects in the CVD group presented pathological
venous reflux but were free of venous obstruction.
No differences in age, height, weight and body
mass index (BMI) were found between the groups.
Venous dynamic blood flow
Popliteal vein blood FV increased during calf con-
tractions in both CVD and Control groups with a
P ¼ 0.008 and 0.012, respectively, for first contrac-
tion. But peak FV decreased from first to 10th con-
traction (P ¼ 0.028) in CVD group but in Control
group no significant differences (P ¼ 0.093) were
found between first and 10th contraction. Dynamic
blood FV in popliteal vein was lower in the CVD
group compared with the Control group during
both the first (P ¼ 0.021) and the 10th contraction
(P ¼ 0.024) of the tip-toe movement set (Figures 1
and 2). Peak FV, expressed as percentage augmenta-
tion, was lower in the CVD group compared with
the Control group during the first contraction
(530.6 [115.2]% versus 831.5 [353.4]%, P ¼ 0.027).
Nevertheless, the mean FV augmentation during
the first contraction and peak FV augmentation in
10th contraction did not differ between groups.
No differences in venous baseline haemodynamics
were found between the two experimental groups
(Table 3).
GM architecture
Table 4 presents the anatomical data of GM in CVD
and Control groups. Muscle thickness, pennation
angle and muscle fascicles length were similar in
both groups for all the three ankle joint positions.
No relationship could be noted between clinical
severity (measured by CSCEAP and VCSS) in
CVD patients and gastrocnemius architecture as
well as between clinical severity and dynamic
popliteal vein blood flow. In CVD patients, peak
FV in the first contraction increased with MG
Figure 2 Mean and standard deviation of venous peak flow
velocity in the popliteal vein during baseline, first and 10th tip-toe
contractions in chronic venous disease and control groups obtained
during retesting and showing the results from Wilcoxon signed-rank
test: () significantly different from baseline, (#) significantly different
from first contraction of control group; (§) significantly different from
tenth contraction; and (&) significantly different from 10th contraction
of control group
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muscle fascicle length in dorsiflexion (r ¼ 0.63; P ¼
0.041) and decreased with this muscle’s pennation
angle in dorsiflexion (r ¼ 2 0.68; P ¼ 0.044). Peak
FV during the last contraction of the tip-toe
set also increased with MG pennation angle in
neutral position (r ¼ 0.73; P ¼ 0.025) and with
Table 3 Differences between CVD and Control group of the venous haemodynamics in popliteal vein
Group N Mean (SD) P
Baseline peak flow velocity (cm/second) CVD 9 6.6 (2.3) 0.370
Control 8 6.9 (1.3)
Baseline mean flow velocity (cm/second) CVD 9 2.7 (1.7) 0.963
Control 8 2.4 (1.2)
Baseline cross-sectional area of popliteal vein (cm2) CVD 9 0.6 (0.2) 0.673
Control 8 0.5 (0.2)
Baseline peak flow volume (cm3/second) CVD 9 3.5 (1.4) 0.743
Control 8 3.5 (1.4)
Baseline mean flow volume (cm3/second) CVD 9 1.3 (0.6) 0.743
Control 8 1.2 (0.6)
First contraction peak flow velocity (cm/second) CVD 9 40.6 (11.8) 0.021
Control 8 62.4 (22.1)
First contraction mean flow velocity (cm/second) CVD 9 17.1 (5.0) 0.083
Control 8 26.7 (12.5)
Tenth contraction peak flow velocity (cm/second) CVD 9 30.4 (9.1) 0.024
Control 8 49.5 (22.7)
Peak flow velocity augmentation in first contraction (%) CVD 9 530.6 (115.2) 0.027
Control 8 831.5 (353.4)
Mean flow velocity augmentation in first contraction (%) CVD 9 721.5 (532.2) 0.124
Control 8 1319.0 (1234.7)
Peak flow velocity augmentation in 10th contraction (%) CVD 9 379.0 (123.9) 0.068
Control 8 623.5 (302.4)
CVD, chronic venous disease
The results were assessed in second week
Significant with P, 0.05 for Mann-Whitney U test
Table 4 Differences between CVD and control group in gastrocnemius muscle architecture
Group N Mean (SD) P
MG thickness in neutral (mm) CVD 16 18.0 (2.5) 0.890
Control 15 17.8 (2.7)
MG thickness in plantar flexion (mm) CVD 16 17.0 (2.6) 0.968
Control 15 17.5 (3.5)
MG thickness dorsiflexion (mm) CVD 16 19.1 (2.2) 0.654
Control 15 19.7 (3.2)
LG thickness in neutral (mm) CVD 16 12.2 (3.3) 0.384
Control 15 13.2 (3.6)
MG pennation angle in neutral (degrees) CVD 16 19.5 (2.3) 0.664
Control 15 19.1 (1.3)
MG pennation angle in plantar flexion (degrees) CVD 16 42.2 (8.8) 0.165
Control 15 46.3 (5.4)
MG pennation angle in dorsiflexion (degrees) CVD 16 17.6 (3.1) 0.572
Control 15 17.3 (2.0)
DMG pennation angle (degrees) CVD 16 24.6 (8.0) 0.096
Control 15 29.0 (5.5)
MG fascicle length in neutral (mm) CVD 16 54.3 (7.7) 0.874
Control 15 54.8 (8.7)
MG fascicle length in plantar flexion (mm) CVD 16 25.0 (4.8) 0.580
Control 15 24.7 (6.4)
MG fascicle length in dorsiflexion (mm) CVD 16 65.3 (15.8) 0.477
Control 15 66.5 (11.2)
MG, medial gastrocnemius muscle; LG, lateral gastrocnemius muscle; DMG, angle between maximal active dorsiflexion and plantar flexion in
medial gastrocnemius; CVD, chronic venous disease
Differences are significant with P, 0.05 for Mann-Whitney U test
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the range of change in pennation angle between
ankle dorsiflexion and plantar flexion (r ¼ 0.70;
P ¼ 0.025).
Test–retest reliability
Ultrasound measures of GM architecture were
generally highly reproducible. High immediate
test–retest reliability (ICC.0.94) for ultrasound
measures of muscle thickness was found for MG
and for LG, and for pennation angle andmuscle fas-
cicles length of MG in ankle neutral position. The
reliability in popliteal vein blood velocity in first
and 10th contractions was low, with an ICC,0.5.
However, peak FV and mean FV in the first con-
traction presented good immediate test–retest
reliability, with an ICC.0.74. None of the haemo-
dynamic measures showed acceptable test–retest
reliability (i.e. ICC.0.5) (Table 5). The Bland–
Altman plot analysis reveals a poor agreement for
dynamic popliteal vein FV measures (Figure 3).
For the estimation of probe movement bias, the
peak FV was 57.8 (14.9) cm/second during the
actual tip-toe movement and 52.8 (17.3) cm/second
during the simulated tip-toe movement with an
ICC ¼ 0.85[0.35;0.98] and P ¼ 0.005, and a bias ¼
4.9 cm/second (lower bound: 210.7 cm/second;
upper bound: 20.7 cm/second).
Discussion
Patients with primary CVD have venous reflux that
is commonly accompanied by calf muscle pump
dysfunction.7–9 The efficacy of calf muscle pump
relies on the integrity of venous valves and in the
contraction ability of the calf muscles, together
with an adequate range of motion at the ankle
joint.7–10 Any alteration in these factors potentially
affects venous blood flow in the lower limb and pre-
disposes to the development of venous hyper-
tension.10 Qiao et al.5 reported that CVD patients
present muscle atrophy affecting the calf muscles,
accumulation of blood lactate during mild exercise
and elevated venous pressure that persists after
ceasing the physical effort. Reduced blood perfu-
sion to leg muscles also characterizes CVD, which
in severe situations may cause tissue necrosis.5,6
However, the size of the calf muscles per se seems
not to be a key determinant of muscle pump effi-
cacy and of the amount of venous blood flow
including in cases with venous ulceration.19 In
fact, in our study the patients had mild CVD (only
one subject was C4) with no differences in GM
size compared with the control participants. In
addition, no relationship existed between clinical
severity of CVD and GM architecture or with
venous blood FV.
In contrast, we found a number of correlations
between venous FV and few GM architecture fea-
tures. In our CVD group, a higher peak FV at the
end of the tip-toe movement repetition set was
associated with higher MG pennation angle in
ankle neutral position, and a higher change of this
angle occurring between maximum active dorsi-
flexion and maximum active plantar flexion.
Higher peak FV in the first contraction in the CVD
group (that was lower than in the Control group)
Table 5 Test–retest reliability of venous haemodynamics and muscle architecture measures
N Mean (SD) ICC (range) P
Immediate test–retest reliability
First contraction peak flow velocity (cm/second) 17 50.9 (20.2) 0.74 (0.52–0.88) 0.000
First contraction mean flow velocity (cm/second) 17 21.6 (10.3) 0.78 (0.58–0.90) 0.000
Tenth contraction peak flow velocity (cm/second) 17 39.4 (19.1) 0.49 (0.20–0.75) 0.000
Medial gastrocnemius thickness (mm)† 31 17.9 (2.5) 0.98 (0.96–0.99) 0.000
Lateral gastrocnemius thickness (mm)† 31 12.7 (3.5) 0.98 (0.97–0.99) 0.000
Fibre length of medial gastrocnemius (ankle at 908) (mm)† 31 54.5 (8.0) 0.94 (0.87–0.97) 0.001
Pennation angle of medial gastrocnemius muscle fascicles
(ankle at 908) (degrees)†
31 19.3 (1.8) 0.94 (0.89–0.97) 0.000
Delayed test–retest reliability
First contraction peak flow velocity (cm/second) 17 53.7 (7.0) 20.06 (20.46 to 20.40) 0.253
First contraction mean peak flow velocity (cm/second) 17 21.7 (6.1) 0.28 (20.47 to 20.50) 0.487
Tenth contraction peak flow velocity (cm/second) 17 48.1 (33.1) 0.10 (20.39 to 20.54) 0.722
Mean (SD): results from the tree measures in the same day for immediate test–retest reliability and from the measures of first and second week for
delayed test–retest reliability
Intraclass correlation coefficient (ICC) significant with P, 0.05, with range (lower bound2 upper bound) at 95% confidence interval
Calculated with subgroup with retest
†calculated with all subjects
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was related to lower pennation angle and higher
muscle fascicle length of MG in dorsiflexion. The
exact meaning of these findings is unclear but
lower pennation angle and longer muscle fascicle
may indicate higher ankle-joint range of motion
and higher muscle stiffness. These two factors
likely affect blood pumping function of calf
muscles, through increased muscle activity20 and
strength21–23 of the GM. Also, increased tissue
hydrostatic pressure and tissue oedema in the
lower leg likely restricts ankle dorsiflexion and
GM lengthening and can be related to less efficient
CMPF.7–10,24
The results of this study show a clear increase in
venous blood flow caused by calf contractions in
individuals with CVD and control participants.
Previous reports, which examined flow velocity at
the popliteal vein employing duplex scanning,
show an increase in FV in response to voluntary
calf contraction in upright position to a mean
value of 70 cm/second,25 which is comparable to
our findings. Moreover, such increase in venous
flow velocity is considerably higher than that result-
ing from calf muscle electrical stimulation or leg
compression at the same leg position.25,26
Popliteal peak FV was maximal during the first
contraction of the tip-toe set. A highest venous
flow enhancement, consistently observed at the
beginning of calf contractions in the two groups,
likely results from a full venous reservoir at this
stage. In the CVD group, but not in the Control
group, venous flow augmentation diminished
during the contractions set. This suggests lower
ability of the calf muscles to pump venous blood
in the CVD participants compared with the
control participants. Such apparent calf pump dys-
function might be related to weak calf muscles
in CVD patients.5,9 In addition, abnormal venous
blood reflux from deep to superficial venous
system through incompetent perforator veins may
blunt blood flow through the popliteal vein. Pre-
vious reports, which examined flow velocity at the
popliteal vein employing duplex ultrasonography,
also found progressive decrease in blood flow
acceleration with repetitions of calf dynamic con-
tractions.27 Furthermore, in this study the healthy
participants were slightly younger and with
lower BMI compared with the CVD participants.
Younger age and less weight are usually associ-
ated with stronger muscles,28,29 which also may
contribute to improve the venous flow velocity
during contractions.
The present finding of blunted popliteal blood
velocity enhancement by calf contractions in the
CVD group is compatible with lower ejectionFi
g
u
re
3
Bl
an
d
an
d
A
ltm
an
Pl
ot
of
th
e
tw
o
m
ea
su
re
s
of
fir
st
co
nt
ra
ct
io
n
pe
ak
flo
w
ve
lo
ci
ty
,fi
rs
tc
on
tra
ct
io
n
m
ea
n
flo
w
ve
lo
ci
ty
an
d
1
0
th
co
nt
ra
ct
io
n
pe
ak
flo
w
ve
lo
ci
ty
,w
ith
bo
un
ds
an
d
bi
as
at
9
5
%
of
co
nfi
de
nc
e
in
te
rv
al
Original article R S S Criso´stomo et al. Evaluation of the efficacy of CMPF in primary CVD
254 29Phlebology 2014; :247–256
volume as measured with air-plethysmography in
this population.12 Although air-plethysmography
provides a non-invasive and accurate assessment
of calf pump function, it does not allow examining
individual veins. Assessing blood flow in a given
vein and during dynamic conditions, such as
muscle contraction or ankle motion, might be
important for understanding the role of these
factors on venous insufficiency and for therapeutic
decisions. For instance, a better understanding of
calf pump dysfunction might depend on the
ability to assess the blood flow through both the
deep and superficial venous system, which can be
achieved using duplex scanning but not air-
plethysmography.
In this study, the ultrasound measures of GM
architecture were highly reproducible, which is in
agreement with previous studies.21,30 In contrast,
those of popliteal venous blood flow are highly
variable whenmeasured within a week interval.31,32
In the present study, the reliability of peak FV
during the first contraction of the tip-toe task was
high within the same testing session but low
reproducibility (i.e. reliability and agreement)
when measured within one-week interval. The
poor reliability of ultrasound measures taken in
dynamic conditions are likely due to probe un-
steadiness, combined with short sampling time of
venous velocity.31,32 We attempted to determine
the effect of the leg movement on probe steadiness
and blood FV measures by contrasting such
measures with those collected with subjects per-
forming similar foot movement while standing sup-
ported on the opposite limb. The results showed
very high reproducibility and agreement of popli-
teal vein FV in the two conditions. This suggests
that probe movement relative to the underlying
vein is not a strong limitation to the use of
continuous-wave Doppler ultrasound in evaluating
venous haemodynamics in the lower extremity
during dynamical weight-bearing conditions. Not-
withstanding, the poor test–retest reliability found
for popliteal vein FVmeasures during tip-toe move-
ments points to the need for strict standardization
regarding probe positioning and movement task
conditions if use of ultrasound techniques is war-
ranted to assess CMPF.
In summary, duplex ultrasound demonstrated
lower efficiency of calf muscles in patients with
mild CVDwhen compared with a group of controls.
However, no differences in GM architecture and
baseline popliteal venous FV existed between the
CVD group and the Control group. Few associ-
ations were found between GM parameters and
muscle pump efficacy but no relationship between
these measures and CVD severity existed. Ultra-
sound evaluation of CMPF shows good reliability
if measures are in the same testing session.
However, reliability and agreement of this tech-
nique was poor when tests are repeated in separate
days. Future studies should evaluate the role of
calf muscles fatigue in calf pump function and
assess antegrade and retrograde flow in deep and
superficial veins during movements.
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Original Article
Manual lymphatic drainage in chronic
venous disease: A duplex ultrasound study
Rute Sofia dos Santos Criso´stomo1,2,3, Miguel Sandu Candeias4,
Ana Margarida Martins Ribeiro3, Catarina da Luz Belo Martins3
and Paulo AS Armada-da-Silva1,2
Abstract
Objectives: To compare the effect of call-up and reabsorption maneuvers of manual lymphatic drainage on blood flow in
femoral vein and great saphenous vein in patients with chronic venous disease and healthy controls.
Methods: Forty-one subjects participated in this study (mean age: 42.68(15.23)), 23 with chronic venous disease
(chronic venous disease group) with clinical classification C1–5 of clinical-etiological-anatomical-pathological (CEAP)
and 18 healthy subjects (control group). Call-up and reabsorption maneuvers were randomly applied in the medial
aspect of the thigh. The cross-sectional areas, as well as the peak and the mean blood flow velocity at femoral vein and
great saphenous vein, were assessed by Duplex ultrasound at the baseline and during maneuvers. The venous flow
volume changes were calculated.
Results: The venous flow volume in femoral vein and great saphenous vein increased during both manual lymphatic
drainage maneuvers and in both groups (P< 0.05). The two maneuvers had a similar effect on femoral vein and great
saphenous vein hemodynamics, and in both the chronic venous disease and control groups. As a result of the call-up
maneuver, the flow volume augmentations, as a result of call-up maneuver, decreased with the severity of chronic venous
disease in those patients measured by the clinical classification of CEAP (r¼0.64; P¼ 0.03).
Conclusions: Manual lymphatic drainage increases the venous blood flow in the lower extremity with a magnitude that
is independent from the specific maneuver employed or the presence of chronic venous disease. Therefore, manual
lymphatic drainage may be an alternative strategy for the treatment and prevention of venous stasis complications in
chronic venous disease.
Keywords
Manual lymphatic drainage, chronic venous disease, duplex ultrasound, venous flow
Introduction
Manual lymphatic drainage (MLD) is a specialized
manual technique that stimulates superﬁcial lymphatic
vessels to remove excessive interstitial ﬂuid1,2 and
increase lymph ﬂow.3,4 There are four recognized tech-
niques of MLD: the Fo¨ldi,3 Vodder,5 Casley-Smith6
and Leduc,7 and these consist of a skin massage that
includes substantial skin-stretching8 but which applies
very low pressure to the underlying tissues.9,10 The evi-
dence of MLD for the treatment, for example, of breast
cancer-related lymphedema9 and in sports medicine
and rehabilitation11 is unclear, and it is suggested as
being minor, despite some clinical and statistical incon-
sistencies in the studies. Nevertheless, MLD when com-
bined with other treatments, like low-stretch
bandaging, exercise and skin care (called decongestive
lymphatic therapy)4,8,12 may reveal itself as eﬀective in
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the treatment of lymphedema of the lower and upper
limb related to cancer.13,14
MLD has also been used as a conservative treatment
for chronic venous disease (CVD),15 often applied
along the course of the great saphenous vein.10,16,17
Molski et al.17 studied the eﬀect of MLD before surgery
in patients with CVD and found signiﬁcant improve-
ments in the clinical class of clinical-etiological-
anatomical-pathological (CEAP) classiﬁcation, quality
of life, depression, anxiety and in reﬂux volume index
after surgery when compared with a control group not
receiving MLD treatment.
There is also the assumption that MLD has an eﬀect
on blood ﬂow in superﬁcial veins, especially through
the call-up maneuver.10 Nevertheless, the real impact
of MLD in hemodynamics is unclear, although it has
been suggested as being insigniﬁcant.18 In the lower
extremity, the call-up maneuver, a technique belonging
to the so-called Leduc method, initiates with inciting
(or call-up) maneuvers in the inguinal region and then
progresses distally along the lower extremity down to
the edematous region, in order to stimulate lymph
ﬂow.18,19 The reabsorption maneuver, another Leduc
technique is then applied over the edematous region
to drain the interstitial ﬂuid and soluble macromol-
ecules through the lymphatic circulation.2,18,19 The
whole procedure ﬁnishes with a second round of call-
up maneuvers that are then applied in the reverse dir-
ection, ending at the groin region.18,19
As for the lymphatic circulation, these MLD maneu-
vers may have an impact on venous blood ﬂow both on
superﬁcial and deep veins of the lower extremity. Thus,
the present study was designed to assess the eﬀect of the
two low-pressure manual skin-stretching maneuvers:
the call-up and the reabsorption on both deep and
superﬁcial venous blood ﬂow in patients with CVD.
For this purpose, vascular ultrasonography was used
to measure the cross sectional area (CSA) and blood
velocity at the femoral vein (FV) and great saphenous
vein (GSV), when each of the MLD maneuvers was
applied to the medial aspect of the thigh in CVD and
healthy participants. We hypothesize that both tech-
niques will enhance venous blood ﬂow and that this
will be apparent by an elevated blood ﬂow in both the
superﬁcial and the deep veins of the lower extremity.
Methods
Subjects
Twenty-three participants (13 women and 10 men) with
a diagnosis of CVD (CVD group), most of whom were
outpatients in a local health unit, and 18 healthy con-
trol participants (10 women and 8 men), participated in
this study. All CVD participants presented venous
blood reﬂux of at least 0.5 s duration in the lower
extremity and CEAP clinical classiﬁcation in the
range C1–5. Before study enrolment, subjects were
informed about the purpose and procedures of the
study and signed an informed consent. The study
received ethical approval by the review board of the
scientiﬁc council of the Faculty of Human Kinetics,
Technical University of Lisbon. The exclusion criteria
in this study included the presence of severe cardiac
insuﬃciency, acute venous or arterial obstruction,
arterial insuﬃciency, renal insuﬃciency, uncompen-
sated thyroid dysfunction, pregnancy, neoplastic
pathology, systemic or limb infection, recent musculo-
skeletal injury in the lower limb, and peripheral neur-
opathy in the lower limb. Seven subjects were excluded:
two participants presented active ulcer (C6); two par-
ticipants were diagnosed with cardiac insuﬃciency; and
three participants had severe arterial insuﬃciency.
Three participants from the CVD group had not had
their GSV evaluated due to previous surgery on this
vein. In three other participants from this group, the
FV was not evaluated due to time constraints.
Clinical evaluations
The clinical history, the symptoms (fatigue, heavy sen-
sation, itching, cramps, and skin irritation), the severity
of the disease according to clinical classiﬁcation of
CEAP and the venous clinical severity scores
(VCSS)20 were collected.
The anatomical location (i.e. superﬁcial, perforating
and/or deep vein system) and severity of the venous
blood reﬂux were determined. The control participants
also went through a thorough vascular ultrasound of
both lower extremities to conﬁrm that they were free
from CVD. All ultrasound tests were performed by a
certiﬁed vascular sonographer and with the same ultra-
sound equipment (ESAOTE mylab 30cv, with 7mm
linear array-transducer, scanned at 6–12MHz). The
leg self-reported as presenting the worst symptoms
and clinical signs and the dominant leg were chosen
for subsequent measurements, respectively in the
CVD group and the control group.
Venous hemodynamics during baseline and during
call-up and reabsorption maneuvers
Doppler vascular ultrasound was employed to evaluate
venous blood hemodynamics in FV and GSV. The FV
and GSV were scanned below conﬂuence of the super-
ﬁcial inguinal veins and the superﬁcial vein, and imme-
diately below conﬂuence of the superﬁcial inguinal
veins, respectively. Both veins were scanned in
B-mode for 4 s and the image presenting the larger
CSA was selected. The vein’s CSA was measured by
2 Phlebology 0(0)
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tracing its contour in the ultrasound scan. Venous ﬂow
velocity (mean and peak) was measured during 4-s
intervals, using the time integral calculation. Three
measurements of CSA and of blood ﬂow velocity
were taken for both FV and GSV, and the average
was computed for analysis.
Ultrasound measurements were taken ﬁrst at base-
line (with no maneuver) and thereafter during ran-
domly applied call-up and reabsorption maneuvers to
the medial aspect of the thigh (Figure 1). Before the
measurements were taken, the participants rested for
5min in a supine position and then remained in this
position during the whole testing procedure. Blood
ﬂow volume in the FV and GSV was calculated based
on measurements of CSA and blood ﬂow velocity using
the following relation:21 Flow volume (ml/s)¼ vein
CSA (cm2)mean ﬂow velocity (cm/s).
The augmentation of CSA and venous hemo-
dynamics (peak and mean ﬂow velocity and ﬂow
volume) percent augmentations were calculated using
the following relation: Augmentation (%)¼
(Maneuver  Baseline)/(Baseline) 100.
The venous blood ﬂow parameters and percentage
augmentation can easily be assessed with Doppler
ultrasound and have been used in many studies which
evaluate venous hemodynamic in the lower limb in
response to treatments.22,23 Also, venous ﬂow volume
calculation based on CSA and Doppler ultrasound
measurements are accurate.24
Ultrasound data were collected by a certiﬁed sono-
grapher kept in the blind regarding the application of
manual techniques. The MLD maneuvers, based on the
Leduc technique, were performed with two hands
placed onto the medial aspect of the thigh and applying
a pressure just suﬃcient to stretch the skin during a
minimum time interval of 4 s. The maneuver started
and ended on command of the sonographer and in syn-
chronization with ultrasound recording. The call-up
maneuver initiates with the most proximal part of the
proximal hand and ends with both hands touching the
skin while producing a skin stretching. This MLD man-
euver is applied to promote the increase of lymph ﬂow
by enhancing the contractility of lymphagions of lymph
collectors.18,19 The reabsorption maneuver initiates
with the most distal part of the distal hand and ends
with both hands touching the skin while applying skin
stretching. This maneuver is applied to stimulate the
reabsorption of macromolecules and the excess of
venous ﬁltration from interstitial space to lymphatic
capillaries by stretching leak ﬁlaments (connections
between connective tissue to endothelial cell of lymph-
atic capillaries) when the skin is mobilized.2,18,19 Skin-
stretching is applied in the two maneuvers in a proximal
direction respecting the course of the lymph and venous
ﬂow (Figure 2).
Statistical analysis
All statistical tests were performed with the help of the
statistical software package SPSS Inc. v.17 (SPSS Inc.,
Chicago, USA). Normal distribution was checked using
Shapiro–Wilk-Test. Group diﬀerences were tested with
two-tailed Student’s t-test, while diﬀerences between
maneuvers and between maneuvers and baseline were
tested by repeated-measures ANOVA. The Bonferroni
correction was used to correct for multiple compari-
sons. The relationship between the magnitude of the
eﬀect of the maneuvers, in terms of percentage augmen-
tation from baseline, and CVD severity, in terms of
CEAP and VCSS classiﬁcation was calculated using
Spearman coeﬃcient of correlation. The signiﬁcance
level was set at P< 0.05.
Figure 1. Randomization for duplex ultrasound assessment.
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Results
The demographic and clinical data pertaining to the
participants are presented in Table 1. No diﬀerences
in age, height, weight, and body mass index were
found between the CVD and control group.
Baseline
The CSA of the GSV was higher in CVD group
(0.14(0.06) cm2) than in the control group (0.09(0.04)
cm2), with P¼ 0.007. Nevertheless, the CSA of FV and
the mean ﬂow velocity, the peak ﬂow velocity, and the
ﬂow volume of both FV and GSV at baseline were simi-
lar in CVD and in the control group (Tables 2 and 3).
Call-up and reabsorption maneuver
During the call-up maneuver the FV blood ﬂow volume
increased signiﬁcantly (P< 0.05) from baseline
(Figure 3). The FV peak ﬂow velocity only increased
during call-up maneuver in the control group
(P¼ 0.032), and during reabsorption maneuver in the
CVD group (P¼ 0.000) and in both groups pooled
together (P¼ 0.008). The FV mean ﬂow velocity only
increased during call-up and reabsorption maneuvers in
the CVD group (P¼ 0.000 and P¼ 0.000, respectively)
and in both groups pooled together (P¼ 0.000 and
P¼ 0.008, respectively). The CSA of FV increase
from the baseline during the call-up maneuver only in
the CVD group (P¼ 0.006) and with all groups pooled
together (P¼ 0.002), and during reabsorption in both
the CVD (P¼ 0.003) and the control group (P¼ 0.007)
and with the two groups pooled together (P¼ 0.000).
The GSV blood ﬂow (peak and mean ﬂow vel-
ocity and ﬂow volume) increased signiﬁcantly
(P< 0.05) from the baseline during call-up and
reabsorption maneuvers (Figure 4). The CSA of
GSV, however, remained unchanged during the
maneuvers.
The venous blood ﬂow (mean, peak ﬂow velocity
and ﬂow volume) and CSA augmentations from the
baseline of FV and GSV were similar in both call-up
and reabsorption maneuvers, with the exception of the
CSA augmentation of FV that was lower during call-up
maneuver when compared with reabsorption in the
control group (12.45(30.00)% and 23.05(32.89)%,
respectively; P¼ 0.004) and with the two groups
pooled together (12.70(23.85)% and 34.76(58.40)%,
respectively; P¼ 0.021). The CSA (in absolute values)
of FV during call-up was also lower than during
reabsorption maneuver in the control group
(0.49(0.19) cm2 and 0.53(0.19) cm2 for call-up and
reabsorption maneuvers respectively; P¼ 0.042) and
with the two groups pooled together (0.50(0.19) cm2
and 0.57(0.19) cm2 for call-up and reabsorption maneu-
vers respectively; P¼ 0.042), but no diﬀerences were
found between maneuvers in the CVD group. In add-
ition, no diﬀerences were found between call-up and
reabsorption maneuvers in CSA for GSV and in
blood ﬂow for FV and for GSV.
Severity of chronic venous disease and maneuvers
The CVD group presents a higher CSA of the GSV
than the control group during call-up (P¼ 0.001) and
reabsorption maneuvers (P¼ 0.001), but the CSA aug-
mentations were similar. No other diﬀerences were
Figure 2. Evaluation context with curtain separating sonographer, therapist and participant, during the assessment of the cross
sectional area and blood flow of FV and GSV during baseline and during call-up maneuvers (A, B and C sequence) and reabsorption
maneuvers (D, E and F sequence).
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found between the CVD and the control group during
the application of each maneuver.
Blood ﬂow (peak and mean ﬂow velocity and the
ﬂow volume) augmentations in FV during call-up man-
euvers decreased with the severity of CVD, as measured
by VCSS (r¼0.51, P¼ 0.026 for peak ﬂow velocity;
r¼0.51, P¼ 0.023 for mean ﬂow velocity; and
r¼0.49, P¼ 0.034 for ﬂow volume). The ﬂow
volume augmentation for the same vein also decreased
with the severity of CVD, measured by CEAP clinical
classiﬁcation (r¼0.64; P¼ 0.03). The GSV ﬂow
volume augmentation was not aﬀected by the severity
of the CVD disease.
Discussion
This study reveals that MLD maneuvers (call-up and
reabsorption) are able to increase venous blood ﬂow in
the deep (FV) and the superﬁcial venous systems
(GSV), with no diﬀerences between maneuvers in this
outcome, as well as between the CVD and the control
groups. According to Leduc’s technique, MLD maneu-
vers, especially the call-up maneuver, are believed to
aﬀect blood ﬂow only on superﬁcial veins.10 To the
best of our knowledge, the eﬀect of MLD on venous
hemodynamics was assessed in just one study in which
MLD application produced no eﬀect on venous return
Table 1. Demographic and clinical data.
CVD group
(n¼ 23)
Control group
(n¼ 18) P
All subjects
(n¼ 41)
Age (years) 46.83 (13.24) 38.72 (15.96) 0.083 42.68 (15.23)
Height (m) 1.67 (0.91) 1.64 (0.97) 0.419 70.62 (15.03)
Weight (kg) 74.04 (14.63) 66.08 (13.50) 0.082 1.66 (0.10)
BMI (kg/m2) 26.53 (4.01) 24.36 (3.67) 0.081 25.58 (4.11)
Gender
Female 13 (56.52) 10 (55.56) – 22 (57.89)
Male 10 (43.48) 8 (44.44) – 16 (42.11)
CEAP clinical classification
C1 5 (21.74) – – –
C2 3 (13.04) – – –
C3 5 (21.74) – – –
C4 6 (26.09) – – –
C5 4 (17.39) – – –
VCSS 5.65 (3.62) – – –
Anatomical reflux
Superficial veins 3 (13.04) – – –
Deep veins 1 (4.34) – – –
Superficialþ deep veins 7 (30.43) – – –
Superficialþ perforator veins 6 (26.09) – – –
Superficialþ deepþ perforator veins 4 (17.39) – – –
Comorbidities
Surgical removal of great saphenous vein 3 (13.04) – – –
Lower limbs symptoms
Fatigue 18 (78.26) – – –
Cramps 9 (39.13) – – –
Heavy legs 14 (60.87) – – –
Pain 14 (60.87) – – –
Skin irritation 8 (34.78) – – –
Itching 11 (47.82) – – –
Without symptoms 2 (8.70) – – –
Quantitative variable: mean (SD); categorical variable: frequency (%). Differences between groups (CVD and control) were significant with P< 0.05 for
two-tailed Student’s t-test.
VCSS: Venous Clinical Severity Score, total scale range 0–30 (best to worst); CEAP: Clinical Etiological Anatomical Pathological Classification.
Criso´stomo et al. 5
XML Template (2013) [27.8.2013–12:33pm] [1–10]
//blrnas3/cenpro/ApplicationFiles/Journals/SAGE/3B2/PHLJ/Vol00000/130049/APPFile/SG-PHLJ130049.3d (PHL) [PREPRINTER stage]
in patients with chronic heart failure and lower extrem-
ity edema.18 However, this study did not evaluate the
blood ﬂow in the lower extremity veins directly. MLD
is commonly indicated for patients with CVD as a strat-
egy to treat edema, especially when the lymphatic
system is also compromised.25 Employing MLD in
patients with CVD awaiting for surgery, appears to
decrease the severity of the disease and lead to an over-
all improvement in quality of life in these patients.17
Also, MLD might have a real eﬀect on improving
venous hemodynamics (reﬂux volume index) in CVD
patients.17
The present study reveals that MLD techniques
based on manual skin-stretching of the thigh increases
Table 3. Venous blood flow in great saphenous vein.
CVD group
(n¼ 20)
Control group
(n¼ 18)
P
All subjects
(n¼ 38)
Great saphenous vein Mean (SD) Mean (SD) Mean (SD)
Cross-sectional area (cm2) Baseline 0.14 (0.06) 0.09 (0.04) 0.007b 0.12 (0.05)
Call-up 0.16 (0.07) 0.09 (0.04) 0.001b 0.12 (0.06)
Reabsorption 0.16 (0.06) 0.10 (0.04) 0.001b 0.13 (0.06)
Peak flow velocity (cm/s) Baseline 15.82 (8.06) 21.09 (17.52) 0.240 18.38 (13.66)
Call-up 26.22 (13.65)a 33.31 (28.96)a 0.313 29.45 (22.61)a
Reabsorption 28.58 (15.66)a 35.19 (29.05)a 0.393 31.84 (23.10)a
Mean flow velocity (cm/s) Baseline 10.05 (4.63) 14.56 (14.29) 0.194 12.22 (10.72)
Call-up 16.64 (8.13)a 24.18 (25.29)a 0.215 20.23 (18.92)a
Reabsorption 18.09 (9.03)a 24.77 (23.16)a 0.224 21.31 (17.62)a
Flow volume (ml/s) Baseline 1.35 (0.82) 1.49 (1.91) 0.784 1.42 (1.45)
Call-up 2.69 (2.49)a 2.32 (2.92)a 0.686 2.50 (2.68)a
Reabsorption 3.08 (2.80)a 2.35 (2.24)a 0.390 2.71 (2.53)a
aSignificantly different from baseline (P< 0.05).
bDifferences between CVD group and control (healthy) group were significant (P< 0.05).
Table 2. Venous blood flow in femoral vein.
CVD group
(n¼ 20)
Control group
(n¼ 18)
P
All subjects
(n¼ 38)
Femoral vein Mean (SD) Mean (SD) Mean (SD)
Cross-sectional area (cm2) Baseline 0.47 (0.16) 0.46 (0.21) 0.992 0.45 (0.18)
Call-up 0.52 (0.20)a 0.49 (0.19) 0.661 0.50 (0.19)a
Reabsorption 0.60 (0.19)a 0.53 (0.19)a,b,c 0.229 0.57 (0.19)a,b,c
Peak flow velocity (cm/s) Baseline 19.38 (8.77) 21.37 (9.36) 0.504 20.32 (8.99)
Call-up 24.85 (10.92)a 25.67 (8.82)a 0.803 25.24 (9.85)a
Reabsorption 25.96 (10.32)a 25.04 (6.83) 0.754 25.51 (8.69)a
Mean flow velocity (cm/s) Baseline 12.14 (5.67) 14.20 (7.47) 0.342 13.11 (6.57)
Call-up 16.62 (8.27)a 17.12 (7.15) 0.843 16.86 (7.66)a
Reabsorption 15.88 (7.30)a 15.37 (4.76) 0.807 15.63 (6.12)a
Flow volume (ml/s) Baseline 5.47 (3.40) 6.05 (4.22) 0.644 20.32 (8.99)
Call-up 8.20 (4.72)a 7.99 (3.87)a 0.883 25.24 (9.85)a
Reabsorption 9.42 (4.73)a 7.98 (3.89)a 0.320 25.51 (8.69)a
aSignificantly different from baseline (P< 0.05).
bSignificantly different from call-up maneuver (P< 0.05).
cSignificantly different from call-up maneuver for percentage augmentation from baseline [((maneuverbaseline)/baseline) 100] (P< 0.05).
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venous blood ﬂow in the lower extremity, in superﬁcial
veins, as has already been suggested,10 and also in deep
venous system (FV) beneath the deep fascia, which is a
novel observation.
Current concepts regarding MLD indicate that each
maneuver should take around 4 s from beginning to
end.19 We strictly followed this recommendation when
applying the two MLD techniques in the present study,
Figure 4. Left: image of blood flow velocities of great saphenous vein (GSV) during baseline, call-up maneuvers and reabsorption
maneuvers of manual lymphatic drainage. Right: mean and error (95% of confidence interval) of flow volume in the GSV in the CVD
group (patients with chronic venous disease) and the control group (healthy subjects) during baseline and manual lymphatic drainage
maneuvers (call-up and reabsorption), showing the results from Bonferroni-adjustment (*) significantly different from the baseline.
Figure 3. Left: image of blood flow velocities of FV during baseline, call-up maneuvers and reabsorption maneuvers of manual
lymphatic drainage. Right: mean and error (95% of confidence interval) of flow volume in femoral vein in the CVD group (patients with
chronic venous disease) and the control group (healthy subjects) during baseline and manual lymphatic drainage maneuvers (call-up and
reabsorption), showing the results from Bonferroni-adjustment (*) significantly different from the baseline.
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as well as starting the technique from proximal to distal
(the call-up maneuver) which enhances venous blood
ﬂow, whereas applying skin-stretching from distal to
proximal (the reabsorption maneuver) only has an
eﬀect on lymph ﬂow and ﬂuid reabsorption.19 Our ﬁnd-
ings do not substantiate this diﬀerential eﬀect between
the two maneuvers which, in general, enhance venous
blood ﬂow both in FV and in GSV. The only diﬀerence
between the two MLD maneuvers occurred in changes
of the CSA of FV and only for the control group.
Skin and deep fasciae are connected by skin liga-
ments on thigh, knee, popliteal fossa and leg, which
give stability to the skin, like an anchor, during lower
limb movements.26 The skin-stretching applied during
MLD in this study may produce enough increase in
pressure on the underlying structures to enhance
venous ﬂow in superﬁcial and deep veins, as does the
physiological skin-stretching during movement.27
Venous blood ﬂow was found to be similar in the
CVD and the control groups, which is a typical obser-
vation when venous blood ﬂow is assessed at rest.28
Nevertheless, the CSA of GSV was found to be
higher in the CVD group which is in accordance with
previous observations,29 revealing that the diameter of
GSV can be a good predictor of the presence/absence
and severity of CVD.
With the severity of CVD, the percentage augmen-
tation of ﬂow volume during reabsorption maneuvers
appears to decrease. The severity of the disease is
related to the diﬃculty in evacuating the venous
blood from the periphery towards the heart,30 and
with a corresponding increase in the reﬂux volume
index and venous stasis.30,31 Moreover, the link
between blood Fow velocity, deep vein thrombosis
and the risk of pulmonary embolism is well known.22
The triad composed by stasis, vessel damage, and
hypercoagulability is accepted as a major factor in
thrombogenesis.22 Preventing venous stasis is a main
goal in CVD treatment and decisive in preventing
venous complications. In this regard, MLD maneuvers
maybe an alternative treatment procedure to enhance
venous ﬂow. Nevertheless, this intervention needs spe-
cialized professionals, and could be an expensive health
care treatment. In addition, middle and long-term
eﬀects of MLD in venous ﬂow are unknown.
Teaching caregivers or patients simple lymphatic drain-
age, despite the lower eﬃcacy showed in the treatment
of lymphedema, when compared with MLD applied for
professionals,9 could be an alternative.
Intermittent pneumatic compression, with a pressure
setting of 80mmHg, increases venous ﬂow velocity in
FV and in GSV, but produces an increase in ﬂow
volume just in the FV, belonging to the deep venous
system.32 With a pressure setting of 40mmHg, venous
ﬂow velocity at the FV rises to 35–60 cm/s and raising
the pressure setting to 120mmHg, ﬂow velocity reaches
100 cm/s.22 With foot compression, the increase typic-
ally goes up to 20–40 cm/s in the FV. In this study, the
peak ﬂow velocity in FV during the MLD maneuvers
reached around 25–26 cm/s, slightly lower than with
intermittent pneumatic compression at low pressure
setting. Compression (bandages and stoking) is the con-
servative treatment more often advocated for CVD30
which also increases venous ﬂow velocity in GSV and
the Popliteal vein.33 When compression exceeds the
40mmHg, then the CSA of GSV and FV starts to
decrease,34 showing that the pressure applied in this
study was within the range indicated for this technique
(lower than 40mmHg).7 Although compression above
40mmHg produces large increase in blood ﬂow
velocity,22,34 this is limited to deep veins. The manual
maneuvers employed in the present study produced
mild enhancement in venous blood ﬂow velocity and
ﬂow volume, but in this case in both the deep and the
superﬁcial venous systems.
The mean and peak ﬂow velocity in FV also increase
during the active and the passive movement of the
ankle joint.35 The venous blood ﬂow velocity registered
during the active movement of the ankle increased by
20–40%,35 which is similar to the increase in blood ﬂow
velocity found during the call-up and reabsorption
maneuvers in this study. The increase in blood ﬂow
velocity in the superﬁcial GSV during active and pas-
sive movements of ankle is also similar to that observed
here using call-up and reabsorption maneuvers.36 In the
standing position and during active tip-toe movements,
blood ﬂow velocity in the popliteal vein also increases
in response to calf muscle pump contractions,28 but in
this case and contrary to what was observed in the pre-
sent study, healthy subjects demonstrated larger
enhancement in venous blood ﬂow as a result of the
tip-toe movement.28
There are few studies that describe and demonstrate
the eﬃcacy of MLD maneuvers on venous blood ﬂow.
Therefore, this study is a preliminary attempt to assess
the potential role of MLD in treating CVD patients.
The mechanisms explaining the increases in venous
ﬂow during MLD are still unknown. A likely mechan-
ism would be that skin traction increases the pressure
over superﬁcial vessels reducing their caliber and leads
to an increase in blood ﬂow velocity. The increased
blood ﬂow in the superﬁcial veins would result in
higher blood ﬂow across perforating veins and into
the deep veins, thereby raising blood ﬂow in the deep
venous system as well. The pressure applied to the skin
would probably cause movement in the muscles under-
neath, and pressure would also increase in deep seated
structures and deep veins further stimulating blood
ﬂow. Also, muscle tone might increase during the inter-
val of time that MLD techniques are being applied.
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Although participants were instructed to remain as
relaxed as they possibly could during the MLD sessions,
unnoticed muscle contraction could have occurred
either induced by the manual stimulation, or in response
to the movement of the lower extremity, which could
have contributed to the observed increase in venous
blood ﬂow.
The major limitation in this study is the non-
existence of data regarding the level of bias and reliabil-
ity of the ultrasound measurements of blood velocity
and veins’ CSA during manual maneuvers. Future stu-
dies should evaluate the test–retest accuracy of these
measurements.
In conclusion, the call-up and reabsorption MLD-
maneuvers, applied to the medial aspect of the thigh,
improve venous blood ﬂow in FV and GSV in CVD
patients and healthy subjects. The blood ﬂow-
enhancing eﬀect of MLD was similar between the
CVD patients and the healthy participants. However,
the eﬃcacy of the reabsorption maneuvers in increasing
venous blood velocity decreased with CVD severity.
Future studies should evaluate the eﬀect of MLD man-
euvers in venous blood ﬂow when applied to regions
of the lower extremity other than the medial aspect of
the thigh.
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10.3 Annex 3 - Chronic Venous Disease Quality of Life Questionnaire 
(CIVIQ-20)
Auto-Questionário de Qualidade de Vida na Insuficiência Venosa 
 
  
 Muitos portugueses queixam-se de dores nas pernas. Procuramos saber qual a 
frequência dos problemas das pernas, e de que maneira estes problemas podem afectar a 
vida quotidiana dos que sofrem deste problema. 
 Vai encontrar adiante, um número de sintomas, sensações ou incómodos que 
pode ou não sentir e que podem tornar a vida do dia a dia mais ou menos difícil. Para 
cada sintoma, sensação ou incómodo mencionados, pedimos-lhe que responda a duas 
perguntas: 
1- Na coluna I, indique se sentiu realmente o a frase descreve, em caso afirmativo, 
e com que intensidade. Cinco respostas são previstas, coloque um círculo em 
volta da que melhor corresponda à sua situação: 
1 - se não se considerar afectada(o) pelo sintoma, ou a sensação ou 
incomodo descrito. 
2, 3, 4 ou 5 se os tiver experimentado com maior ou menor intensidade. 
 
2- Na coluna II, indique a importância que a atribui a este sintoma, sensação ou 
incómodo na sua vida quotidiana. 
  
 Algo pode ser sentido intensamente, sem no entanto ocupar um lugar importante 
na sua vida de todos os dias. Para avaliar a importância que dá a cada um dos sintomas 
ou sensações experimentados, foram previstas cinco respostas que vão de 1 (nenhuma 
importância) a 5 (extrema importância). Faça um círculo naquela que parece 
corresponder ao seu caso.  
 QUALIDADE DE VIDA NA INSUFICÊNCIA VENOSA 
 
 Coluna I   Coluna II  
P1 a) Nas últimas 4 semanas sentiu dores nos tornozelos ou nas pernas? E qual 
foi a intensidade dessas dores? 
(Faça um círculo no número correspondente à sua resposta.) 
P1 b) Que importância dá a estas dores na sua vida actual? 
(Faça um círculo no número correspondente à sua resposta.) 
Nenhuma 
dor  
Dores leves  
Dores 
moderadas 
Dores 
importantes 
Dores intensas 
Nenhuma 
importância 
Pouca 
importância 
Importância 
moderada  
Muita 
importância 
Importância 
extrema 
1 2 3 4 5 1 2 3 4 5 
 
P2 a) Nas últimas 4 semanas em que medida se sentiu incomodado(a) no seu 
trabalho ou nas suas outras actividades quotidianas devido aos seus 
problemas de pernas? (Faça um círculo no número correspondente à sua resposta.) 
 
P2 b) Que importância dá a este incómodo na sua vida actual? 
(Faça um círculo no número correspondente à sua resposta.) 
Nenhum 
incómodo 
Um pouco 
incomodado(a) 
Moderadamente 
incomodado 
Muito 
incomodado(a) 
Extremamente 
incomodado(a) 
Nenhuma 
importância 
Pouca 
importância 
Importância 
moderada  
Muita 
importância 
Importância 
extrema 
1 2 3 4 5 1 2 3 4 5 
          
P3 a) Nas últimas 4 semanas, aconteceu-lhe dormir mal devido aos seus 
problemas de pernas, e com que frequência? 
(Faça um círculo no número correspondente à sua resposta.) 
P3 b) Que importância dá a estas perturbações do sono na sua vida 
actual? 
(Faça um círculo no número correspondente à sua resposta.) 
Nunca  Raramente Frequentemente 
Muito 
frequentemente  
Todas as 
noites 
Nenhuma 
importância 
Pouca 
importância 
Importância 
moderada  
Muita 
importância 
Importância 
extrema 
1 2 3 4 5 1 2 3 4 5 
  
  P4 a) Nas últimas 4 semanas em que medida os seus problemas de pernas 
o (a) incomodaram durante os movimentos ou actividades indicadas a 
seguir? 
(Para cada enunciado inscrito na coluna esquerda, indique em que medida é 
incomodado(a,  fazendo um círculos no número escolhido.) 
P4 b) Que importância dá a este incómodo na sua vida actual? 
 
(Indique a importância atribuída a cada incomodo fazendo um circulo no 
número escolhido) 
Nenhum 
incómodo 
Um pouco 
incomodado(a) 
Moderadamente 
incomodado(a) 
Muito 
incomodado(a) 
Impossível 
de fazer 
Nenhuma 
importância 
Pouca 
importância 
Importância 
moderada  
Muita 
importância 
Importância 
extrema 
Permanecer 
muito tempo em 
pé  
1 2 3 4 5 1 2 3 4 5 
Subir encostas 
ou escadarias 
1 2 3 4 5 1 2 3 4 5 
Agachar-se 
/ajoelhar-se 
1 2 3 4 5 1 2 3 4 5 
Caminhar com 
passo decidido 
1 2 3 4 5 1 2 3 4 5 
Viajar de carro, 
de comboio 
1 2 3 4 5 1 2 3 4 5 
Realizar tarefas 
domésticas 
(cozinhar, levar 
uma criança nos 
braços, passar a 
ferro, limpar o 
chão ou os 
móveis, fazer 
bricolage, ir as 
compras… 
1 2 3 4 5 1 2 3 4 5 
Ir ao café, a 
festividades 
(casamentos), 
convívios… 
1 2 3 4 5 1 2 3 4 5 
Fazer desporto, 
esforços físicos 
importantes 
(carregar pesos, 
deslocar 
moveis…) 
1 2 3 4 5 1 2 3 4 5 
  
 P5 a) Os problemas de pernas podem igualmente afectar o seu ânimo. Em que 
medida as frases abaixo indicadas correspondem ao que experimentou nas 4 
últimas semanas? 
   (Para cada enunciado inscrito na coluna esquerda, faça um círculo no 
número escolhido.) 
P5 b) (Para cada sensação experimentada) 
Que importância representa isto para si na sua vida actual? 
 
(Indique a importância atribuída a cada sensação experimentada  fazendo 
um circulo no número escolhido) 
Nada Um pouco Moderadamente  Muito  Completamente 
Nenhuma 
importância 
Pouca 
importância 
Importância 
moderada  
Muita 
importância 
Importância 
extrema 
Sinto-me 
nervoso(a), 
tenso(a)  
1 2 3 4 5 1 2 3 4 5 
Canso-me 
depressa 
1 2 3 4 5 1 2 3 4 5 
Sou um fardo 
para os outros 
1 2 3 4 5 1 2 3 4 5 
Devo tomar 
sempre 
precauções (por 
exemplo esticar 
as pernas, evitar 
permanecer 
muito tempo 
em pé…) 
1 2 3 4 5 1 2 3 4 5 
Sinto embaraço 
em mostrar as 
pernas 
1 2 3 4 5 1 2 3 4 5 
Irrito-me 
facilmente, 
estou de mau 
humor 
1 2 3 4 5 1 2 3 4 5 
Tenho a 
impressão de 
ter uma 
deficiência 
1 2 3 4 5 1 2 3 4 5 
Sinto 
dificuldade para 
começar o dia 
1 2 3 4 5 1 2 3 4 5 
Não me apetece 
sair de casa  
1 2 3 4 5 1 2 3 4 5 
